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2. Abbreviation 
N-acetylneuraminic acid Neu5Ac
Glucuronic acid GlcA
Mannose Man
N-acetylglucosamine GlcNAc
Glucose Glc
Fucose Fuc
N-acetylgalactosamine GalNAc
Galactose Gal
Xylose Xyl
Iduronic acid IdoA
2. Abbreviation 
ADAM  a disintegrin and metalloproteinase  LLO Lipid-linked oligosaccharide  
ADAMTS A disintegrin and metalloproteinase with 
thrombospondin type 1 repeats 
Kcat Turnover number 
BSA Bovine serum albumin LC Liquid chromatography 
CAZy  Carbohydrate-Active enZYmes database m/z Mass to charge ratio 
CDG Congenital disorders of glycosylation  mAb Monoclonal antibody 
Cer Ceramide MALDI Matrix associated laser desorption ionization  
DMEM Dulbecco's modified eagle's medium MPI Phosphomannose-isomerase  
ECL Enhanced chemiluminescence MRM Multiple reaction monitoring  
ECM Extracellular matrix MS Mass spectrometry 
EDTA Ethylenediaminetetraacetic acid OGT O-GlcNAc transferase  
EGF Epidermal growth factor OST Oligosaccharyltransferase  
EndoHf  Endoglycosidase Hf  PAGE Polyacrylamide gel electrophoresis 
ER Endoplasmic reticulum  PBS Phosphate buffered saline 
ERAD  ER-associated degradation  pI Isoelectric point 
ESI Electron spray ionization  PIP Phosphatidylinositolphosphate 
FCS Fetal calf serum  PNGase F Peptide N-glycosidase F 
FPLC Fast protein liquid chromatography POFUT1 Protein O-fucosyltransferase 1  
FT Fourier transformation  POFUT2 Protein O-fucosyltransferase 2 
GAG Glycosaminoglycan  PPS Peters Plus syndrome  
GDP Guanosine diphosphate RT Room temperature 
GHs Glycosidases  SDS Sodium dodecyl sulfate  
GnT GlcNAc transferase  SEC Size-Exclusion Chromatography 
GPI Glycosylphosphatidylinositol Tf Transferrin  
GTs Glycosyltransferases  TIC Total ion counts 
HEK293T Human embryonic kidney cells with SV40 
large T antigen  
TOF Time of flight 
HM High-mannose type TSR4 4th TSR from F-spondin  
HPLC High performance liquid chromatography TSP-1 Thrombospondin-1 
IEF Isoelectric focusing TRAP Thrombospondin-related anonymous  protein  
IMAC Immobilized metal affinity chromatography UDP Uridine diphosphate  
IP Immunoprecipitation  VEGF Vascular endothelial growth factor 
 
Abbreviation of amino acids                                               Symbolic representation and abbreviation of sugars 
Ala A Alanine  
Arg R Arginine  
Asn N Asparagine  
Asp D Aspartic acid  
Cys C Cysteine  
Gln Q Glutamine  
Glu E Glutamic acid  
Gly G Glycine  
His H Histidine  
Ile I Isoleucine 
Leu L Leucine  
Lys K Lysine 
Met M Methionine  
Phe F Phenylalanine 
Pro P Proline  
Ser S Serine  
Thr T Threonine  
Trp W Tryptophan  
Tyr Y Tyrosine  
Val V Valine  
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3. Abstract 
3. Abstract 
Protein O-fucosylation is a post-translational modification found on epidermal growth 
factor-like (EGF) repeats and thrombospondin type 1 repeats (TSR). The EGF 
modification was shown to regulate embryonic development by controlling the ligand 
specificity of Notch (Chapter 5.1) but the role of protein O-fucosyltransferase 2 
(POFUT2) -dependent fucosylation of TSRs is less understood. Nevertheless, recent 
work on Pofut2 knockout mice found that O-fucosylation of TSRs is essential for 
restricting epithelial to mesenchymal transition, correct patterning of mesoderm and 
localization of endoderm, suggesting a critical role of POFUT2 in the early 
development of the mouse embryo (Du et al, 2010). More than 50 human proteins, 
located either on the membrane or being secreted, contain the TSR consensus 
sequence for POFUT2-dependent fucosylation. Together, these proteins regulate a 
wide variety of biological processes such as anti-angiogenesis, growth factor release 
or innate immunity response (Chapter 5.4). 
In order to better understand O-fucosylation on TSRs we carried out a structural and 
functional analysis of human POFUT2. Crystal structures of native POFUT2 reveals 
that the protein folds into GT-B superfamily of glycosyltransferase (Chapter 5.3 and 
Chapter 6.2). HPLC mass-spectrometry enzyme activity measurements of wild-type 
POFUT2 show that the full activity of POFUT2 is divalent metal ion dependent 
(Chapter 6.2) and that KM value of wild-type POFUT2 of GDP-fucose and TSR4 are 
10 µM and 30 µM, respectively. Based on the structure of POFUT2 and activity 
assays of POFUT2 mutants, we proposed that E54 is the catalytic base. The 
structure of GDP-fucose in complex with E54A-POFUT2 shows that GDP-fucose 
locates in a conserved minor cleft on the C-terminal domain. Mutations of conserved 
residues involved in GDP-fucose interaction abolish POFUT2 activity (Chapter 6.2). 
The in vivo fucosylation assays of TSR4 mutants (Chapter 6.3) and in vitro 
fucosylation assays of mini-TSR provide a model of how POFUT2 recognizes a 
properly folded TSR and transfers fucose on it (Chapter 6.1 and 6.3).  
Our experimental findings give insight into the catalytic mechanism and the special 
structural requirements of POFUT2 modifying a completely folded protein sugar 
acceptor that transiently forms a protein-protein interaction. 
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4. Research Objective  
4. Research Objective 
In order to better understand the mechanism of O-fucosylation on TSRs, we aimed at 
characterizing the catalytic mechanism and substrate specificity of POFUT2 by 
solving the structure of POFUT2 and performing enzyme kinetic assays. To achieve 
the goals we divided the work into different steps: 
1. Expression and purification of properly folded TSR4 for the POFUT2 activity 
assay (Chapter 6.1)  
2. Expression, purification and crystallization of wild-type POFUT2 (Chapter 6.2) 
3. Expression and characterization of POFUT2 mutants (Chapter 6.2) 
4. Crystallization of the GDP-fucose-E54A-POFUT2 binary complex (Chapter 6.2) 
5. In vitro and in vivo fucosylation assays of TSR mutants and mini-TSR (Chapter 
6.1 and 6.2) 
 
  5 
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5. General Introduction 
5.1 Protein Glycosylation  
Glycan is one of the most common molecules in all cell types. In the bacterial cell 
wall, glycan polymerizes with amino acids to form peptidoglycan that forms a mesh-
like layer outside the plasma membrane (Typas et al, 2012). In plants, the energy 
produced by photosynthesis is stored as starch, which is a polymer of glucose. 
Glycans can exist alone or attached to lipids, proteins, and DNA to create a variety of 
glycoconjugates. The most common way to classify glycans in eukaryotic cells is 
according to the nature of the linkage to the aglycone (Varki & Sharon, 2009). For 
example, lipids and proteins modified with glycans are called glycosphingolipids and 
glycoproteins, respectively (Fig. 5.1.1). Attachment of glycans to glycoproteins can 
be via N- and O-linkages; therefore, the glycans on proteins can be further divided 
into N-glycans and O-glycans. Other types of glycans also exist in cells (Fig. 5.1.1). 
This chapter will provide only a brief overview of glycoproteins in animal cells and will 
focus on the structure and function of unusual glycosylations of the epidermal growth 
factor (EGF) repeat and thrombospondin repeat (TSR).  
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Adapted from (Varki & Sharon, 2009) 
Figure 5.1.1 Common classes of animal glycans  
Glycans can be found on glycoproteins with N- or O-linkages on Asn and Ser/Thr, 
respectively. Different types of glycans can be covalently linked to lipids to form 
glycosphingolipids. GPI-anchored glycoproteins are a group of proteins anchored to the 
cell surface by lipids via four monosaccharides. Proteoglycans consist of a protein core 
and the covalently attached glycosaminoglycan chains on Ser. Unlike other 
glycoconjugates, O-GlcNAc glycoproteins appear in the cytosol and nucleus. The core 
structures of different types of glycosylation are highlighted with a green background.    
N‐Glycans  
An N-linked glycan consists of an oligosaccharide covalently attached to an 
asparagine residue with the consensus sequence Asn-X-Ser/Thr. All N-glycans 
harbor the same pentasaccharide core structure: three mannose groups on GlcNAc-
GlcNAc (highlighted in green background in Fig. 5.1.1). High-mannose-type N-
glycans have an additional two to six mannose groups on the pentasaccharide core. 
In the complex-type glycans, two mannose groups on the core are modified by 
GlcNAc, and different glycans can link to this GlcNAc. In the hybrid-type N-glycans, 
the mannose groups are attached on the Manα1-6 arm of the core, and are extended 
with GlcNAc on the Manα1-3 arm (Fig. 5.1.2). 
 
Modified from (Stanley et al, 2009) 
Figure 5.1.2 Types of N-glycans  
N-glycans added to the amide group of Asn of the conserved Asn-X-Ser/Thr motif are 
classified into three different types, which share the same Man3GlcNAc2 core structure.  
The transfer of N-glycans takes place in the endoplasmic reticulum (ER) by 
oligosaccharyltransferase (OST), which is a protein complex with nine subunits in 
yeast, that transfers the preformed dolichol-P-P-GlcNAc2Man9GlcNAc2 to nascent 
proteins with the conserved sequon (Schwarz & Aebi, 2011). From the ER to the 
Golgi apparatus, many glycosyltransferases and glycosidases may be involved in 
processing the N-glycan structure on the protein. The process of adding/removing 
glycans is not template-driven; therefore, the same protein expressed in different cell 
types or even the same cell type but in different physical conditions may have a 
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different N-glycan structure, which depends on many factors such as the nutritional 
condition and the types of glycosyltransferases and glycosidases in the cellʼs 
secretory pathway. 
The functions of N-glycans include quality control of proteins, maintenance of half-life 
of proteins in the cell, and regulation of cell-cell and cell-matrix interactions (Lowe & 
Marth, 2003; Ruddock & Molinari, 2006). In humans, a growing number of diseases 
with impairments in the N-glycosylation pathway have been identified, and the 
importance of a group of diseases called congenital disorders of glycosylation (CDG) 
is emerging (Chapter 5.3).  
O‐GalNAc modification   
O-glycosylation is a common protein modification on the hydroxyl side chain of serine 
and threonine. The most abundant type of protein O-glycosylation is O-linked N-
acetylgalactosamine (GalNAc) via an α-linked O-glycosidic bond to proteins. Many 
mucins (a type of glycoprotein in mucus) are highly glycosylated with O-linked 
GalNAc; therefore, O-GalNAc glycans are also called mucin O-glycans. The 
synthesis of mucin type O-glycans is initiated by transferring GalNAc from UDP-
GalNAc to Ser/Thr on proteins catalyzed by the enzyme N-
acetylgalactosaminyltransferase (ppGalNAcT). The α-linked GalNAc on the protein is 
called the Tn antigen, and all mucin O-glycans have this core structure (Table 5.1.1). 
PpGalNAcT is a type II membrane protein with a short transmembrane domain and a 
catalytic domain facing the lumen of the Golgi (Fritz et al, 2006). The consensus 
sequence on the protein for recognition by ppGalNAcT has not been determined, but 
it is known that a proline next to the Ser/Thr may increase the occupancy of O-
GalNAc, which may be because proline can cause a β-turn on the protein to expose 
the hydroxyl group of Ser/Thr to ppGalNAcT.  
Table 5.1.1 Core structures of mucin O-glycans 
 
Adapted from (Brockhausen et al, 2009) 
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The GlcNAc of the Tn antigen can be extended at 3- and 6-hydroxul group, which 
results in different core structures (Table 5.1.1). Synthesis of the core 1 structure is 
catalyzed by core 1 β1,3 galactosyltransferase (C1GalT-1), which transfers a 
galactose to the 3-position of GalNAc and produces core 1 Galβ1-3GalNAc 
dissacharide (Fig. 5.1.3). The core 1 structure can be branched at the 6-position of 
GalNAc by a GlcNAc residue, and the trisaccharide product is the core 2 structure. 
This reaction is catalyzed by C2 β1-6 N-acetylglucosaminyltransferase (C2GnT).  
 
Adapted from (Brockhausen et al, 2009) 
Figure 5.1.3 Biosynthesis of core 1 to core 4 O-GalNAc structures 
The core structures of mucin O-glycans are synthesized by different 
glycosyltransferases. The final structure of the O-glycan may be determined by the 
activities of different glycosyltransferases. For example, if the activity of 
sialyltransferase is high, the chains will normally be short and terminated with sialic 
acid.  
The core 3 structure is synthesized by elongation of the Tn antigen with GlcNAc on 
the 3-position. An additional GlcNAc linked to the 6-position GalNAc on the core 3 
structure produces the core 4 structure (Fig. 5.1.3). The glycosyltransferases 
responsible for synthesizing the core 3 and core 4 structures are β1,3 and β1,6 N-
acetylglucosaminyltransferase, respectively. Core 5 to Core 8 structures are more 
tissue specific, and the enzymes that synthesize these structures remain to be 
characterized.  
Different glycan epitopes such as ABO blood group antigens and Lewis-type 
antigens can be linked to different core structures; fucose, sialic acid, and sulfate that 
are common on other glycoconjugates can also be found on mucin O-glycans. 
Overall, the different core structures and diverse glycan structures that can extend 
from the core structure make mucin O-glycans complicated molecules for analysis.  
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O-GalNAc glycans on mucins are important for the function of mucins. These glycans 
are usually hydrophilic with a negatively charged sialic acid that promotes the binding 
of water and salt on mucins and contributes to the viscosity and adhesiveness of 
mucus. These properties provide the physical barrier between the lumen and 
epithelium. O-GalNAc glycans are also involved in the interaction between 
leukocytes and endothelial cells; hence, they regulate leukocyte homing and 
inflammation. The interaction is mediated by the selectins expressed on the 
endothelial cell and sialyl LewisX antigen on core 2 O-glycans. Mice lacking C2GnT-1 
activity, the key enzyme for core 2 O-glycan synthesis, have severe deficiencies in 
their immune system, such as reducing neutrophil rolling on substrates bearing E-, L-, 
and P-selectins (Ellies et al, 1998). Changes in the biosynthesis of glycan structures 
have been observed in cancers (Chapter 5.3). A recent study showed that increased 
expression of C2GnT-1 and the resulting up-regulation of the sialyl LewisX epitope on 
core 2 O-glycans mediated the adhesive and invasive behaviors of human 
carcinomas, which may influence their metastatic potential (St. Hill et al, 2011). 
O‐GlcNAc modification  
O-GlcNAc is a unique type of protein glycosylation compared to N-glycans and mucin 
O-glycans. (1) O-GlcNAc exists as a single sugar modification, and is not extended 
by other glycans. (2) The O-GlcNAc modification is reversible; the O-GlcNAc groups 
can be attached and removed multiple times from proteins. (3) The “classic” O-
GlcNAc reaction occurs in the nuclear and cytoplasmic compartments, while other 
glycosylations occur in the ER or Golgi in secretory pathways. Although a rare O-
linked GlcNAc has been found on the EGF repeat, it is catalyzed by a distinct 
glycosyltransferase that will be discussed later. 
The enzyme that catalyzes O-GlcNAcylation is O-GlcNAc transferase (OGT), which 
is a cytosolic and nuclear protein with two distinct regions: the tetratricopeptide 
repeat and a multidomain catalytic region (Lazarus et al, 2011). Unlike other 
glycosylations, which are generally static, the cycling of O-GlcNAcylation has been 
observed, which is coordinated by a cytosolic and nuclear β-N-
acetylglucosaminidase (O-GlcNAcase) (Fig. 5.1.4). The cycling of O-GlcNAc on 
regulatory proteins responds rapidly to metabolic and environmental signals at rates 
comparable to phosphorylation (Hart et al, 2007). 
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Adapted from (Hart et al, 2007) 
Figure 5.1.4 Cycling of O-linked GlcNAc  
O-GlcNAcylation on serine or threonine is controlled by two highly conserved enzymes: 
OGT and O-GlcNAcase. The cycling rate of O-GlcNAcylation is similar to that of O-
phosphorylation in response to various stimulations.  
The activity of OGT is controlled by the concentration of its sugar-donor UDP-GlcNAc, 
which is sensitive to metabolic molecules such as glucose, fatty acids, and 
nucleotides, making it an ideal sensor for nutritional status (Hart & Akimoto, 2009). In 
the cell, approximately 2%–5% of intracellular glucose enters the hexosamine 
biosynthesis pathway and produces GlcNAc. Hyperglycemic cells have a higher 
concentration of GlcNAc and UDP-GlcNAc, and therefore up-regulate the activity of 
OGT. Thus, the extent of protein O-GlcNAcylation is often considered to be sensitive 
to nutrient availability. 
The importance of O-GlcNAc is partially contributed by the fact that O-GlcNAc is 
ubiquitous in proteins belonging to different functional classes, ranging from proteins 
involved in transcription/translation to protein metabolism in response to stress and 
signaling (Hart & Akimoto, 2009). Furthermore, O-GlcNAc can interplay with O-
phosphorylation (Fig.5.1.5). O-GlcNAc and O-phosphate can compete for the same 
site, and the site occupied by one modification excludes the other modification or 
there can be two adjacent available modification sites, and the O-linked GlcNAc is 
required for O-linked phosphorylation on the adjacent site (Hart et al, 2007).  
 
Adapted from (Hart et al, 2007) 
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Figure 5.1.5 Dynamic interplay between O-GlcNAc and O-phosphate 
(A) In some proteins, O-GlcNAc and O-phosphate compete dynamically for the same 
modification site. (B) In other proteins, O-GlcNAc and O-phosphate can occur next to 
each other. The presence of O-GlcNAc can increase the occupancy of the phosphate 
site. 
The ubiquitous existence of O-linked GlcNAc on proteins in various functional 
classes may reflect the diverse function of O-GlcNAc glycans. Similar to protein 
phosphorylation, the specific function of O-GlcNAc is related to the O-GlcNacylated 
protein. For example, if O-GlcNAc is on the transcription factor Sp1, the modification 
will interfere with the binding of Sp1 to other transcription factors, and thus, it will 
down-regulate gene expression controlled by Sp1 (Lim & Chang, 2009). OGT can 
also sense the nutritional status and respond by up- or down-regulating its activity 
accordingly. This regulation is mediated by the concentration of UDP-GlcNAc. In cells 
with high concentration of glucose, the concentration of UDP-GlcNAc is also high, 
which increases the activity of OGT. Studies have shown that increased O-GlcNAc 
on proteins mimics hyperglycemia, which caused insulin resistance in a mouse 
model, and mice overexpressing OGT displayed features of type II diabetes (McClain 
et al, 2002; Vosseller et al, 2002b). These results indicate that O-GlcNAc is 
increased in response to high glucose, and elevated levels of O-GlcNAc on proteins 
inhibits insulin signaling (Vosseller et al, 2002a). 
Glycosylation of epidermal growth factor repeat 
Notch receptors are transmembrane proteins of around 300 kDa that play an 
important role in developmental pathways (Rana & Haltiwanger, 2011; Stanley, 2007). 
The dysregulation of Notch signaling pathways can cause developmental diseases 
and some types of cancer (Bolos et al, 2007). Drosophila possess only one Notch 
receptor, while there are four Notch receptors in mammals (Kopan & Ilagan, 2009).  
The extracellular domain of Notch receptors consists primarily of 26–36 EGF-like 
repeats; some of these EGF repeats mediate interactions with Notch ligands. EGF 
repeats are small protein motifs with six conserved cysteines that form three disulfide 
bonds, which contribute to the unique three-strand three-dimensional structure of the 
small EGF protein (Hiruma-Shimizu et al, 2010). On the EGF repeat of Notch 
proteins, in addition to the conventional N-glycans, three other rare O-linked glycans 
have been observed: O-fucose, O-glucose, and O-GlcNAc (Matsuura et al, 2008; 
Moloney et al, 2000b). Recent studies of these rare O-linked glycosylations have 
shown the importance of glycosylation on regulating Notch signaling.  
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In the Notch signaling pathway in Drosophila, Delta which is the Notch ligand on the 
signal-sending cell binds to the extracellular domain of Notch receptors (NECD) on 
signal-receiving cells. The receptor-ligand binding activates three sequential 
proteolytic cleavages. The first cleavage is at the S2 site (Figs. 5.1.6 and 5.1.7) 
catalyzed by the ADAM10 metalloprotease. This cleavage generates a membrane-
bound Notch extracellular truncation (NEXT) and releases NECD (Fig. 5.1.6). 
Sequential cleavages then occur at the S3 and S4 sites catalyzed by the γ-secretase 
complex, which releases the Notch intracellular domain (NICD). The NICD is 
translocated to the nucleus, and then complexes with the CSL family of transcription 
factor (CBF1 in vertebrates, Su in flies and Lag1 in worms), recruits the co-activator 
Mastermind (Maml), and activates Notch target genes, including transcriptional 
regulators such as Hey genes (Jarriault et al, 1995). 
 
Adapted from (Jafar-Nejad et al, 2010) 
Figure 5.1.6 Notch signaling pathway 
Notch synthesis begins in the ER where it is glycosylated by Pofut1 and Rumi, which 
generate O-linked fucose and glucose, respectively. In the Golgi, GlcNAc and xylose 
are added to fucose and glucose by Fringe and GXYLT, respectively. The S1 cleavage 
generates a heterodimeric form of Notch, which is composed of the extracellular 
(NECD, black box) and intracellular (NICD, red box) domains of Notch. Binding of 
ligands to the NECD results in the S2 cleavage of Notch. Notch is further cleaved at the 
S3/S4 sites. NICD is then translocated into the nucleus, and activates target genes with 
other components. 
O-Fucosylation on the EGF repeat was first described on pro-urokinase (Kentzer et 
al, 1990), and this modification has since been found on the other proteins with EGF 
repeats such as the Notch receptor and coagulation factors with the consensus 
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sequence C2XXXX(S/T)C3 (Haines & Irvine, 2003; Moloney et al, 2000b). EGF 
repeats with this consensus sequence are substrates for the protein O-
fucosyltransferase 1 (POFUT1). POFUT1 is a soluble ER-resident enzyme that 
recognizes properly folded EGF repeats and transfers fucose from GDP-fucose to the 
consensus site (Luo & Haltiwanger, 2005). The importance of Pofut1 was revealed 
by mice lacking POFUT1 activity; Pofut1-/- mice died at midgestation (E10) with 
severe defects in somitogenesis, vasculogenesis, cardiogenesis, and neurogenesis, 
similar to mice with blocked Notch signaling pathways due to global inactivation of 
Notch receptor signaling (Shi & Stanley, 2003). Down-regulation of OFUT1 (the 
POFUT1 homolog in Drosophila) by RNAi demonstrated that OFUT1 regulates Notch 
signaling via Fringe-independent and Fringe-dependent pathways (Okajima & Irvine, 
2002). In the Fringe-independent pathway, OFUT1 acts as a molecular chaperone 
and promotes the folding and secretion of Notch to the cell surface. Notch 
accumulated in the ER in OFUT1 mutant cells and the phenotype can be rescued by 
an enzymatically inactive R254A OFUT1. These data suggest that the enzyme 
activity is indispensible (Okajima et al, 2005). However, the chaperone-like activity of 
OFUT1 that aids in the secretion of the Notch receptor to the cell surface is limited to 
Drosophila. In mammalian cell systems, murine Pofut1-/- cells showed the same 
expression level of the Notch receptor compared to wild-type cells, although deficient 
Notch signaling in Pofut1-/- cells was observed (Stahl et al, 2008). These data 
suggest that differences exist between OFUT1 in Drosophila and POFUT1 in 
mammals with respect to the regulation of Notch receptor secretion. 
 
Modified from (Jafar-Nejad et al, 2010) 
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Figure 5.1.7 O-Glycosylation on EGF repeats 
A schematic representation of full-length Drosophila Notch is shown. Thirty-six EGF 
repeats followed by the negative regulatory region (NRP) constitute the extracellular 
domain. Four Notch cleavage sites (S1–S4) are indicated with arrows before the trans-
membrane (TM) domain. The intracellular domain contains an RBP-J association 
module (RAM), two nuclear localization signals (NLS), seven Ankyrin repeats (ANK), 
and a PEST domain. The consensus sequences for O-linked glucose, fucose, and 
GlcNAc on EGF repeats are highlighted in boxes. Glycosyltransferases involved in the 
glycosylation of the three O-glycosylation pathways are given next to the 
monosaccharides represented in cartoons.  
Interestingly, Fringe was known to play an important role in the regulation of dorsal-
ventral boundary formation in Drosophila wings, presumably via the Notch signaling 
pathway, before it was identified as a glycosyltransferase (Cohen et al, 1997; Irvine & 
Wieschaus, 1994; Panin et al, 1997). Later, Fringe was shown to be the 
glycosyltransferase responsible for transferring a GlcNAc specifically to the O-linked 
fucose on the EGF repeat. More importantly, the glycosyltransferase activity of 
Fringe regulates Notch signaling (Bruckner et al, 2000; Moloney et al, 2000a). How 
does glycosylation regulate Notch signaling? Recombinant Notch expressed on the 
cell surface with Fringe was shown to bind significantly better to cells expressing 
Delta than to cells expressing Serrate. In contrast, Notch was shown to bind better to 
Serrate than to Delta when Notch was expressed in the absence of Fringe. These 
results suggest that Fringe determines the ligand specificity of Notch (Okajima et al, 
2003). Another experiment using purified components in the Notch signaling pathway 
demonstrated that the addition of GlcNAc to O-fucose in vitro was sufficient to both 
enhance Notch binding to the Delta ligand and to inhibit Notch binding to the Serrate 
ligand (Xu et al, 2007). These observations suggest that GlcNAc-Fuc-O disaccharide 
produced by POFUT1 and Fringe works as a boundary-specific cell-signaling 
molecule that is responsible for dorsal-ventral cell interactions during wing 
development (Fig. 5.1.8). 
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Adapted from (Panin et al, 1997) 
Figure 5.1.8 Notch component interactions at the dorsal–ventral compartment border  
Delta (DI in pink) and Notch (N in brown) are broadly expressed during early wing 
development, while Fringe (Fng in blue) and Serrate (Ser in green) are restricted to 
dorsal cells. For clarity, not all proteins and potential protein interactions have been 
included. Expression of Fng allows dorsal cells to respond to Dl, resulting in Notch 
activation, which leads to transcription of downstream genes, including Ser. Ser signals 
back from dorsal to ventral cells, activating Notch, which leads to the transcription of 
downstream genes, including Dl. Fng blocks the ability of Ser to signal to other dorsal 
cells. 
In Drosophila, the final product of the O-linked fucosylation pathway is the GlcNAc-
Fuc disaccharide, and this disaccharide is sufficient for binding to Delta and 
modulating the Notch signaling pathway (Xu et al, 2007). In mammals, O-fucose can 
be extended further to a tetrasaccharide containing Siaα2,3/6Galβ1,4GlcNAcβ1,3 
Fucα1-O-Ser/Thr (Fig. 5.1.7) (Harris & Spellman, 1993). Elongation of the 
disaccharide is catalyzed by the Golgi-resident glycosyltransferases β1,4-
galactosyltransferase (β4GalT-1) and α2,3/6-sialyltransferase (Fig. 5.1.7). It has 
been shown that in the CHO cell system, GlcNAcβ1,3Fuc disaccharide is necessary, 
but not sufficient, for the Notch receptor to inhibit Jagged-1-induced Notch activation. 
By restoring the tetrasaccharide on the EGF repeat by transfecting β4GalT-1 into the 
cell, the Notch receptor regained the ability to inhibit Jagged-1-induced signaling. 
Therefore, in mammalian cells, β4GalT-1 is required for Fringe to modulate Jagged1-
induced Notch (Chen et al, 2001). 
O-Glucose was first identified on the EGF repeat from bovine blood coagulation 
factors VII and IX (Hase et al, 1988; Hase et al, 1990), and was later found on the 
EGF repeat of the Notch receptor. O-Glucose on the EGF repeat can be extended to 
Xylα1,3Xylα1,3Glcβ1-O-Ser (Moloney et al, 2000b). In contrast to the well-
  16 
5. General Introduction 
characterized O-fucosylation on the Notch signaling pathway, the importance of the 
O-glucose trisaccharide has emerged just recently. The glycosyltransferase 
responsible for transferring glucose from UDP-glucose to serine on the consensus 
C1-X-S-X-P-C2 sequence on the EGF repeat was first identified in Drosophila and 
was named Rumi (Acar et al, 2008). Rumi is a soluble, ER-retained protein. Loss of 
Rumi activity in flies caused a temperature-sensitive Notch phenotype, since Notch 
could not be cleaved properly despite normal binding to Delta. Notch also 
accumulated inside the cell and at the cell surface in flies without Rumi activity. The 
authors suggested that the lack of Rumi activity did not affect Notch binding to its 
ligand, but prevented S2 cleavage and affected the surface expression of Notch 
(Acar et al, 2008; Jafar-Nejad et al, 2010). The ortholog of Rumi in humans has also 
been recently identified (Takeuchi et al, 2011). Interestingly, the authors observed 
that Rumi is not only a glucosyltransferase, but also a xylosyltransferase that can 
transfer xylose from UDP-xylose to proteins with almost the same efficiency as 
glucose. The specificity for the dual substrates of Rumi is partially affected by the X 
residue after the glycosylated serine. Rumi only adds xylose when the second X is 
serine in the consensus sequence (C1-X-S-S-P-C2) (Takeuchi et al, 2011). This result 
suggests that the specificity of Rumi for donor substrates is influenced by the 
structure of the sugar acceptor. In a mouse model, the Rumi-/- mouse embryos died 
before embryonic day 9.5 with posterior axis truncation and defects in neural 
development, somitogenesis, cardiogenesis, and vascular remodeling (Fernandez-
Valdivia et al, 2011). These data indicate that O-glucosylation, like O-fucosylation on 
Notch, also plays a crucial role during mammalian development.  
Other xylosyltransferases that extend Glc-O-Ser have been identified. Two enzymes 
named GXYLT1 and GXYLT2 (glucoside xylotransferase 1 and 2) are responsible for 
elongating Glc-O-Ser to Xyl-Glc-O-Ser (Sethi et al, 2010). The final 
glycosyltransferase that transfers the last xylose to the Xylα1,3-Glu disaccharide to 
generate the final trisaccharide product Xylα1,3Xylα1,3Glcβ1-O-Ser on the EGF 
repeat has recently been reported to be XXYLT1 (xyloside xylosyltransferase 1) 
(Sethi et al, 2012).  
The last rare O-glycosylation on the EGF repeat is O-linked GlcNAc. Modification site 
mapping by mass spectrometry and amino acid substitution studies revealed that the 
O-GlcNAc modification occurs on a serine or threonine located between the fifth and 
sixth cysteine residues within the EGF domain (Fig. 5.1.7). Although O-GlcNAc has 
been found on cytoplasmic and nuclear proteins, O-GlcNAc on the EGF repeat was 
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the first example of the modification on an extracellular protein (Matsuura et al, 2008). 
The glycosyltransferase for O-GlcNAc on the EGF repeat is not OGT, which 
catalyzes the modification on intracellular proteins (Kreppel et al, 1997). The novel 
glycosyltransferase responsible for O-GlcNacylation was recently reported to be 
Eogt1 in Drosophila and mice (Sakaidani et al, 2012; Sakaidani et al, 2011). The 
function of O-GlcNAc on the EGF repeat is still unknown.   
Glycosylation on the thrombospondin type 1 repeat  
The TSR is a cysteine-rich motif of ~50 amino acids with three disulfide bonds (the 
detailed structure of the TSR is presented in Chapter 5.4). Two types of 
glycosylations have been demonstrated on TSRs (Fig. 5.1.9). The Glcβ1,3Fuc 
disaccharide was first identified from the urine of a normal individual with an O-linked 
fucose (Hallgren et al, 1975). More than 20 years later, the same disaccharide was 
identified on the protein from CHO cell line by size-exclusion chromatography and 
high pH anion-exchange chromatography (Moloney et al, 1997). Later Jan 
Hofsteenge and coworkers identified this disaccharide when they were analyzing 
another rare glycosylation, C-mannosylation on TSRs of thrombospondin-1 
(Hofsteenge et al, 2001). Since then, the disaccharide has been reported to be 
present on TSRs of F-spondin, properdin, ADAMTS13, and ADAMTS-like punctin-1 
(Gonzalez de Peredo et al, 2002; Ricketts et al, 2007; Wang et al, 2007). The 
consensus sequence CX2-3(S/T)CX2G of O-fucosylation was determined by analyzing 
14 TSR peptides from F-spondin, properdin, and TSP-1 by mass spectrometry 
(Gonzalez de Peredo et al, 2002). The database search with the consensus 
sequence identified 51 proteins with various numbers of the fucosylation sequence in 
mice (Table 5.1.2), which included 10 transmembrane proteins and 41 secreted 
proteins that regulate diverse cellular processes such as cell adhesion, differentiation, 
and anti-angiogenesis (Du et al, 2010; Tucker, 2004).  
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Figure 5.1.9 TSR O- and C-glycosylation on thrombospondin-1 
A schematic representation of thrombospondin-1 is shown. The length of the protein 
corresponding to the amino acid is indicated on the top. The sequence with C-linked 
and O-linked glycosylation sites on TSR1 is provided in the box. The synthesis of the 
Glcβ1,3Fuc disaccharide is catalyzed by POFUT1 and β3Glc-T. The 
glycosyltransferase for C-mannosylation hasnʼt been identified. TSN, thrombospondin 
N-terminal domain; vWC, von Willebrand factor type A domain; T, thrombospondin type 
1 repeat; E, EGF-like domain; TSR3, thrombospondin type 3 domain; TSC, 
thrombospondin C-terminal domain.  
Both EGF repeats and TSRs are protein motifs that can be O-fucosylated in the ER, 
but these two proteins are fucosylated by different O-fucosyltransferases (Luo et al, 
2006b). The fucosyltransferase for O-fucosylation of TSRs is protein O-
fucosyltransferase 2 (POFUT2). POFUT2 is located to the ER, although no ER-
retaining sequence has been identified. POFUT2 transfers fucose from GDP-fucose 
to properly folded TSRs (Luo et al, 2006a). While the function of O-fucosylation on 
EGF repeats has been explored extensively in the Notch signaling pathway, the 
molecular mechanism of O-fucose on TSRs remains unknown. Mutations in the 
fucosylation sites in ADAMTS13 and ADAMTS-like-1/punctin-1 decrease the 
secretion of these two proteins. Moreover, the secretion efficiency of these two 
proteins in Lec13 cells was restored when fucose was supplemented in the culture 
medium, suggesting that O-fucosylation catalyzed by POFUT2 is required for protein 
secretion. The importance of O-fucosylation on TSRs has recently been shown in 
Pofut2-/- mice. The homozygous embryos died before E10.5, i.e., when gastrulation 
and organogenesis occur. These data demonstrated that O-fucosylation of TSRs is 
essential for restricting the epithelial-to-mesenchymal transition in the primitive streak, 
correct patterning of the mesoderm, and localization of the definitive endoderm (Du et 
al, 2010).  
 
Adapted from (Du et al, 2010) 
Table 5.1.2 Mouse proteins with a putative fucosylation site on TSRs 
The mouse proteins containing putative fucosylation sites from a database search with 
the consensus sequence are listed in two groups according to different disulfide bond 
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patterns. Proteins with O-linked fucose that have been evaluated experimentally are 
underlined.  
The elongation of O-linked fucose to the Glcβ1,3Fuc-O disaccharide is catalyzed by 
β1,3-glucosyltransferase (β3Glc-T) (Kozma et al, 2006; Sato et al, 2006). β3Glc-T 
uses UDP-glucose as the sugar donor and transfers it to the 3-position of O-linked 
fucose on the TSR. Like POFUT2, β3Glc-T is also localized to the ER compartment, 
but unlike POFUT2, it has a KDEL-like (REEL) retaining signal on the C-terminus. 
Deletion of REEL resulted in the accumulation of β3Glc-T in culture medium 
(unpublished data from Kozma). β3Glc-T can only glycosylate properly folded 
fucosylated TSR4 but not fucosylated EGF repeat although β3Glc-T share 28% 
sequence identity with Fringe (Kozma et al, 2006). In humans, mutations in the gene 
encoding β3Glc-T cause a rare developmental disease called Peters plus syndrome 
(details are in Chapter 5.3).  
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5.2 Structure and catalytic mechanism of glycosyltransferases  
The diverse structures of glycans on molecules are primarily determined by the 
assembling and trimming of the sugars mediated by GTs and glycosidases, 
respectively. Glycosyltransferases are a group of enzymes that catalyze the transfer 
of a sugar from an activated sugar donor to a sugar acceptor. The most common 
activated sugar donors are the nucleotide diphosphate sugars such as GDP-fucose; 
other types of sugar donors, including nucleotide monophosphate sugars (e.g., CMP-
Neu5Ac) or lipid phosphate sugars (e.g., Dolichol-P-mannose), are also used. 
Oligosaccharides, the most common sugar acceptor, as well as proteins, lipids, and 
nucleic acids, can act as substrates for glycosyltransferases (Fig. 5.1.1).  
 
Adapted from (Rini et al, 2009) 
Figure 5.2.1 A variety of donors and substrates are used by glycosyltransferases 
In vertebrates, glycosylation is a two-substrate reaction involving the transfer of the 
sugar moiety from glycosyl donors to the acceptors. The most common sugars and 
acceptors are listed. 
Currently, more than 30,000 glycosyltransferase sequences are known. They 
constitute about 1% of the mammalian genome (Lowe & Marth, 2003). Based on 
protein sequence similarity, they have been further categorized into 94 families in the 
carbohydrate-active enzyme (CAZy) database (Cantarel et al, 2009).  
Structural folds of glycosyltransferase  
In contrast to the diverse substrate specificity of glycosyltransferases and the 
enormous diversity of glycan structures that can be produced, structural analysis has 
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shown that glycosyltransferases only adopt a limited number of folds. The structure 
of GT-A and GT-B folds of glycosyltransferases, which usually utilize nucleotide 
sugars as the donor, are shown in Fig. 5.2.2A and B, respectively. Recently, the 
structure of GT-C, which uses lipid sugars as the donor, was elucidated (Lizak et al, 
2011), and is shown in Fig. 5.2.2C. Details of each structural fold and catalytic 
mechanism of glycosyltransferase are discussed below. 
 
Figure 5.2.2 Structural comparison of glycosyltransferases with different folds  
The GT-A fold in (A) is β4Gal-T1 from Bos taurus, PDB: 1fgx (Gastinel et al, 1999). The 
GT-B fold in (B) is from bacteriophage T4 β-glucosyltransferase, PDB: 1jg7 (Vrielink et 
al, 1994). GT-C is the bacterial oligosaccharyltransferase PglB from Campylobacter lari, 
PDB: 3rce (Lizak et al, 2011). All the structures are represented as ribbons. The α-
helices are colored in yellow, and the β-sheets are colored in blue. The size of each GT 
is indicated below the structure. 
Structure and catalytic mechanism of GT‐A glycosyltransferase 
The overall structure of glycosyltransferases with the GT-A fold consists of β-sheets 
surrounded by α-helices (Fig. 5.2.2A). It consists of two dissimilar Rossmann-like 
motifs tightly associated with each other. The Rossmann-like fold is found on proteins 
that bind nucleotides and is responsible for binding the nucleotide sugar-donor 
substrate in glycosyltransferases.  
Most GT-A glycosyltransferases have the DXD (Asp-X-Asp) signature motif for 
coordinating divalent metal ions. The metal ion plays an important role in binding the 
sugar donor by interacting with one or both acidic residues of the DXD motif and with 
the oxygen atoms from the phosphate group of the nucleotide sugar; therefore, it 
plays a crucial role in sugar-donor binding.  
One of the most well-characterized GT-A glycosyltransferases is β1,4-
galactosyltransferase 1 (β4Gal-T1) (Gastinel et al, 1999; Qasba et al, 2005; Qasba et 
al, 2008; Ramakrishnan et al, 2002; Ramakrishnan & Qasba, 2002). β4Gal-T1 is a 
membrane-bound enzyme that resides in the Golgi; it transfers galactose from 
uridine diphosphate galactose (UDP-Gal) to the terminal GlcNAc residue to form N-
55 Å 50 Å36 Å
A.  GT-A B.  GT-B C.  GT-C
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acetyllactosamine. The reaction catalyzed by β4Gal-T1 follows a sequential ordered 
mechanism (Fig. 5.2.3). The nucleotide sugar donor and metal ion bind to the 
enzyme, which induces a conformational change that converts the enzyme from an 
open conformation to a closed conformation. This conformational change creates an 
acceptor-binding site for the incoming sugar acceptor. After catalysis, the product 
release from the complex is also sequential. The glycosylated acceptor is released 
first, followed by the nucleotide, which converts the enzyme back to the open 
conformation for another cycle of catalysis.  
  
Adapted from (Ramasamy et al, 2005) 
Figure 5.2.3 The catalytic mechanism of β4Gal-T1 
The catalytic cycle of glycosyltransferase starts with the enzyme (E) in the open 
conformation. The binding of nucleotide sugar (N-S) and metal ion (m) converts it to the 
closed conformation (E*). After product release, E* converts back to the open 
conformation.  
The conformational change upon nucleotide sugar binding is not unusual in the 
proteins with a GT-A fold. Although the region that undergoes the conformational 
change may not be identical among glycosyltransferases, it is invariably located near 
the sugar donor-binding site. In β4Gal-T1, two flexible loops have been identified: a 
short loop made up of the residues 313–316 and a long loop made up of the residues 
345–365 (Ramasamy et al, 2003). In the apo-structure (open conformation), the 
active site residues in the loops are located away from the catalytic site. UDP-Gal 
binds to the β4Gal-T1 with the metal ion in the open conformation, which induces a 
conformational change in the flexible loop region (Fig. 5.2.4). The large loop (I345–
H365) flips from the open conformation to close the UDP-Gal binding site. The closed 
conformation also provides interactions between the long-loop residues and UDP-Gal 
and reduces accessibility to water in the active site. In addition, W314 in the short 
loop is oriented to bind to UDP in the closed conformation. The conformational 
change also creates an acceptor-binding site. Thus, an ordered binding of the donor 
and acceptor substrates is ensured. 
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Adapted from (Qasba et al, 2008) 
Figure 5.2.4 Conformational change upon sugar nucleotide binding 
The loops shown by green ribbons are in the open conformation. In the closed 
conformation (magenta), W314 faces the catalytic pocket.   
Structure and catalytic mechanism of GT‐B glycosyltransferase  
Similar to the GT-A fold, the architecture of the GT-B fold consists of two Rossmann-
like domains. While the two domains have dissimilar sizes and are in close proximity 
in the GT-A fold, the sizes of the two Rossmann-like domains in the GT-B fold are 
similar and they are further apart, which creates a cleft between the two domains (Fig. 
5.2.2B). 
The prototypical GT-B fold of glycosyltransferases is β-glucosyltransferase (BGT) 
from the bacterial phage T4 (Vrielink et al, 1994), which uses UDP-glucose as the 
sugar donor and 5-hydroxymethylcytosine (5-HMC) in the viral DNA as the acceptor. 
Glycosylation of DNA can protect the DNA from host restriction enzymes.  
The structure of BGT is comprised of two Rossmann-like folds (Fig. 5.2.5), separated 
by a central cleft. The structure of BGT in complex with DNA and UDP revealed that 
UDP and the 13-mer DNA bind to the inter-domain cleft (Lariviere & Moréra, 2002).   
 
DNA
UDP
D100
N-terminal domain C-terminal domain
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Figure 5.2.5 Structure of BGT in complex with DNA and UDP 
The structure of BGT in complex with a 13-mer DNA and UDP (Lariviere & Moréra, 
2002). BGT is shown by cartoon representation with α-helices colored in yellow and β-
sheets colored in blue. The DNA and UDP are shown as sticks. D100 indicated in the 
structure acts as the catalytic base in the direct-displacement catalytic mechanism.  
The conformational change observed in GT-A glycosyltransferases upon sugar-donor 
binding has also been observed in GT-B glycosyltransferases. Comparison of the two 
apo-BGT structures in different crystal forms with the UDP-BGT binary complex 
indicated that the UDP-BGT complex structure is more compact (Fig. 5.2.6). In the 
presence of UDP, BGT adopts a closed conformation. The conformational change 
originates from rigid body movement of the C-terminal to the N-terminal domain; the 
C-terminal domain of the UDP-BGT rotates 14º to the N-terminal domain compared 
to the apo-BGT structure. In contrast to the conformational change induced by 
binding to UDP, binding of a metal ion had no obvious effect on the structure of BGT 
(Moréra et al, 2001).  
  
Adapted from (Moréra et al, 2001) 
  Figure 5.2.6 Stereo view of rigid body movement in BGT 
Superposition of BGT on the N-terminal domains from apo-BGT (dark blue: tetragonal 
crystal, and orange: orthorhombic crystal), BGT-UDP-Mg2+ complex (light blue), and 
metal-free UDP-BGT complex (red). The Mg2+ is shown as a light blue sphere. UDP is 
shown by red sticks.  
The combined structural and biochemical data of BGT indicate the catalytic 
mechanism of BGT. Asp100 (D100) acts as the catalytic base, which is in close 
proximity to the C1 carbon of UDP-glucose and 5-hydroxymethyl group of 5-HMC 
(Larivière et al, 2003). D100 deprotonates 5-HMC, which then attacks the anomeric 
C1 carbon of UDP-glucose, and forms the oxocarbenium ion transition state (see 
below). The crystal structure of the D100A-BGT mutant in complex with UDP-glucose 
further confirms that D100 is the catalytic base. UDP-glucose was hydrolyzed to UDP 
and glucose in the crystallization process in the presence of an active enzyme; 
however remained intact in the D100A complex structure (Larivière et al, 2003).       
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Structure and catalytic mechanism of GT‐C glycosyltransferase  
Glycosyltransferase with the GT-C fold were first predicted by amino acid sequence 
analysis; 5 families were determined to contain the GT-C fold (Liu & Mushegian, 
2003). Currently, family 22, 39, 50, 57, 58, 59, 66, 83, 85 and 87 in the CAZY 
database are predicted to adopt the GT-C fold. The architecture of the GT-C fold was 
predicted to have an integral transmembrane domain composed of 8–13 α-helices 
located in the ER or plasma membrane and a soluble region with the active site in 
the lumen. Very recently, the structure of PglB (Fig. 5.2.2C), which is an 
oligosaccharide transferase (OST) for N-glycan synthesis, was determined and 
provided experimental data for the structure of the GT-C fold (Lizak et al, 2011). 
The structure of PglB was solved with the sugar acceptor, which is a six-amino acid-
long peptide (DQNATF). The peptide is located in the region between the 
transmembrane and cytoplasmic domains (Fig. 5.2.7A). The peptide forms a loop 
that turns 180º in the peptide-binding cavity, and presents the glycosylation site to 
the active site. This turn restricts the glycosylation site of PglB, so it must be 
presented on a flexible and surface-exposed loop that allows the peptide to be 
accommodated into the active site. The threonine at the +2 position of the 
glycosylation site stabilizes the interaction with PglB by forming three hydrogen 
bonds with the conserved WWD motif.  
Like other ion-dependent GTs, the activity of OST is dependent on metal ion binding 
(Sharma et al, 1981). A metal ion was identified in the structure of PglB, which is 
located on the right side of the active site cavity (Fig. 5.2.7B). Consistent with the 
DXD motif in the GT-A fold, the GT-C fold has a DXD motif on the connecting loop of 
the transmembrane domain to coordinate the metal ion (D154 and D156). The metal 
ion in the active site also involves binding of the sugar donor. Unlike metal ion 
binding in the GT-A fold, E319 and D56 directly interact with the metal ion through 
the formation of a salt bridge with the metal ion, in addition to the binding interactions 
provided by the DXD motif. These data are consistent with mutational studies where 
single amino acid mutations of D154, D56, or E319 did not completely inactivate the 
enzyme, but double mutations such as D56A/E319A did abolish activity.  
The authors proposed a three-step catalytic mechanism for PglB (Fig. 5.2.7C). The 
binding of the peptide to PglB induces a conformational change of the EL5 loop on 
the transmembrane domain. The EL5 in the apo-PglB is predicted to be flexible and 
disordered; binding orders the loop and restricts the movement of the acceptor in the 
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active site. This conformational change also moves E319 on EL5 to the active site. 
The binding of the sugar donor lipid-linked oligosaccharide (LLO) in the active site 
leads to nucleophilic attack of the amide nitrogen and creates an N-glycan on the 
peptide. The N-glycosylated peptide is then released from PglB, and EL5 moves 
back to the apo-PglB conformation.    
 
Adapted from (Lizak et al, 2011) 
Figure 5.2.7 Structure and catalytic mechanism of PglB  
The periplasmic domain of PglB is colored in green, and the transmembrane domain is 
colored in blue. In (A), the acceptor peptide, shown as sticks, turns 180º in the active 
site. The metal ion is shown in purple, and the sugar donor is modeled in the active 
pocket in white (B). The proposed catalytic mechanism of PglB is shown in (C). The 
first step is the binding of the peptide acceptor (yellow ribbon) in the active site, which 
also induces the conformational change of EL5. The second step is the binding of LLO, 
which results in the glycosylation. The products in the third step return EL5 to its 
original state.  
Catalytic mechanism of glycosyltransferases  
Glycosyltransferases catalyze the formation of a glycosidic bond between the sugar 
donor and the acceptor. During the reaction the configuration of the glycosidic bond 
can be either inverted, which has a different anomeric stereochemistry from the 
sugar donor, or resulted in retention, which retains the same stereochemistry (Fig. 
5.2.8). Based on the outcome of the stereochemistry, glycosyltransferases can be 
classified as either retaining or inverting enzymes, which is correlated to different 
catalytic mechanisms of the glycosyltransferases (Coutinho et al, 2003).   
A C
B
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Adapted from (Lairson et al, 2008) 
Figure 5.2.8 Inverting and retaining reactions  
Glycosyltransferase catalyzes glycan transfer with either inversion or retention of the 
anomeric stereochemistry.  
Mechanism of inverting glycosyltransferases  
Similar to the well characterized catalytic mechanism of the inverting glycoside 
hydrolases, the inverting glycosyltransferases use an SN2 reaction mechanism 
(Murray et al, 1996), which usually uses a general base residue (such as aspartic 
acid, glutamic acid, or histidine) to deprotonate the hydroxyl group on the acceptor. 
The deprotonated acceptor works as a nucleophile and attacks the electrophilic 
center on the sugar donor. A new bond with an inverted anomeric configuration is 
created through the oxocarbenium ion-like transition state (Fig. 5.2.9) 
 
Adapted from (Lairson et al, 2008) 
Figure 5.2.9 Catalytic mechanism of inverting glycosyltransferases  
The inverted anomeric configuration is created via SN2-like reaction mechanism 
through the oxocarbenium ion-like transition state. Rʼ, in light blue, is the acceptor, and 
the sugar is colored in red.   
Mechanism of retaining glycosyltransferases  
The mechanism of retaining glycosyltransferases has been proposed to use a 
double-displacement mechanism with a glycosyl-enzyme intermediate (Fig. 5.2.10). 
In the double-displacement mechanism, an aspartic acid or glutamic acid side chain 
  28 
5. General Introduction 
in the active site attacks the sugar donor resulting in the inversion of the anomeric 
configuration. At this stage, the sugar is covalently linked to the active residue of the 
enzyme, and forms the glycosyl-enzyme intermediate. The phosphate group from the 
sugar donor acts as a base catalyst that deprotonates the sugar acceptor, which then 
attacks the glycosyl-enzyme intermediate in the second displacement step. In the 
second step, the conformation of the glycosyl-enzyme intermediate is again inverted, 
which results in overall retention of the stereochemistry.  
 
Adapted from (Lairson et al, 2008) 
Figure 5.2.10 Double-displacement mechanism for retaining glycosyltransferases  
In the first step, an acidic residue on the enzyme acts as a catalytic residue to attack 
the sugar donor at the C1 position and forms a glycosyl-enzyme intermediate with 
inverted stereochemistry. In the second step, the sugar acceptor attacks the 
intermediate and displaces the sugar to the acceptor with another inversion of the 
configuration. Overall, the stereochemistry is retained.  
  29 
5. General Introduction 
5.3 Dysregulation of Glycosylation and Human Diseases 
The importance of glycosylation has increased in the last decade because of its 
emerging role in human diseases. Based on the differences in the onset of 
dysregulation of glycosylation, diseases can be divided into two types: acquired 
diseases and inherited diseases. This chapter will summarize the human diseases 
related to glycosylation defects.  
Acquired human diseases 
In tumor environment, changes in the glycosylation levels are associated with 
increase in the invasive and metastatic properties of tumor cells. Aberrant 
glycosylation has been shown to be involved in different stages of tumor 
development, such as tumor proliferation, invasion, angiogenesis, and metastasis. 
The function of glycoconjugates in these steps will be discussed in this section. 
 
 
Adapted from (Fuster & Esko, 2005) 
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Figure 5.3.1 Glycans are involved in tumor development  
Various growth-factor receptors are modulated by glycans through oligomerization of 
their respective receptor tyrosine kinase receptors in lipid rafts; this process is 
mediated by gangliosides. (A) GM1 can modulate heterodimerization of the ERBB2-
ERBB3 receptor, and therefore, activate downstream signaling pathways. (B) Up-
regulation of ST6GalNAc I increases the presentation of STn antigen on mucin-type O-
glycans, which facilitates the dissociation of tumor cells. (C) Dissemination of tumor 
cells through the bloodstream is facilitated by the association of tumor cells with 
leukocytes and platelets. The association is modulated by SLea and SLex epitopes on 
the tumor cells and L- and P-selectin on leukocytes and platelets, respectively. E-
selectin on the endothelium arrests tumor cells and facilitates metastasis. (D) 
Angiogenesis is the process of sprouting new blood vessel endothelial cells in 
response to pro-angiogenic factors such as vascular endothelial growth factor (VEGF). 
Heparan sulfate on the endothelial cell surface facilitates VEGF binding and activation 
of downstream signaling.  
Glycoconjugates in tumor proliferation  
Mucins are glycoproteins that contain clustered O-glycans on the core protein 
(Chapter 5.1). Mucins are expressed in most carcinomas in a secretory form or as a 
membrane-bound protein. Altered expression of mucins has been reported in tumors, 
including the up-regulation of MUC4 on the cell surface of adenocarcinoma cells 
(Sherblom et al, 1980). MUC4 contains two EGF-like repeats that can act as ligands 
for the receptor tyrosine kinase ERBB2 (Carraway et al, 1992). The up-regulated 
EGF-like motif can activate ERBB2 in the absence of typical ligands in breast 
carcinoma. In a nude mice model, MUC4 overexpression was shown to 
autophosphorylate ERBB2 and contribute to the suppression of apoptosis (Komatsu 
et al, 2001).   
Gangliosides are a group of sialic acid-containing glycosphingolipids. Gangliosides 
can interact with tyrosine kinase receptors and regulate their phosphorylation. 
Overexpression of ganglosides has been reported in many cancer types (Hakomori, 
1990). In the membrane of breast cancer cells, gangliosides regulate the formation of 
heterodimer receptors as lipid rafts on the membrane (Fig. 5.2.1A). The formation of 
the heterodimer receptor is crucial for responding to growth factor stimulation, 
thereby inducing cell proliferation (Nagy et al, 2002).  
Glycoconjugates in tumor invasion  
Invasion is a process whereby the tumor cell detaches from the original location and 
migrates to other tissues, which requires the cell to modify the receptors and ligands 
on its cell surface in order to reduce the affinity for its original location. Proteases and 
glycosidases may also be released for remodeling the ECM and increasing the 
dissociation of tumor cells. Modification of the structures of N- and O-glycans has 
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been identified to be involved in the invasion of tumor cells (Fuster & Esko, 2005). 
One of the most prominent changes regarding glycosylation on tumor cells is the 
enhanced expression of sialic acid. Because of the negative charge of sialic acid, the 
enhanced expression of sialic acid could promote cell detachment through charge 
repulsion. Sialic acid has been found to affect both N- and O-glycans. On N-glycans, 
the capping of the terminal galactose with sialic acid, catalyzed by ST6Gal I (Lin et al, 
2002), can reduce cell-cell interactions, and therefore, promote invasion. One of the 
most well studied tumor-associated antigen is sialyl Tn (STn) antigen, which is an O-
linked GalNAc (Tn antigen) with a sialic acid on the 6-OH group of GalNAc. The 
emergence of STn antigen in many cancers has been related to a defect in COSMC, 
which is a chaperone involved in the maturation of the galactosyltransferase acting 
on the Tn antigen (Ju & Cummings, 2002). Lack of galactosyltransferase activity 
results in the accumulation of Tn antigen, thereby increasing STn formation. 
Transfection of breast cancer cell lines with cDNA encoding ST6GalNAc I that is 
responsible for transferring sialic acid to Tn antigen can increase STn expression and 
also increase the migration potential of the transfected cells (Julien et al, 2001). The 
STn antigen on mucins generates a negative charge on the cell surface and induces 
cell-cell dissociation by repulsion (Fig. 5.2.1B).  
Glycoconjugates in adhesion and metastasis  
After entry of the tumor cell into the blood vessel, it can adhere to the platelets and 
leukocytes, and eventually to the endothelial cells in distant tissues (Fig. 5.2.1C) 
(Läubli & Borsig, 2010). The cell-cell interaction between tumor cells and other cells 
is modulated by ligand-receptor interactions. The receptor that regulates the 
interaction is called selectin, which is a lectin that binds to sialyl Lewis x (SLex) and 
sialyl Lewis a (SLea) structures. Different cell types have different subtypes of 
selectin: platelets, leukocytes, and endothelium have P-, L-, and E-selectin, 
respectively. Solid tumors such as colon and pancreatic carcinomas frequently 
overexpress SLea and SLex on glycoproteins or glycolipids on the cell surface. These 
overexpressed SLea and SLex act as ligands that bind to P-, L-, and E-selectin on 
different cells, and enhance migration and adhesion of tumor cells. The level of 
expression of these ligands is inversely correlated with patient survival (Baldus et al, 
1998). 
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Glycoconjugates in angiogenesis 
Angiogenesis is a crucial process for solid tumors to acquire nutrition and oxygen 
through newly synthesized blood vessels. Up-regulation of heparan sulfate 
proteoglycans (HSPGs) had been found on the microvascular endothelia, but not on 
macrovascular endothelia, which implicates a role of HSPGs in angiogenesis 
(Marcum & Rosenberg, 1985). HSPGs can bind to pro-angiogenic factors such as 
fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and 
platelet-derived growth factor (PDGF). In case of VEGF (Fig. 5.3.1D), binding of 
HSPGs to VEGF regulates the interaction with the VEGF receptor (Gitay-Goren et al, 
1992). The binding can be abolished by treating the cell with heparinase, which 
digests the cell surface HSPGs and prevents the binding of VEGF to its receptor 
(Gitay-Goren et al, 1992).  
Inherited human diseases 
Glycosylation of proteins is the most common form of post-translational modification. 
More than 50% of proteins are glycosylated, and 1% of the genetic material is 
involved in glycosylation processes (Lowe & Marth, 2003). These glycoconjugates 
are involved in a variety of biological roles such as cell-cell interactions, protein 
folding, and signal transduction. Therefore, dysregulation of glycoconjugate 
biosynthesis can often cause diseases. Congenital disorders of glycosylation (CDG) 
are a group of disorders marked by defects in the glycosylation of proteins or lipids. 
Since the first patient identified in 1980 (Jaeken et al, 1980), the number of patients 
with these disorders has grown tremendously (Fig. 5.3.2). Defects in the 
glycosylation pathway are not limited to hypoglycosylation of N- and O-glycans on 
proteins; recent cases have identified hyperglycosylation of glycoprotein as another 
defect (Jaeken, 2010).   
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Adapted from (Freeze, 2007) 
Figure 5.3.2 The growing number of CDG since 1980 
Since the first case discovered in 1980 on N-linked proteins, the number of CDG cases 
has rapidly increased owing to the availability of gene sequences and cooperation 
between clinicians and scientists. 
Defects in N‐glycosylation 
N-glycosylation is a complex process comprising three parts: assembly, attachment, 
and processing. Moreover, these steps occur in three different compartments: 
assembly of LLO in the cytosol, attachment of LLO to nascent proteins in the ER, and 
processing of N-glycan structures in the ER and Golgi complex (Fig. 5.3.3). 
Conventionally, CDG with defects in the N-glycan biosynthesis pathway can be 
categorized into two sub-types: type I CDG and type II CDG (Fig. 5.3.3). In type I 
CDG, the defect abolishes or reduces the efficiency of one of the sequential steps in 
the biosynthesis of LLO in the cytosol. Isoelectric focusing (IEF) analysis of serum 
transferrin from patients with type I CDG shows an increase in the levels of di- and 
asialotransferrin (Fig. 5.3.4). Type II CDG defects impair the steps involved in 
trimming, remodeling, and decorating N-glycan structures with a variety of 
monosaccharides (Fig. 5.3.3). The transferrin pattern of type II CDG shows the 
isoforms of transferrin with one to six sialic acids (Fig. 5.3.5). Differences in the 
results of IEF analyses of transferrin between type I and type II CDG are caused by 
the defects in different parts of N-glycosylation. For type I CDG, mutations were 
found in the assembly of LLO, and aberrant LLOs may result in proteins with 
unoccupied N-glycosylation sites. In case of type II CDG, the occupancy of the N-
glycosylation site is not altered, but the structure of N-glycans is impaired, which 
leads to different degrees of sialylation on the N-glycans of transferrin (Fig. 5.3.3 and 
5.3.4). In this section, the most prevalent CDGs will be introduced.  
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Adapted from (Freeze, 2006) 
Figure 5.3.3 Defects in the N-linked glycosylation pathway 
The N-glycan biosynthesis pathway is illustrated in three different cellular 
compartments. The names of the CDG (CDG-X) and corresponding gene (boxed with 
blue background) are also indicated. The nomenclature of CDG in the text is in 
accordance with a new system, which is not consistent with this figure. The new 
nomenclature uses the official gene symbol follow by “-CDG” (Jaeken et al, 2009). 
PMM2-CDG is the most prevalent CDG with more than 500 patients worldwide and 
an estimated incidence of 1/20,000. The mutation occurs in phosphomannomutase 2 
(PMM2) that converts mannose-6-phosphate to mannose-1-phosphate, which is the 
precursor of GDP-mannose (Fig. 5.3.3). The mutation in PMM2 causes a reduction in 
the levels of GDP-mannose and LLO. Shortage of substrate for 
oligosaccharidetransferase leads to the production of glycoproteins with unoccupied 
N-glycosylation sites. Nearly 90 mutations have been identified in PMM2, which have 
been shown to decrease PMM2 activity, reduce affinity for mannose-6-phosphate, or 
result in complete loss of activity in a few cases (Kjaergaard et al, 1999). The most 
commonly identified mutation in patients is R141H on PMM2, which is an inactive 
enzyme in in vitro assays (Kjaergaard et al, 1999; Pirard et al, 1999). The R141H 
mutation on PMM2 has never been found in the homozygous state, suggesting that 
PMM2 activity is crucial for survival and total loss of PMM2 activity is likely lethal 
(Kjaergaard et al, 1999; Pirard et al, 1999).  
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Adapted from (Jaeken, 2010) 
Figure 5.3.4 Isoelectric focusing of transferrin  
The number of sialic acids on N-glycans of transferrin is indicated on the left from 0 to 6. 
The samples from healthy individuals are termed as controls (C), and those from 
patients with type 1 CDG and type 2 CDG with N-linked glycosylation defects are 
termed as type 1 and type 2. 
Another cytosolic enzyme in the GDP-mannose synthesis pathway is 
phosphomannose-isomerase (MPI) (Fig. 5.3.3). MPI-CDG patients have a milder 
phenotype compared to those with PMM2-CDG, and MPI-CDG is the only known 
CDG with an efficient treatment protocol. Orally supplemented mannose (1 g/kg body 
weight) can be converted to mannose-6-phosphate by hexokinases, thus bypassing 
the defect and effectively treating the disease (de Lonlay & Seta, 2009).  
Type II CDG seems to be less frequent than type I CDG, but this may reflect the lack 
of awareness or lack of efficient analytical methods rather than actual prevalence 
(Freeze, 2007). Two patients with MAG2-CDG (CDG-IIa) have been independently 
reported with similar phenotypes including severe mental retardation, chronic feeding 
problems with severe diarrhea, and growth retardation (Jaeken et al, 1993; 
Ramaekers et al, 1991). The gene responsible for the disease was identified as N-
acetylglucosaminyltransferase II (Fig. 5.3.3) that transfers GlcNAc to Man, which is 
one of the key steps for synthesizing hybrid and complex type N-glycans.  
Recently, mutations in the OST complex have been identified in patients with 
autosomal recessive mental retardation (Garshasbi et al, 2008; Molinari et al, 2008). 
The mutations are not in central components such as Stt3, but in two mutually 
exclusive paralogs, i.e., Tusc3 and IAP. These two proteins share 70% sequence 
identity and possess identical membrane topology. The function of these two proteins 
in humans has not been clarified. The homologous proteins of Tusc3 and IAP in 
yeast are OST3p and OST6p, respectively. A study on the OST3p and OST6p in 
yeast showed oxidoreductase activity (Schulz et al, 2009). Based on sequence 
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similarity, Tusc3 and IAP are proposed to possess oxidoreductase activity. 
Interestingly, neither the IEF analysis of the transferrin nor the N-glycan profile 
obtained by the mass spectrometry analysis of serum proteins showed difference 
between samples from patients and normal individuals. Furthermore, OST 
complexes from the patients also had similar activity as the wild-type OST complex, 
in in vitro assay (Molinari et al, 2008). The authors proposed that Tusc3 and IAP in 
humans, with their oxidoreductase activity, might aid in the folding of brain specific 
proteins. Misfolding of these proteins causes mental retardation syndromes in 
patients.        
Defects in O‐glycosylation  
O-Glycosylation defects that cause human diseases have been noted in O-mannose, 
O-xylose, and O-fucosylation pathways (Jaeken, 2010). Defects in O-
mannosyltransferase 1 and O-mannosyltransferase 2 can cause Walker-Warburg 
syndrome (POMT1/POMT2-CDG), a rare disease characterized by congenital 
muscular dystrophy. Glycans that are O-linked through xylose to serine are called 
glycosaminoglycans. Xylose can be extended to tetrasaccharide by the addition of 
two galactose residues and one glucuronic acid residue, which is the precursor of 
heparan sulfate and dermatan sulfate (Freeze, 2007). Mutations in EXT1 and EXT2 
(EXT1/EXT2-CDG), which are the enzymes required to extend xylose with galactose 
and glucuronic acid, cause multiple cartilaginous exostoses in patients (Ahn et al, 
1995).    
Two defects have been identified in the glycosyltransferase in the O-fucosylation 
pathway (Fig. 5.3.5). Under normal circumstances, the O-fucose on the EGF-like 
repeat can be extended by Fringe, which is a β1,3-N-acetylglucosaminyltransferase 
that adds GlcNAc to position 3 of fucose. Patients with spondylocostal dysostosis 
type 3 disease (SCD3) have a homozygous mutation in Fringe (Sparrow et al, 2006), 
wherein a conserved phenylalanine at position 188 is mutated to leucine. Although 
F188 is not directly involved in substrate binding and is not an active site residue, the 
F188L mutation still abolishes enzyme activity (Sparrow et al, 2006). The activity of 
Fringe modulates the substrate specificity of the Notch receptor, and therefore, plays 
an important role in development and other important biological events (Luther & 
Haltiwanger, 2009; Stanley, 2007).   
Another disease related to the O-fucosylation pathway is Peters Plus syndrome, 
which is caused by inactivating biallelic truncating mutations in β1,3-
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glucosyltransferase (β3Glc-T) (Heinonen et al, 2003; Kozma et al, 2006; Lesnik 
Oberstein et al, 2006). β3Glc-T is involved in the synthesis of an unusual Glc-β1,3-
Fuc-O- dissacharide unit on the thrombospondin type 1 repeat (Fig. 5.3.5). TSR is 
found in extracellular and membrane proteins that function in angiogenesis, neuronal 
guidance, and tissue remodeling during development (Tucker, 2004). Although TSR-
containing proteins are presumed to be involved in these biological processes, the 
detailed mechanism underlying the regulation of the function of TSR-containing 
proteins by glycosylation is still unclear.      
 
Figure 5.3.5 The CDG related to O-fucosylation pathways 
O-Fucosylation on EGF-like repeats is initiated by POFUT1 and can be extended to 
GlcNAc-β1,3-Fuc-O-disaccharide by Fringe. Fringe mutations cause spondylocostal 
dysostosis type 3 syndrome. In the O-fucosylation pathway of TSR, O-fucose is 
extended to Glc-β1,3-Fuc disaccharide by β3Glc-T. Defects in β3Glc-T cause Peters 
Plus syndrome. 
Other type of CDGs 
Most CDGs result from hypoglycosylation. Diseases that result from the gain of 
glycosylation sites are relatively unexplored. Three children with susceptibility to 
mycobacterial diseases were identified as homozygous for a missense mutation in 
the gene of interferon γ receptor ligand-binding chain (IFNᵧR2) (Vogt et al, 2005). 
The mutation creates a new N-glycosylation site at the position 168 (T168N) in 
IFNᵧR2. This additional N-glycan in IFNᵧR2 does not affect the expression of the 
protein; it, however, is necessary and sufficient to abolish the function of IFNᵧR2. By 
searching the Human Gene Mutation Database for mutations resulting in the gain of 
N-glycosylation sites on secretary proteins, 142 mutations in 77 genes that 
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correspond to 1.4% of mutations and 13.3% of the secretary protein genes were 
identified. The high prevalence of human proteins in secretory pathways with gain-of-
N-glycosylation-site mutations might be responsible for uncharacterized human 
genetic diseases. Their pathogenic effects may be a direct consequence of the 
additional N-glycan in the protein.    
Clinical approaches to identify patients with CDG  
The most popular analytical approach to identify a CDG related to N-glycosylation 
pathways is IEF analysis of transferrin. Transferrin is a glycoprotein with two N-linked 
glycans. In healthy individuals, the majority of N-linked glycans on each glycosylation 
site are biantennary, containing one or two sialic acids; a small fraction of the sugar 
chain has a triantennary structure with three sialic acids. The transferrins in IEF gels 
are separated according to the differences in the number of negatively charged sialic 
acids, which may range from 2 to 6 in healthy individuals (Fig. 5.3.4), which 
represents 1–3 sialic acid residues on each N-glycan. 
IEF analysis of transferrin is an inexpensive, efficient, and reproducible approach 
feasible in an experienced laboratory. However, false-negative results have been 
obtained using this method. Moreover, defects in CDG are not limited to the N-
glycosylation pathway. Apolipoprotein, a serum protein with mucin-type O-
glycosylation, has been proposed to be used as a indicative marker to detect defects 
in the mucin-type O-glycosylation pathway (Wopereis et al, 2007), which can 
complement IEF analysis of transferrin. IEF analysis of transferrin combined with that 
of apolipoprotein provides an efficient method to identify defects in the biosynthesis 
pathways of N-glycans and mucin-type O-glycans. 
Mass spectrometry has also been used to characterize CDG. An automated online 
immunoaffinity liquid chromatography-mass spectrometry method has been 
developed to analyze transferrin (Lacey et al, 2001). This method was first used to 
purify transferrin from 25 µL of serum by using an affinity column. The transferrin 
elution fraction was loaded onto a C4 column with a 9-min gradient, and then 
subjected to mass spectrometry. This approach was used to analyze the N-
glycosylation site occupancy of intact transferrin. Other approaches that have 
analyzed tryptic peptides with N-glycan and mucin-type O-glycan have also been 
reported (Tajiri et al, 2005). An approach using immunopurification-mass 
spectrometry has been established to analyze samples from patients with Peters 
Plus syndrome (Hess et al, 2008). The properdin from serum samples was 
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immunopurified and digested with trypsin. The digested samples were analyzed by 
mass spectrometry using multiple-reaction monitoring that offers high sensitivity and 
specificity. The results showed that only Fuc-O- was found on all four O-fucosylation 
sites from the properdin purified from patientsʼ serum, but in normal individuals, 
properdin carried Glc-β1,3-Fuc-O- disaccharide on the fucosylation sites. This 
approach highlights the importance of dedicated analytical approaches to identify 
rare glycosylation defects that cannot be elucidated by using general methods.  
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5.4 Thrombospondin type 1 repeat  
Thrombospondin (TSP) was first identified as a glycoprotein released from the α-
granules of platelets in response to thrombin stimulation (Baenziger et al, 1971). TSP 
is a multi-modular protein with two major groups. In humans, two genes encode 
Group A TSPs (TSP-1 and TSP-2). The TSPs in Group A can form homotrimers with 
their N-terminal oligomerization domain. Following the oligomerization domain, there 
is a von Willebrand Factor Type C (vWC) domain, three thrombospondin type 1 
repeats (TSR), three epidermal growth factor (EGF)-like repeats, a calcium-binding 
wire, and a lectin-like C-terminal domain (Fig. 5.4.1A). TSP-3, TSP-4, and TSP-5 in 
Group B TSPs form pentamers with their N-terminal oligomerization domain, with one 
additional EGF-like repeat, but they lack TSR and vMC modules. 
 
(Carlson et al, 2008) 
Figure 5.4.1 Modular structures of thrombospondin families and a model of Group A TSP 
(A) The modules of TSPs. The members of group A TSPs (TSP-1 and TSP-2) form a 
homotrimer. TSP-3, TSP-4, and TSP-5 comprise Group B and form pentamers. The 
modules are color-coded as follows: TSP-N (red), coiled-coil (orange), vWC (yellow), 
TSR1-3 (green), EGF-like repeat (blue), calcium-binding wire (blue), and lectin-like 
module (purple). (B) The structure of a Group A TSP was modeled in silico; the module 
structures were solved individually. The colors of the modules in the structure are the 
same as in (A). The flexible sites are labeled with black text, and the sites with co- and 
post-translational modifications are colored with red and cyan, respectively. 
Because of the large size, flexibility between modules, and post-translational 
modifications on the protein, NMR-based elucidation of the structure of entire TSP is 
impossible, while it is quite challenging by X-ray crystallography. Electron microscopy 
and low-resolution biophysical studies have been used to elucidate the structure of 
the individual modules and describe the molecular organization of TSP-1 (Fig. 
5.4.1B) (Carlson et al, 2008).   
The TSR was first described in human TSP-1 in 1986 (Lawler & Hynes, 1986). 
However, TSRs are not limited to TSP-1 and TSP-2, but are also present in other 
multi-modular proteins. In humans, there are 65 proteins that contain TSRs 
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(Pfam:00090), such as the proteins involved in the formation of extracellular matrix 
(Spondin-1), metalloproteases (ADAMTS family), and the proteins in the complement 
pathway (C6, C7, C8). The number of TSR modules in different proteins varies from 
1 to 24. These TSR-containing proteins constitute a TSR superfamily with functions 
related to matrix organization, cell-cell interactions, and cell guidance (Tucker, 2004). 
This chapter addresses the structure, post-translational modifications, and function of 
TSRs, as well as the pharmaceutical applications of the TSR-derived peptides.   
Structure of TSR 
TSRs are about 55-amino acid long, of which 12 residues are highly conserved. The 
sequence alignment of different TSRs and the 3D structure of TSR revealed that 
these conserved residues provide crucial interactions for the unique three-strands 
anti-parallel structure (Tan et al, 2002). The structure of TSR[2,3] was first solved in 
2002, from human TSP-1, to 1.9 Å resolution (Tan et al, 2002) (Fig. 5.4.2). The 
overall structure of each TSR is compact with dimensions of 15 × 20 × 55 Å and 
contains three pairs of conserved disulfide bonds. Each TSR has three anti-parallel 
strands: the irregular A-strand with a unique ripple conformation and the B- and C-
strands form a β-sheet structure. Pro472 between TSR2 and TSR3 creates a 180º 
turn that allows the two TSRs to face in opposite directions. This linkage between two 
TSRs is relatively rigid and inflexible because of the Cys422-Cys471 disulfide bond 
and a hydrophobic interface on the loop between two TSR modules. Interestingly, the 
linkage between TSR1 and TSR2 also has a Pro at a similar position, which may also 
create the 180º turn between TSR1 and TSR2.  
 
Figure 5.4.2 Structure of hTSR[2,3] from human thrombospondin-1  
The disulfide bonds (in yellow) and O-linked fucose moieties (in cyan) at Thr432 and 
Thr489 are drawn in stick representation. The A-B-C-strands and fucose in the TSR2 
domain are indicated. Side chains that are involved in the WR layers in TSR2 and 
TSR3 are shown as sticks.  
The anti-parallel structure of TSR is maintained by unique CWR layers among the 
three strands. On the A-strand, three conserved tryptophan residues in a W**W**W 
motif constitute the W layers. The guanidinium group of arginines form the R*R*R 
motif on the B-strand, sandwiched by two adjacent W layers comprise the R layers 
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C
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(Fig. 5.4.2). The alternative stacking of aromatic tryptophans and the planar cationic 
groups of arginine form multiple cation-π interactions that provide the main stabilizing 
energy for TSR folding. The distance between the tryptophan and arginine layers is 
about 4.6 Å throughout TSR2 and TSR3. Furthermore, the WR layers are capped by 
disulfide bonds on both sides of the layers. The first disulfide bond between the B-C-
strand (Cys444–Cys456 in TSR2) caps the left side of the WR layer, and the second 
disulfide bond between the A-C-strand (Cys429–Cys466 in TSR2) caps the other 
side of the layer (Fig. 5.4.2). The stacking side chains from the tryptophan and 
arginine residues and the disulfide bonds create the CWR layers between three 
strands; these layers comprise the characteristic core of the TSR structure. The CWR 
layers provide stabilization energy for the TSR structure, and it creates a front face 
for proposed interactions. Because of the inherent strand twist, these layers have a 
right-handed spiral groove with a positive charge on the surface, which is proposed 
to interact with negatively charged ligands such as heparin sulfate. Based on the 
disulfide bond patterns, TSRs can be divided into two main groups (Fig. 5.4.3) (Tan 
et al, 2002). In group 1 TSRs, the disulfide pattern is C1-C5, C2-C6, and C3-C4. This 
group of TSRs includes TSP, ADAMTS, and properdin. Another structural feature of 
group 1 TSRs is two hydrogen bonds between a structural motif called jar handle and 
the N-terminus, which pulls the A-strand closer to the TSR core structure and 
stabilizes the conformation. In group 2 TSRs, which includes F-spondin and TRAP, 
the disulfide bond pattern is C1-C4, C2-C5, and C3-C6. The group 2 TSRs do not have 
a jar handle created by hydrogen bonds; instead, the N-terminus of the A-strand is 
stabilized by a disulfide bond between C1 and C4 (Fig. 5.4.3).  
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Adapted from (Tan et al, 2002) 
Figure 5.4.3 Multiple sequence alignments of TSRs 
The alignment of TSRs from the same or different proteins is categorized into different 
groups according to their disulfide bond pattern. Group 1 and 2 TSRs are shown in the 
upper and lower panels, respectively. Two hydrogen bonds between the N-terminus 
and jar handle are drawn as red lines. The cysteine residues that are involved in 
forming the disulfide bonds are in yellow. The regions of A-, B-, and C-strands are 
indicated above the sequence. The tryptophan and arginine residues that create the 
core region are colored in green and cyan, respectively, in the alignment.    
Although there is a different disulfide bond pattern between group 1 and 2 TSRs, the 
overall structures are similar. Three structures from group 2 TSRs, i.e., TSR1 and 
TSR4 from F-spondin and TRAP-TSR from P. falciparum, were determined by NMR 
(Pääkkönen et al, 2006; Tossavainen et al, 2006). Comparison of the structures of 
TSRs from F-spondin (group 2), TSP-1 (group 1), and TRAP-TSR (group 2) shows 
that the loop between the A- and B-strands superimpose with RMSDs from 1.0 Å to 
2.1 Å between the structures. The overall structure shows high structural similarity 
with an RMSD from 2.3 Å to 2.9 Å (Fig. 5.4.4).   
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Modified from (Tossavainen et al, 2006) 
Figure 5.4.4 Comparison of TSR structures  
Cartoon structures of (A) TSR4 from F-spondin (1VEX), (B) TRAP-TSR (2BBX), and (C) 
TSR2 from TSP-1 (1LSL) are shown. The cysteine, arginine, and tryptophan residues 
in the CWR layers are shown in sticks and colored in yellow, green, and blue, 
respectively. The overall fold of the TSRs is similar, although there are differences in 
the disulfide-bonding pattern. 
Glycosylation on the thrombospondin type 1 repeat 
TSRs undergo two types of unique glycosylation: one is C-mannosylation on a 
tryptophan of the A-strand and the other is O-fucosylation on a serine/threonine on 
the loop between the A- and B-strands (Gonzalez de Peredo et al, 2002; Hofsteenge 
et al, 2001). C-Mannosylation is a co-translational 
modification. The α-mannosyl residue is linked to the C-2 
atom of the tryptophan through a C-C bond (scheme on the 
right). The modification occurs in the ER by a 
glycosyltransferase, which has not been identified. The 
unknown C-mannosyltransferase can recognize a synthetic W-X-X-W peptide and 
transfer the mannose to the first W, which indicates that C-mannosylation can 
transfer mannose to an unfolded protein with the consensus motif (Doucey et al, 
1998). A study on TSP-1 from human platelets showed that C-mannosylation was 
very abundant; the occupancy of C-mannose on the consensus sequence was more 
than 90% in the determined sites. However, these sites on the recombinant TSRs 
from insect cells revealed lower or no C-mannosylation (Hofsteenge et al, 2001). In 
the structure of TSR2-TSR3 from F-spondin (Tan et al, 2002), no electron density 
was observed for C-mannosylation, probably because the TSR was expressed in 
insect cells, which lacks the C-mannosylation machinery. However, the C2 positions 
on the side chains of all tryptophans were pointing away from the Cα backbone, 
which makes the modification site more accessible for the unidentified C-
mannosyltransferase. Recently, the crystal structure of TSR with C-mannosylated-
tryptophan was determined from the human complement component C8 (Lovelace et 
al, 2011). Compared to the structure of TSR[2,3] expressed in insect cells, C8 was 
purified from human plasma; hence, the tryptophan on the W-X-X-W motif could be 
modified by mannose (Fig. 5.4.5). The structure confirmed that the mannose was on 
the C2 position of tryptophan, but it lacked the O-fucose that was found on the 
structure of TSR[2,3] because of a proline instead of a serine or threonine at the 
consensus site. Interestingly, they also observed a clear electron density that fit 
better to a β- rather than α-mannosyl substituent (Lovelace et al, 2011). However, the 
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authors did not provide an explanation for this unique finding. It should be noted that 
C-mannosylation is not limited to the TSR module, it has also been found on proteins 
such as ribonuclease 2 (de Beer et al, 1995), and mucins (Perez-Vilar et al, 2004).    
 
Figure 5.4.5 C-Mannosylation on complement C8 
The structure of TSR from the complement C8α is shown as a cartoon representation 
(PDB: 3OJY). The side chains of the tryptophan and arginine residues involved in the 
core layer formation are presented as sticks. The mannose is found on the first 
tryptophan of the W**W motif.  
The function of C-mannosylation is still not known mainly because the C-
mannosyltransferase has not been identified. The results from a recent study suggest 
that C-mannosylation affects the secretion of the TSR-containing protein punctin-1. A 
point mutation on the C-mannosylation site or the expression of punctin-1 in C-
mannosylation-deficient cells (Lec35.1) decreased the secretion of punctin-1 (Wang 
et al, 2009). They proposed that C-mannosylation provides a quality control 
mechanism for punctin-1 secretion. Interestingly, a similar function of C-
mannosylation was also proposed on MUC5AC and MUC5B (Perez-Vilar et al, 2004). 
The MUC5AC mutant (AXXW instead of WXXW) showed decreased secretion and 
accumulation in the cell. These data suggest that the function of C-mannosylation in 
secretion/folding is not limited to TSRs, but it has a global effect on C-mannosylated 
proteins. An alternative approach to investigate the function of C-mannosylation has 
been to identify its protein-binding partner by using a synthetic peptide with C-
mannose (C-Man-WSPW) in cell culture (Ihara et al, 2010); heat shock cognate 
protein 70 (Hsc70) was found to have a higher affinity for the C-mannosylated 
peptide than for the non-mannosylated peptide. Furthermore, a downstream 
signaling pathway induced by Hsc70 was enhanced more in the presence of the C-
mannosylated peptide. These results demonstrate the TSR-derived peptide with C-
mannosylation may regulate cellular signaling through binding to Hsc70.    
The other type of glycosylation on TSR is O-fucosylation. O-Fucosylation takes place 
in the ER by O-fucosyltransferase 2 (POFUT2), which adds a fucose by an α-linkage 
to a serine or threonine on the loop between the A- and B-strands (Luo et al, 2006a; 
Luo et al, 2006b; Tan et al, 2002). The fucose can be extended to Glc-β1,3-Fuc 
Mannose
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disaccharide by β1,3-glucosyltransferase (β3GlcT) that is also present in the ER 
(Kozma et al, 2006; Sato et al, 2006). The biological function and importance of the 
O-fucosylation pathway are in Chapter 5.1.  
Function of thrombospondin type 1 repeat 
The functions of the TSR are diverse. TSR is involved in many important biological 
processes such as inflammation, neuronal development, angiogenesis, and parasite 
infection (Adams & Tucker, 2000; Lopez-Dee et al, 2011; Matuschewski et al, 2002; 
Tucker, 2004). The function of the TSR depends on the protein that contains the TSR, 
its cellular location, and the timing of the protein expression. In this section, I will only 
address the role of the TSR module plays in Plasmodium infection and anti- 
angiogenesis.  
Plasmodium is the causative agent of malaria. During its life cycle, the sporozoite is 
the transmissible form of the parasite, spreading the disease from mosquitoes to 
humans. Sporozoites are released into human blood vessels from the salivary glands 
of mosquitoes, and later they infect liver cells. The thrombospondin-related 
anonymous protein (TRAP) is a transmembrane protein with a TSR domain in the 
cytosol. The TSR module is necessary for the entry of sporozoites into the 
hepatocytes; replacement of the residues in the WR layers (Fig. 5.4.2) with alanine in 
the TSR of TRAP resulted in non-invasive sporozoites (Matuschewski et al, 2002). 
Glycosaminoglycan chains (GAGs) on the host cell surface have been reported to be 
the receptors for invasion of Plasmodium sporozoites (Frevert et al, 1996). GAG is a 
sulfated molecule with a negative charge on the surface, which binds to the positively 
charged residues on the N-terminal region of TSR (Tossavainen et al, 2006). The 
TSR presumably facilitates invasion by recruiting GAGs via a charged interaction, 
and this interaction allows sporozoites to invade the host cell (Matuschewski et al, 
2002).  
TSP-1 was the first natural protein with anti-angiogenic properties that can restrain 
tumor growth (Good et al, 1990). The domains responsible for anti-angiogenic activity 
are predominantly located in the TSRs (Fig. 5.4.6). Using synthetic peptides, 
WSHWSPW, VTGC, and GVITRIR motifs were identified to have the ability to bind 
vascular endothelial growth factor (VEGF) (Lawler & Detmar, 2004). The binding of 
TSP to VEGF can mediate the uptake and clearance of VEGF, and therefore, inhibit 
angiogenesis (Greenaway et al, 2007). Another pathway of TSRs to inhibit 
angiogenesis is through binding to CD36 (Dawson et al, 1997), which is an integral 
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membrane receptor expressed on microvascular endothelial cells. The binding of 
TSRs to CD36 activates the caspase-3-like protease pathway, which then induces 
receptor-mediated apoptosis in activated microvascular endothelial cells (Jimenez et 
al, 2000). The CSVTCG motif on TSR (Fig. 5.4.6) was identified as the region for 
CD36 binding (Asch et al, 1992). Interestingly, this peptide harbors the O-
fucosylation site on TSRs, but the effect of fucose or fucose-glucose on TSRs on the 
binding to CD36 remains to be clarified. The ability of TSP-1 to activate transforming 
growth factor β (TGFβ) may also contribute to arresting tumor growth and inhibiting 
tumor progression (Crawford et al, 1998). The motifs responsible for the binding and 
activation of TGFβ were identified on the TSR2 of TSP-1. As a first step in the 
activation of TGFβ, the sequence WSHWSPW on TSR binds to the VLAL sequence 
on TGFβ, which allows the RFK sequence on the N-terminal of TSR to activate TGFβ 
(Young & Murphy-Ullrich, 2004a; Young & Murphy-Ullrich, 2004b) (Fig. 5.4.6). 
 
Adapted from (Kazerounian et al, 2008) 
Figure 5.4.6 Domain structure of TSP-1  
TSP-1 has multiple functional domains. The highlighted amino acid sequences of TSR2 
are involved in the activation of TGFβ and inhibition of angiogenesis.  
The anti-angiogenic and apoptosis-inducing properties of TSR make it an attractive 
drug candidate for cancer therapy. Because of the size and multiple biological 
functions of intact TSP-1, it is not suitable to use intact TSP-1 for therapy. Several 
peptides derived from the different motifs of TSRs have been developed as 
angiogenic inhibitors (Henkin & Volpert, 2011). ABT-510 is a peptide derived from the 
sequence GVITRIR in the TSR2 of TSP-1 (Reiher et al, 2002). It was the first 
compound shown to mimic the anti-angiogenic function of TSR in a clinical trial. ABT-
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510 was shown to effectively block angiogenesis in a mouse model and to regress 
tumor lesions in dogs (Haviv et al, 2005). However, ABT-510 did not have a 
significant effect on phase II clinical trials as a monotherapy and is no longer in 
clinical development (Baker et al, 2008; Markovic et al, 2007).   
Other proteins with TSR domains have been found to have anti-angiogenic activity. A 
disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) are a group 
of multi-domains proteins with the ability to cleave aggregating chondroitin sulfate 
proteoglycans (Nakamura et al, 2000). ADAMTS-1 inhibits angiogenesis through two 
mechanisms. It binds to the VEGF receptor, which prevents VEGF binding to the 
VEGF receptor, and it releases anti-angiogenic peptides from TSP-1 and -2 through 
its protease activity (Luque et al, 2003; Vazquez et al, 1999).  
Failure of anti‐angiogenic peptides derived from TSP‐1 
Tumor cells are able to evolve drug resistance to peptides that interrupt tumor 
angiogenesis. Recent investigations of peptides targeted in the VEGF pathway in 
preclinical studies suggested that although they inhibited primary tumors, the 
peptides could accelerate metastasis and decrease the overall survival rate in mice 
(Ebos et al, 2009; Paez-Ribes et al, 2009). ABT-510 derived from TSR of TSP-1 
failed to show antitumor effects in phase II clinical trials (Baker et al, 2008; Markovic 
et al, 2007). To identify why these peptides have anti-angiogenic properties, but do 
not show antitumor activity, the role of TSP-1 in tumor progression has been re-
evaluated using a prostate cancer model (Firlej et al, 2011). In this interesting work, 
they first found that TSP-1 strongly stimulated migration of cultured cancer cells, and 
the CD36 receptor was necessary for migration to occur. In addition, the anti-
angiogenic property of TSP-1 was found to increase hypoxia of the tumor cells, which, 
in turn, enhanced TSP-1 production and secretion. The cycle of hypoxia and 
increased TSP-1 expression in prostate tumors promoted cell migration. They 
proposed that the ability to increase hypoxia and to trigger cell migration were 
inherently linked, and that this link was shared by the endogenous and 
pharmacologic inhibitors of angiogenesis (Firlej et al, 2011).  
In summary, the diverse functions of TSR-containing proteins in biological activities 
are related to the TSR modules. An in-depth understanding of TSR, including co- and 
post-translational modifications, will aid in identifying the functions and roles of TSR-
containing proteins. 
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6. Results 
6.1 Expression and purification of rat F‐spondin TSR4 
Introduction 
O-Fucosylation is a relatively rare protein glycosylation modification that is only found 
on EGF-like repeats, TSRs, and PMP-C. The EGF repeat is a protein motif about 40 
amino acids in length with six conserved disulfide bonds. These cysteines form a 
specific disulfide bond pattern: Cys1-Cys3, Cys2-Cys4, and Cys5-Cys6 (Campbell & 
Bork, 1993). TSR, which is ~60-amino acid-long in length, also contains six 
conserved cysteines with three disulfide bonds. The disulfide pattern in F-spondin 
TSR4 is Cys1-Cys4, Cys2-Cys5, and Cys3-Cys6. The fucosyltransferases that transfer 
fucose from GDP-fucose to EGF repeats and TSRs have been identified. POFUT1 is 
responsible for the fucosylation of EGF repeats, and POFUT2 specifically recognizes 
TSRs. Although there are similarities between the two O-fucosylation pathways, 
POFUT1 and POFUT2 have high specificity for their own substrate and do not cross-
react (Luo et al, 2006b). One of the aims of my thesis was to characterize the 
mechanism of human POFUT2 and elucidate the substrate specificity of POFUT2.  
To achieve this goal, a correctly folded TSR is required in the activity assay to 
determine the activities of wild-type and mutant POFUT2. Previously in our laboratory, 
TSR4 from rat F-spondin has been recombinantly expressed in HEK293T cells with a 
C-terminal Myc-His6-tag (Gonzalez de Peredo et al, 2002). The TSR4 was purified 
and used to characterize C-mannosylation on tryptophan. The same protein module 
has also been expressed and purified in an E. coli expression system to characterize 
the activity of β1,3-glucosyltransferase (Kozma et al, 2006). The rat and human F-
spondin TSR4 modules are highly conserved. Of 53 amino acids, only a single amino 
acid is changed in the C strand: human TSR4 has an alanine and rat TSR4 has a 
valine (Fig. 6.1.1). The position of this amino acid is not on the consensus sequence 
of O-fucosylation, and we do not expect the difference in a single amino acid will 
affect the specificity of POFUT2. 
 
Figure 6.1.1 Sequence alignment of human and rat F-spondin TSR4 
The amino acid difference between human and rat TSR4 is highlighted in blue.    
PCLLSPWSEWSDCSVTCGKGMRTRQRMLKSLAELGDCNEDLEQAEKCMLPECP
PCLLSPWSEWSDCSVTCGKGMRTRQRMLKSLAELGDCNEDLEQVEKCMLPECP
Human F-spondin TSR4
Rat F-spondin TSR4
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Cysteine scrambling and multimeric TSR4 concatemer formation occurred when rat 
TSR4 was expressed in E. coli (Kozma et al, 2006). To circumvent these problems, 
we expressed the protein at a lower temperature (20 ºC instead of 37 ºC) by using an 
autoinduction expression system and BL21 Rossetta 2 cells, which have been 
engineered to enhance the expression of eukaryotic proteins containing rare codons 
in E. coli. The His6-tag on the C-terminus was moved to N-terminus following a 
human rhinovirus 3C cleavage site. We established a three-step protocol to purify 
His6-3C-TSR4 from E. coli. Moreover, we were also interested in determining the 
fucosylation efficiency of mini-TSR ( a minimal POFUT2 substrate, Chapter 6.2) and 
TSR23*. TSR23* consists of the TSR2 and TSR3* modules from human 
thrombospondin-1 with a T to A mutation on the O-fucosylation site of TSR3. The 
results of preliminary purification of GST-His6-3C-mini-TSR and GST-His6-3C-
TSR23* and initial fucosylation efficiency will be described in this chapter.  
Materials and methods 
Expression of rat TSR4 in E. coli 
Rat F-spondin TSR4 containing an N-terminal His6-3C-tag was cloned into the 
pOPINF vector (Berrow et al., 2007) and was used to transfect E. coli (Rosetta 2) 
cells. The freshly transfected E. coli cells were grown overnight in 20 ml of GS96 
medium containing 1% glucose. The overnight culture was diluted 1:100 into 0.5 l of 
auto-induction medium (Studier, 2005) containing 34 µg/ml chloramphenicol and 50 
µg/ml carbenicillin. Cells were grown at 37 ºC at 225 rpm for 4 h, then the 
temperature was decreased to 20 ºC, and the cells were grown for another 20 h. 
Cells were harvested by centrifugation at 6500 g for 30 min. The cell pellet from 1 l of 
culture was resuspended in 36 ml of lysis buffer [50 mM Tris-HCl pH 7.5, 500 mM 
NaCl, 20 mM imidazole, 0.2% Tween20, and complete protease inhibitor (Roche)], 
and stored at -80 ºC for later purification. In total, 48 L of E. coli culture was prepared 
for large-scale TSR4 production. 
Purification of His6‐3C TSR4 
For purification, 8 L of the cell pellet was resuspended in 400 ml of lysis buffer and 
lysed by a high-pressure cell disruptor. The lysate was cleared by centrifugation at 
30,000 g for 30 min at 4 ºC. The cleared lysate was decanted into a fresh tube and 
incubated with Ni-NTA agarose (Qiagen) for 2 h at 4 ºC with gentle rolling. The resin 
and lysate mixture was poured into a column (Econo-Column, Bio-Rad), and the 
  51 
6. Results 
column was connected to an ÄKTA purifier. The unbound fraction was collected at a 
flow rate of 1 ml/min. The resin was washed five times with the gel volume of lysis 
buffer, and TSR4 was eluted in 50 mM Tris-HCl pH 7.5, 500 mM NaCl, and 500 mM 
of imidazole. The eluted fraction was loaded onto a Superdex-75 16/60 PG column 
(GE Healthcare) in 20 mM Tris-HCl pH 7.4, 150 mM NaCl. Fractions containing TSR4 
were pooled and buffer exchanged into 20 mM Tris-HCl pH 7.4, 10 mM NaCl by 
using a HiPrep 26/10 desalting column. The sample was then loaded onto a MonoQ 
5/50 column (GE Healthcare), and TSR4 was eluted using a linear gradient of 0–500 
mM NaCl over 50 min. TSR4 was concentrated using an Amicon-4 centrifugal filter 
(3000 NMWL) to 3.6 mg/ml or 7 mg/ml and stored at -80 ºC for later applications.   
In vitro fucosylation assay  
The description of the method is included in Chapter 6.2. 
Mass spectrometry (MS) analysis of mini‐TSR and TSR23* 
The description of the method is included in Chapter 6.2. 
Results 
Expression and purification of His6‐TSR4 by Ni‐NTA affinity chromatography and 
size exclusion chromatography 
For the in vitro POFUT2 assay, one of the key steps is to prepare properly folded, 
pure TSR. The methods for studying the expression and purification of C-terminally 
tagged rat F-spondin TSR4 from E. coli has been established previously (Kozma et al, 
2006). Using the structures of POFUT2 and TSR2-TSR3 from TSP-1 (Tan et al, 
2002), we modeled the POFUT2-TSR complex (Fig. 6.2.5). Based on the model, we 
predicted that the C-terminal Myc-His6 tag of TSR4 might be located in the inter-
domain cleft, which would interfere with the co-crystallization of POFUT2 with GDP-
fucose. Therefore, we designed a new construct with the His6-3C tag on the N-
terminus and used an auto-induction system for protein expression.  
The pellet was thawed from -80 ºC in lysis buffer and lysed by mechanical force. The 
clarified lysates were incubated with Ni-NTA agarose, and the elution fraction from 
the Ni-NTA agarose resin was loaded onto a SDS-PAGE gel to check the purity of 
the protein. Staining of the gel indicated that the sample contained a moiety of the 
predicted size (lane 1 in Fig. 6.1.2B), but the sample contained contaminants. The 
  52 
6. Results 
size of most contaminants was larger than TSR4, so we could further purify the 
protein by size-exclusion chromatography (SEC). 
From the UV280 absorbance shown on the chromatogram (Fig. 6.1.2A), we found 
two major absorbent peaks, the first at 40 ml, which is the void volume of the column, 
and the second at 80 ml that corresponds to the size of monomeric TSR4. The select 
fractions from the SEC column were analyzed by SDS-PAGE; we observed that the 
majority of the contaminants were separated from TSR4 (Fig. 6.1.2B). Proteins larger 
than 50 kDa were fractionated into #8–12. The smearing signal in the fraction #8 at a 
high-molecular weight could indicate protein aggregation. In the fractions #13–#18, 
the molecular weight of contaminating proteins decreased with the elution time. The 
signal with a size close to His6-3C-TSR4 was present in the fraction #19 at ~10 kDa 
under non-reducing conditions. However, we observed another protein that ran 
higher than TSR4 in the non-reducing gel. In the reducing gel, however, these two 
proteins could not be separated, and they ran as a single band. 
 
Figure 6.1.2 Purification of His6-3C-TSR4 by SEC 
After Ni-NTA affinity purification, the sample was further purified by size-exclusion 
chromatography to isolate TSR4. The chromatogram in (A) shows that the proteins 
were separated into two main peaks, which are shown in the non-reducing SDS-PAGE 
gel in (B). Most contaminant proteins were separated from TSR4 by the SEC column; 
only a small fraction of other proteins was eluted with TSR4.  
To confirm that the major band on the gel consists of TSR4 and to identify the 
contaminant protein, we cut these two bands from the gel and performed in-gel 
trypsin digestion for protein identification by MS. The MASCOT search indicated that 
the major protein was rat TSR4 from F-spondin; the contaminant protein was 30S 
ribosomal protein S15. The predicted molecular weight of the S15 is 10,268 Da, 
which is very close to the molecular weight of His6-3C-TSR4 (8194 Da). 
A B
ml
mAu
A280
UV280 mAU
#8–18 #20–26
50 kDa
37 kDa
25 kDa
15 kDa
10 kDa
75 kDa
100 kDa
250 kDa
Elu
te 
of 
Ni
-ag
aro
se
 
Su
pe
rde
x 7
5 #
8
Ma
rke
r 
Su
pe
rde
x 7
5 #
12
Su
pe
rde
x 7
5 #
16
Su
pe
rde
x 7
5 #
18
Su
pe
rde
x 7
5 #
19
Su
pe
rde
x 7
5 #
20
Su
pe
rde
x 7
5 #
21
Su
pe
rde
x 7
5 #
22
Su
pe
rde
x 7
5 #
23
Su
pe
rde
x 7
5 #
24
Su
pe
rde
x 7
5 #
25
Su
pe
rde
x 7
5 #
26
Su
pe
rde
x 7
5 #
27
Su
pe
rde
x 7
5 #
28
Su
pe
rde
x 7
5 #
29
  53 
6. Results 
S15 was removed by a Mono Q anion exchange column 
The similarity in the sizes of S15 and His6-TSR4 makes these two proteins 
inseparable by SEC. However, the isoelectric point (pI) of S15 (10.4) and His6-TSR4 
(5.8) were significantly different; therefore, the two proteins could be separated by 
ion-exchange chromatography. The fractions #20–#26 from the SEC column were 
pooled and buffer exchanged into 20 mM Tris-HCl pH 7.4, 10 mM NaCl, by using a 
HiPrep™ 26/10 desalting column before loading onto the MonoQ column.  
MonoQ anion exchange chromatography was used to remove E. coli S15 (upper 
band in Fig. 6.1.2B lane Superdex 75 #20–#26) from TSR4. Since S15 is a basic 
protein, it should not be retained on the anion exchange column under neutral 
conditions. We injected the mixed sample onto the MonoQ anion exchange column 
under neutral, low salt conditions. On the chromatogram (Fig. 6.1.3A), we observed a 
peak by UV280 absorbance before the gradient was started, indicating the presence 
of a protein that did not bind to the MonoQ column. When we started the gradient, a 
peak was observed at 40 ml by using the gradient of 0% Buffer B to 50% Buffer B 
within 60 min. The purity of the sample separated by the MonoQ anion exchange 
column was checked on a SDS-PAGE gel. After staining the gel, we determined that 
the flow-through fraction contained S15 (Fig. 6.1.3B). On the other hand, His6-TSR4 
was retained on the column in Buffer A, and eluted later with increasing conductivity. 
The major peak from fraction #13 to #18 contained TSR4. On the gel, the protein 
from these fractions was a single band with >99% purity at the predicted size for 
TSR4. Therefore, fractions #13–#18 were pooled and stored at -80 ºC.   
 
Figure 6.1.3 Purification of His6-TSR4 by MonoQ anion exchange chromatography 
The pooled samples after size-exclusion gel filtration were further purified on a MonoQ 
anion exchange column. From the absorbance at UV280 (A), we observed two major 
fractions: the unbound fraction before starting the gradient and major fraction from #12 
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to #18. The SDS-PAGE gel in (B) confirms that the unbound fraction is S15 and that 
the main peak is TSR4.  
Mass spectrometry analysis of purified TSR4  
To confirm that the protein we purified was TSR4 and to investigate the fucosylation 
of N-terminally tagged TSR4, we used reverse-phase HPLC coupled with MS to 
analyze the purified TSR4 sample. In addition, we analyzed the sample after in vitro 
fucosylation. MS results revealed that the molecular weight of our sample was 8194 
Da (Fig. 6.1.4A), which is 152 Da lower than the expected molecular weight of TSR4 
(8349 Da). We hypothesized that 146-Da difference was due to N-terminal 
methionine excision, which has been observed in the cytosolic proteins of E. coli 
(Waller, 1963). N-Terminal methionine excision is catalyzed by a methionyl-
aminopeptidase that removes the methionine if the following amino acid is glycine or 
alanine (Hirel et al, 1989). In our TSR4 construct, alanine is the amino acid following 
methionine, which may lead to excision of the methionine in the purified TSR4. The 
other 6-Da difference likely comes from the formation of three disulfide bonds, which 
may indicate that TSR4 folds properly in E. coli.  
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Figure 6.1.4 ESI-MS analysis of purified rat F-spondin TSR4  
The average mass of purified TSR4 (A) was 8194.1 Da, which corresponds to the 
molecular weight of TSR4 after N-terminal methionine excision and loss of six protons 
following the formation of three disulfide bonds. After in vitro fucosylation assay, the 
molecular weight of TSR4 increased by 146 Da (B), indicating that TSR4 can be 
fucosylated by POFUT2. 
POFUT2 can only transfer fucose to correctly folded TSR4 (Luo et al, 2006b). We 
incubated purified His6-TSR4 with POFUT2 and GDP-fucose and analyzed the 
product by ESI-MS. The molecular weight increased by 146 Da, compared to the 
molecular weight of TSR4 before fucosylation, which corresponds to the attachment 
of one fucose on His6-TSR4. The successful in vitro fucosylation of purified His6-
TSR4 with an excess of GDP-fucose indicates that the His6-TSR4 expressed in E. 
coli is folded correctly.  
The total amount of pure TSR4 isolated from 8 l of E. coli culture with two steps of 
purification was ~2 mg. In total, ~12 mg of His6-TSR4 was prepared from six batches 
of 8-L E. coli culture. His6-TSR4s from different batches were pooled and 
concentrated to 3 mg/ml or 7 mg/ml. The concentrated samples were stored at -80 ºC 
for use in the activity assay of wild-type and mutant POFUT2 (Chapter 6.2). 
Expression and purification of GST‐His6‐WT‐TSR, GST‐His6‐mini‐TSR, and GST‐His6‐
TSR23* 
In Chapter 6.2, we discuss the in vivo and in vitro fucosylation of mini-TSR. However, 
our results suggested that mini-TSR can be fucosylated by POFUT2, but they do not 
explain why the fucosylation rate on mini-TSR is lower than that on wild-type TSR4 
(Fig. 6.2.6). These data were determined from the small-scale expression of mini-
TSR; we had not optimized the large-scale purification of mini-TSR in E. coli. In this 
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section, we describe the ongoing purification and characterization of mini-TSR. We 
also expressed and optimized the purification of TSR23*, which has thrombospondin 
repeats 2 and 3 from TSP-1 with a T to A mutation at the fucosylation site of TSR3. 
One of our goals was to investigate the in vitro fucosylation of these two modules by 
POFUT2.   
TSR23*, wild-type TSR4 (WT-TSR4), and mini-TSR were digested by HRV 3C 
protease, and incubated with Ni-NTA Agarose to remove the HRV 3C protease, the 
GST-His6 tag, and any non-specific contaminant proteins. As shown in Figure 6.1.5A, 
the 3C digestion efficiently removed the GST-His6 tag from TSR23*, as demonstrated 
by the evident band shift from ~37 kDa to 26 kDa. The band at ~26 kDa 
corresponded to the GST-His6 tag, and the band at 16 kDa corresponded to TSR23*. 
Incubation of the digested TSR23* with Ni-NTA resin efficiently removed the N-
terminal tag and 3C protease. The same procedure was applied to mini-TSR and 
WT-TSR4. Similar to TSR23*, we observed that WT-TSR4 appeared at ~10 kDa after 
cleavage and Ni-NTA incubation. However, there were several problems associated 
with the purification of mini-TSR. First, it was not completely digested by 3C 
protease; the tag was not cleaved from ~50% of the protein, despite an excess of 
protease being supplied for the digestion. Second, the digested mini-TSR still bound 
the N-terminal tag. The digested mini-TSR co-eluted with the 26 kDa N-terminal tag 
when we eluted the protein from the Ni-NTA resin (Fig. 6.1.5B).  
 
Figure 6.1.5 Tag removal of WT-, TSR23*, and mini-TSR 
The proteins were digested by 3C protease and digested samples were incubated with 
Ni-NTA Agarose to remove the tag and protease, and then analyzed by SDS-PAGE (A). 
The proteins were eluted from Ni-NTA Agarose, and then analyzed by SDS-PAGE (B).   
Although there was significant sample loss in the purification of mini-TSR, we could 
still observe a blurry signal corresponding to mini-TSR after concentrating the protein 
(Fig. 6.1.6).  
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Figure 6.1.6 Protein quantification  
Different volumes of TSR23*, WT-TSR4, and mini-TSR were loaded onto the gel for 
protein quantification by comparing them to the standard TSR4 of known concentration.  
The concentrations of TSR23*, WT-TSR4, and mini-TSR were determined by 
comparing them to standard TSR4. The concentration of TSR23*, WT-TSR4, and 
mini-TSR were 10 ng/µl, 40 ng/µl, and 10 ng/µl, respectively. Overall, the final yields 
were 15 µg of TSR23*, 60 µg of WT-TSR4, and 0.5 µg of mini-TSR from 250 ml of E. 
coli culture.  
In vitro activity assay of POFUT2 on mini‐TSR and TSR23* 
The same concentration (4 ng/µl) of WT-TSR4, TSR23*, and mini-TSR was 
incubated with an excess of GDP-fucose (200 µM) and 2 ng of POFUT2 to test the 
efficiency of fucosylation. The reactions were quenched by acidification at different 
time points and analyzed by LC-MS with the multiple-ion monitoring mode.  
We observed that the fucosylated WT-TSR4 (red line) eluted earlier than the 
unfucosylated WT-TSR4 (blue line) did (Fig. 6.1.7). About 40% of the WT-TSR was 
fucosylated at 7.5 min. The ratio of fucosylated WT-TSR increased with the reaction 
time. However, after 90 min, we still observed ~3% of unfucosylated WT-TSR. The 
peak shape of unfucosylated WT-TSR4 at 90 min showed two peaks; we 
hypothesized that one of the peaks corresponded to misfolded TSR4, which could 
not be fucosylated.    
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Figure 6.1.7 In vitro fucosylation assay of wild-type TSR4  
The reaction mixture was quenched at different time points and analyzed by LC-MS. 
We monitored the non-fucosylated TSR4 at m/z = 1622 (blue line) and fucosylated 
TSR4 at m/z = 1585 (red). 
When we analyzed the sample from mini-TSR, we observed that mini-TSR was 
eluted in three peaks. The molecular weight of each of these three peaks was 3268 
Da, which corresponds to mini-TSR with two disulfide bonds (Fig. 6.1.8A). The ratio 
of the three peaks was 25.3%, 55%, and 18.7%.  
The ratio of fucosylated mini-TSR (red line) increased with the reaction time. At 7.5 
min, the overall fucosylated mini-TSR was ~1.3% of the total mini-TSR (sum of three 
peaks), and increased to 2.6%, 3.8%, and 15% at 15, 30, and 90 min, respectively. 
Interestingly, by comparing the three peaks of the non-fucosylated form (blue line), 
the fucosylated mini-TSR gives only one peak at 19.8 min, which implies that only 
one of the three non-fucosylated peaks can be fucosylated. To identify a non-
fucosylated peak that can be recognized and fucosylated by POFUT2, we repeated 
the mini-TSR assay with 5-fold more POFUT2 and extended the reaction time to 120 
min (Fig. 6.1.8E). Under these conditions, we found that the non-fucosylated peak at 
20.17 min disappeared, and that the ratio of the fucosylated mini-TSR was 55%, 
which is the ratio of the second non-fucosylated peak. These data suggest that under 
these reaction conditions, all the mini-TSR at the second peak (20.17 min) was 
fucosylated by POFUT2, while the mini-TSR corresponding to the other two peaks 
could not be fucosylated.  
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Figure 6.1.8 In vitro fucosylation of mini-TSR 
The reaction mixture was quenched at different time points and analyzed by LC-MS. 
We monitored the non-fucosylated mini-TSR at m/z = 1090 (blue line) and fucosylated 
mini-TSR4 at m/z = 1138 (red). Mini-TSR with three different disulfide bond patterns 
are illustrated in F. Form 2 is the correctly folded form that is present in WT-TSR.  
Based on the results presented in Figure 6.1.8A-E, we propose that the mini-TSR 
expressed in E. coli may have three different disulfide bond patterns. Mini-TSR has 
four cysteines that can form two pairs of disulfide bonds (Fig. 6.1.8F). In form 1, C1 
bonds to C2, and C3 bonds to C4, thereby creating a long loop between C2 and C3. 
Form 2 is the correct disulfide pattern that can maintain the three-strand structure in 
TSR (Tan et al, 2002). The disulfide pattern in form 3 may create a big loop with two 
strands. According to our model (Fig. 6.2.5), only form 2 can be recognized and 
fucosylated by POFUT2. Therefore, we propose that form 2 is the peak that was 
eluted at 20.17 min, but forms 1 and 3 have not been assigned yet.  
The same reaction conditions that were used for WT-TSR4 and mini-TSR were used 
for TSR23*. In this elution gradient, fucosylated TSR23* could not be separated from 
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the non-fucosylated form. Although the fucosylated TSR23* and non-fucosylated 
TSR23* were inseparable, they could still be quantified individually by their molecular 
weight determined by mass spectrometry. At 7.5 min, 60% of the TSR23* was 
fucosylated, which increased to 80%, 97%, and 100% after 15, 30, and 90 min of 
reaction, respectively (Fig. 6.1.9).  
 
Figure 6.1.9 In vitro fucosylation of TSR23* 
The reaction mixture was quenched at different time points and analyzed by LC-MS. 
We monitored non-fucosylated TSR23* at m/z = 1784 (blue) and fucosylated TSR4 at 
m/z = 1805 (red). 
Interestingly, if we compare the ratio of fucosylated TSR at 7.5 min between the three 
substrates, TSR23* has the highest fucosylation rate, where 80% of the substrate 
was turned into product. About 40% of WT-TSR4 was fucosylated at 7.5 min, while 
only 1.3% of mini-TSR (or 2.1% of the second peak) was fucosylated. The difference 
in the fucosylation rate of POFUT2 on different substrates under the same reaction 
conditions indicates that POFUT2 may catalyze the reaction with different efficiencies. 
Discussion  
In this chapter, we described the expression and purification of different TSR 
constructs in E. coli for different purposes. We first described the large-scale 
expression and purification of His6-3C-TSR4 from rat F-spondin. We purified ~12 mg 
of His6-3C-TSR4 from 48 l of E. coli culture for kinetic assay studies (Chapter 6.2), 
activity assays of POFUT2 (Chapter 6.2), and co-crystallization experiments with 
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POFUT2 and GDP-fucose (that did not crystallize). We also described the purification 
of GST-His6-WT-TSR, GST-His6-mini-TSR, and GST-His6-TSR23*, which were the 
preliminary experiments to establish purification procedures and test the fucosylation 
efficiency of POFUT2. Although the expression and purification of His6-3C-TSR4 was 
tedious, the procedure was very reproducible, and TSR4 was properly folded. On the 
other hand, the expression and purification of GST-His6-TSR23* and GST-His6-mini-
TSR still need optimization. The discussion below will focus on mini-TSR and 
TSR23*.    
Disulfide patterns of the mini‐TSR expressed in E. coli 
The characteristic feature on the TSR module is the CWR-layered core structure 
(Tan et al, 2002), where the side chains of cysteine, tryptophan, and arginine stack in 
layers (Fig. 6.1.10).  
 
Adapted from (Tan et al, 2002) 
Figure 6.1.10 CWR-layered core structure of the TSR domain 
A schematic drawing of the CWR-layered structure; each layer and layer-forming 
residues are labeled. Three tryptophans, namely, W420, W423, and W426, (W layers) 
sandwich with R422, R330, and I438 (R layers). Two disulfide bonds cap the layers.  
The alternate stacking of the planar cationic guanidinium group of arginine and the 
aromatic side chains of tryptophan forms multiple cation-π interactions. This unique 
layered structure provides critical stabilization energy for TSR to maintain its compact 
antiparallel structure. However, in mini-TSR, there is only one tryptophan on the A 
strand and two arginines on the B strand, which could significantly reduce the 
stabilization energy of the structure, and lead to a less stable structure instead of a 
compact TSR domain. The pairing of the disulfide bonds relies on the layers bringing 
the cysteine residues into close proximity. Consequently, the scrambled structure of 
the mini-TSR could result in the incorrect pairing of disulfide bonds. Therefore, we 
propose the three peaks shown in Figure 6.1.8 correspond to mini-TSR with different 
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disulfide bond patterns. However, we have not determined the isoform of each peak. 
Since POFUT2 can recognize only properly folded TSR, we hypothesize that the 
second peak is form 2 in Figure 6.1.8F. Since we can only purify 0.5 µg of mini-TSR 
from 1 l of E. coli culture, we will likely use a highly sensitive method such as MS to 
identify the isoform corresponding to each peak.  
Analysis of peptides digested by a protease is a sensitive approach to identify 
proteins. Ideally, a protease that can hydrolyze mini-TSR under native conditions and 
with characteristic fragments to distinguish the disulfide bond patterns will be useful. 
Thermolysin is a metalloprotease from the gram-positive bacteria Bacillus 
thermoproteolyticus that can cleave proteins at the N-terminus of hydrophobic 
residues such as phenylalanine, leucine, isoleucine, methionine, and alanine.  
Mini-TSR cleavage by thermolysin can generate five fragments (6.1.11). Different 
forms of mini-TSR would have characteristic fragments for identification. Therefore, 
the disulfide bond pattern in each elution peak can be possibly identified by peptide 
mapping with thermolysin digestion.  
 
Figure 6.1.11 Thermolysin cleavage of mini-TSR 
The predicted peptides of mini-TSR with three disulfide bond patterns after cleavage by 
thermolysin 
Fucosylation on TSR23* 
TSRs are usually present in proteins as consecutive modules. For example, human 
thrombospondin-1 has three consecutive TSR modules, followed by three EGF-like 
repeats, and a thrombospondin type-3 repeat (Fig. 6.1.12A). Most TSRs with a 
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fucosylation motif in the consecutive repeats can be O-fucosylated (Gonzalez de 
Peredo et al, 2002). In our POFUT2-TSR model (Fig. 6.1.12B), POFUT2 only binds 
to TSR2 around the fucosylation site on the AB loop; the other part of TSR2 is 
solvent-exposed. TSR3, on the other hand, contacts POFUT2 through part of the A 
strand and BC loop, and leaves the fucosylation site on the AB loop exposed. 
According to the model, we predict that a TSR with two modules may be a better 
substrate because of the larger binding surface with POFUT2, which may increase 
the affinity between the two molecules.  
 
(A) is modified from (Tucker, 2004) 
Figure 6.1.12 The model of POFUT2 in complex with GDP-fucose and TSR23 of TSP-1 
Domain structure of TSP-1 is shown in (A). TSN, thrombospondin N-terminal domain; 
vWC, von Willebrand factor type A domain; TSC, thrombospondin C-terminal domain. 
Amino acid numbers are indicated above. (B)The structure of POFUT2 is shown in gray. 
TSR23 from TSP-1 (PDB:1LSL) is shown as a cartoon model. TSR2 is colored in red, 
and TSR3 is colored in green. GDP-fucose and fucose are shown as sticks.  
The preliminary results of fucosylation on TSR23* shown in Figure 6.1.9 suggest that 
it could be a better substrate than WT-TSR4 (Fig. 6.1.7). At the same time point, the 
ratio of fucosylated TSR23* is always higher than WT-TSR4. However, the 
experiment still needs to be optimized to obtain conclusive results.  
WT-TSR4 was from rat F-spondin, while TSR23* was cloned from human TSP-1. 
Although the structures of the AB loop between TSR2 from TSP-1 and TSR4 from F-
spondin are very similar, the disulfide bond pattern of the two proteins differ. 
Furthermore, the additional jar handle on TSRs from TSR-1 (Tan et al, 2002) that 
lacks in TSR4 from F-spondin may cause the difference in binding to POFUT2. An 
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appropriate way to compare the efficiency of fucosylation will be to express one-
module and two-module TSRs from the same protein such as TSR2 and TSR23* 
from TSP-1. Therefore, differences in the fucosylation efficiency between the proteins 
would be solely due to the number of TSR modules.  
We compared the fucosylation efficiency of POFUT2 on different TSR modules. 
Nevertheless, the catalytic reaction consists of three separate steps; substrate 
association, catalysis, and product dissociation. We did not specifically determine 
how the additional TSR module affects fucosylation efficiency. Other approaches 
such as isothermal titration calorimetry (ITC) that can measure the association rate 
(Ka), enthalpy (∆H) and binding stoichiometry or surface plasma resonance that is 
used to determine ka and dissociation rate (kd) may help in clarifying how the 
additional TSR module affecting POFUT2-catalyzed fucosylation efficiency.  
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6.2 Structure of Human POFUT2: insights into thrombospondin type 1 
repeat fold and O‐Fucosylation 
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Structure of human POFUT2: insights into
thrombospondin type 1 repeat fold
and O-fucosylation
Chun-I Chen, Jeremy J Keusch,
Dominique Klein, Daniel Hess,
Jan Hofsteenge and Heinz Gut*
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
Protein O-fucosylation is a post-translational modification
found on serine/threonine residues of thrombospondin
type 1 repeats (TSR). The fucose transfer is catalysed by
the enzyme protein O-fucosyltransferase 2 (POFUT2) and
440 human proteins contain the TSR consensus sequence
for POFUT2-dependent fucosylation. To better understand
O-fucosylation on TSR, we carried out a structural and
functional analysis of human POFUT2 and its TSR sub-
strate. Crystal structures of POFUT2 reveal a variation of
the classical GT-B fold and identify sugar donor and TSR
acceptor binding sites. Structural findings are correlated
with steady-state kinetic measurements of wild-type and
mutant POFUT2 and TSR and give insight into the catalytic
mechanism and substrate specificity. By using an artificial
mini-TSR substrate, we show that specificity is not pri-
marily encoded in the TSR protein sequence but rather in
the unusual 3D structure of a small part of the TSR. Our
findings uncover that recognition of distinct conserved 3D
fold motifs can be used as a mechanism to achieve sub-
strate specificity by enzymes modifying completely folded
proteins of very wide sequence diversity and biological
function.
The EMBO Journal advance online publication, 15 May 2012;
doi:10.1038/emboj.2012.143
Subject Categories: proteins
Keywords: crystal structure; enzymatic mechanism; GDP-
fucose; protein O-fucosyltransferase 2; thrombospondin type 1
repeat
Introduction
Protein glycosylation is the most abundant and diverse
co- and post-translational modification in life. In eukaryotes,
450% of proteins are modified with carbohydrates
(Apweiler et al, 1999) which together regulate myriad
biological processes. Altered or defective protein
glycosylation pathways cause various developmental
defects as reflected in the rapidly growing number of
congenital disorders of glycosylation (Freeze, 2007; Jaeken
and Matthijs, 2007).
The unusual protein O-linked fucosylation has been de-
scribed on thrombospondin type 1 repeats (TSR) (Hofsteenge
et al, 2001; Gonzalez de Peredo et al, 2002) and epidermal
growth factor-like (EGF) repeats (Bjoern et al, 1991;
Buko et al, 1991; Harris et al, 1992; Nishimura et al,
1992; Harris and Spellman, 1993) and is catalysed by the
protein O-fucosyltransferase 2 (POFUT2) and protein
O-fucosyltransferase 1 (POFUT1), respectively (Harris and
Spellman, 1993; Luo et al, 2006a). Both enzymes transfer
the fucose moiety from GDP-fucose to a serine or threonine
residue of the properly folded acceptor molecule, recognizing
the consensus sequences CX2–3(S/T)CX2G (Hofsteenge et al,
2001) in TSR or CX4–5(S/T)C (Harris and Spellman, 1993) in
EGF repeats, respectively. The fucose residue on TSR can be
elongated to a glucose-b1,3-fucose disaccharide by the b1,3-
glucosyltransferase (b3GlcT) (Kozma et al, 2006; Sato et al,
2006). In EGF repeats, the fucose may be extended to an
NeuAc-a2,3/a2,6-Gal-b1,4-GlcNAc-b1,3-Fuc tetrasaccharide
catalysed by the sequential enzymatic activity of Fringe,
b1,4-galactosyltransferase 1 and a2,3/a2,6-sialyltransferase
(Nishimura et al, 1992; Harris and Spellman, 1993; Stanley,
2007; Luther and Haltiwanger, 2009; Rana and Haltiwanger,
2011). Both TSR and EGF repeats are small cysteine-rich,
layered structural motifs with three conserved disulphide
bonds and little secondary structural elements. TSR and
EGF repeat proteins are sequence-wise very diverse with
only a few structural key residues being conserved. The
glycosyltransferases involved in the O-fucosylation
pathways of TSR and EGF repeats are specific and do not
crossreact (Luo et al, 2006b).
The importance of protein glycosylation on EGF repeats
has been extensively studied in the Notch signalling pathway
(Luther and Haltiwanger, 2009) where the EGF modification
was shown to regulate embryonic development and tissue
renewal by controlling the ligand specificity of Notch
(Stanley, 2007; Stahl et al, 2008). Crystal structures of
C. elegans POFUT1 alone and in complex with GDP-fucose
or GDP have been solved recently and give insight into
overall protein structure and the enzymatic mechanism
(Lira-Navarrete et al, 2011). The role of POFUT2-dependent
fucosylation of TSR on the other hand is less clear. Progress
was made recently by Du et al (2010) using Pofut2 knockout
mice where they found that O-fucosylation of TSR is critical
for restricting epithelial-to-mesenchymal transition, correct
patterning of the mesoderm, and localization of the
endoderm in embryonic development. In C. elegans,
POFUT2-dependent TSR fucosylation was found to be
involved in the regulation of distal tip cell migration
(Canevascini et al, 2006). TSR proteins are expressed in the
secretory pathway with O-fucosylation occurring within the
endoplasmic reticulum. In cell culture experiments, mutation
of fucosylation sites on TSR of ADAMTS13 (Ricketts et al,
2007) and Punctin-1 (Wang et al, 2007) reduced or
completely abolished secretion of the proteins, indicating
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that POFUT2-dependent O-fucosylation on TSR might be
required for optimal secretion of these proteins. No disorder
has yet been directly linked to a genetic defect of the Pofut2
locus in humans. However, mutations in the B3GALTL gene
that encodes the b3GlcT enzyme responsible for glucose
transfer onto O-fucosylated TSR cause the autosomal
recessive disorder Peters Plus syndrome (Lesnik Oberstein
et al, 2006; Hess et al, 2008). This disorder is characterized by
anterior-eye-chamber abnormalities, disproportionate short
stature and developmental delay.
Protein O-fucosylation raises three fundamental questions
about the interaction between glycosyltransferases and their
protein substrate: How does a glycosyltransferase accommo-
date a fully folded protein substrate in its active site? Which
structural features are used to discriminate between the
different families of protein substrates and how can specifi-
city be achieved in the case of sequence-wise degenerated
protein substrates? We have addressed these questions by
determining the structure of human POFUT2 (alone and in
complex with the sugar donor GDP-fucose) and steady-state
kinetic analysis of wild-type and mutant transferase. To
investigate further how POFUT2 interacts with its TSR
sugar acceptor, we have analysed O-fucosylation of wild-
type and mutant TSR in an in-vitro assay and in mammalian
HEK293T cells. The crystal structure shows that POFUT2
belongs to the classical GT-B fold family of glycosyltrans-
ferases with two closely interacting Rossmann-like domains.
The C-terminal domain binds the GDP-fucose moiety while
the TSR substrate is recognized by a large cavity in the centre
of the bilobal structure. Based on our structural data and
steady-state kinetic measurements, we suggest that the con-
served E54 residue acts as the catalytic base, and describe key
catalytic residues located in the active site. Structural and
biochemical knowledge was used to clarify why only TSR
modules can bind to the sugar acceptor site and to design an
artificial minimal TSR module which we show to be sufficient
as sugar acceptor for common TSR glycan modifications
(O-fucose-glucosylation and C-mannosylation). Furthermore,
we investigated how POFUT2 substrate specificity is achieved
despite the large sequence diversity present in TSR containing
the CX2–3(S/T)CX2G fucosylation motif. We present the struc-
ture of a protein glycosyltransferase modifying a completely
folded protein substrate and propose a novel mechanism of
enzyme-protein substrate specificity, based on recognition of
a small conserved 3D structural motif. It explains how site-
specific modifications can take place in the absence of a
conserved protein sequence.
Results
Crystal structure of human POFUT2
We have expressed and purified human D21-POFUT2 from
mammalian cell culture and have determined its crystal
structure at 3.0 A˚ resolution. The protein crystallized in
space group P3221 with two molecules in the asymmetric
unit (a.u.) and the structure was solved by the single iso-
morphous replacement with anomalous scattering (SIRAS)
method using a platinum derivative. Data collection, phasing
and refinement statistics are presented in Table I. The refined
POFUT2 crystal structure displays clear electron density for
residues 41–429 (out of 22–429) and the two molecules in the
a.u. are almost identical with an r.m.s.d. of only 0.49 A˚. The
structure of POFUT2 is composed of two Rossmann-like
domains with b/a/b topology typical of the GT-B fold of
glycosyltransferases (Figure 1A). N- and C-terminal domains
encompass residues 22–242 and 243–429, respectively. The
two domains interact closely with each other (buried surface
area of 1416 A˚2) forming an extended protein unit. Fully
structured loops originating from both the N-terminal
(Q141–V156, E158–N189) and C-terminal domain (T407–
Y429, L293–L309) form a large central cavity in the molecule
with two disulphide bonds stabilizing loop conformations in
each domain (C161–C192 and C412–C419). A second nar-
rower cleft is present in the C-terminal domain, formed
by helices a13 and a14, loop Q93–Q99 and the N-terminal
tip of helix a1 (E54–N57). Electron density for three
N-acetylglucosamine (GlcNAc) moieties is present at residues
N189, 209, and 259 revealing all predicted N-glycosylation
sites occupied. The quality of the electron density allowed
model building of GlcNAc moieties at N189 and N259.
In order to identify functional POFUT2 regions involved in
catalysis and substrate binding, we mapped conserved resi-
dues onto the protein surface and also analysed the electro-
static surface potential (Figure 1B–D). Martinez-Duncker et al
(2003) identified three conserved peptide motifs, which are
shared among all four families of fucosyltransferases. These
peptide motifs (I, II, and III) map onto the bottom and one
wall of the narrow cleft in the C-terminal domain that
branches away from the central large cavity (Figure 1B).
The fact that this cavity also shows a highly positive electro-
static potential at its entrance up to the middle (Figure 1C)
and that superposition of the C. elegans POFUT1 GDP-fucose
complex placed the nucleotide sugar in the same region,
made it very likely that it harbours the GDP-fucose binding
site. Additional conserved residues (Figure 1B and D)
mapped onto a second extended surface patch located at
the bottom of the large cavity formed by N- and C-terminal
loops in the centre of the two domains. Considering the shape
and dimensions of this cavity, we hypothesized the TSR
substrate to bind in this central area.
We searched the Protein Data Bank (PDB) to identify
structurally closely related proteins using DALI (Holm and
Rosenstro¨m, 2010; Supplementary Table SI; Figure 2;
Supplementary Figure S1). A search with the entire
POFUT2 structure revealed the structure of C. elegans
POFUT1 to be most similar (PDB 3ZY2; Lira-Navarrete
et al, 2011) followed by the nodulation fucosyltransferase
NODZ (PDB 2HHC) (Brzezinski et al, 2007), the
lipopolysaccharide heptosyltransferase I WaaC (PDB 2H1H)
(Grizot et al, 2006), and the a1,6-fucosyltransferase FUT8
(PDB 2DE0) (Ihara et al, 2007). If the N-terminal domain
alone was used in the search, then structures of POFUT1 and
NODZ gave the highest Z-scores followed by very distantly
related Rossmann-like fold proteins with low scores. A search
with the C-terminal domain alone on the other hand yielded
POFUT1, NODZ, WaaC, and FUT8 as close structural
neighbours. C. elegans POFUT1 and human POFUT2 (21%
sequence identity) have a very similar core structure in the
two Rossmann fold domains and also share the same
arrangement of N- and C-terminal domains but differ
significantly in many surface exposed structural elements
(Figure 2; Supplementary Figure S1). N-terminally, the
POFUT2 loop 85–103 that is in a coiled conformation is
replaced by an additional short b-hairpin in POFUT1. The
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Table 6.2.1 Data collection and refinement statistics   
Δ
two structures differ dramatically in the POFUT2 region
140–200 where the long structured POFUT2 loop comprising
residues 140–156 is missing in POFUT1. In the C-terminal
domain, three striking structural differences can be identified.
First, the long POFUT2 loop (260–287) that reaches over to
the N-terminal domain opposite of the substrate binding cleft
is not present in the C. elegans POFUT1 structure. Second, the
POFUT2 loop 293–307 that builds the C-terminal wall of the
central protein cleft is replaced by an additional small domain
in POFUT1 (239–283) formed by three short helices that
together restrict access to the central POFUT1 protein cavity.
Third, the POFUT1 sequence is much shorter and the struc-
ture ends after the last C-terminal b strand where POFUT2
continues with a large disulphide linked turn followed by a
long stretch of residues in a rippled conformation defining the
entry to the central protein cavity on the C-terminal side.
Superposition of C-terminal domains of POFUT2, NODZ, and
FUT8 reveals these domains to be similar with the central
b-sheet and surrounding helices superimposing very well
(r.m.s.d. 3.1 and 2.7 A˚, respectively). Nevertheless, more
detailed analyses identify structural differences: Again, the
POFUT2 loop 260–287 opposite of the substrate binding cleft
is not present and also the two last strands of the central
b-sheet of NODZ and FUT8 differ by forming a regular b-sheet
while they are in a rippled conformation with an SS-bridge
connecting the two strands in POFUT2. Superposition of the
entire POFUT2 structure with DALI hits that rank after
POFUT1 show that the N-terminal domains of FUT8 and
WaaC are structurally very different. Only the first and last
helix of the N-terminal domain and some strands of the
central b-sheet overlap well with NODZ and WaaC.
POFUT2 enzymatic activity
To validate our model of POFUT2 interaction with the GDP-
fucose sugar donor and the TSR sugar acceptor, we estab-
lished an LC-MS-based enzyme activity assay and tested the
capability of wild-type and mutant POFUT2 to fucosylate
TSR4 from rat F-spondin. In an initial set of experiments,
we analysed the effect of two different N-terminal boundaries
(D21- and D36-POFUT2) and of varying N-glycan structures,
as well as the influence of different divalent cations on the
enzymatic activity of wild-type POFUT2 (Figure 3). While
neither changing the N-terminal boundary nor having a
different glycoconjugate composition had an effect on the
enzymatic activity, we found that different metal ions influ-
ence catalytic activity in different ways. Mg2þ , followed by
Mn2þ and Ca2þ , activated the enzyme in decreasing order
(100, 90, and 80% relative activity) but Zn2þ completely
abolished its activity. The enzyme was still active in the
presence of EDTA, albeit at a very low level (B5% relative
activity). Having a sensitive enzymatic activity assay avail-
able that monitors directly TSR fucosylation, we determined
the steady-state kinetic parameters for GDP-fucose and
TSR4 using wild-type high mannose type D21-POFUT2
(Supplementary Figure S2). POFUT2 is an efficient enzyme
with KM values of 9.8 and 29.5 mM for GDP-fucose and TSR4,
Table I Data collection and refinement statistics
POFUT2 native POFUT2 Pt derivative POFUT2 GDP-fucose complex
Data collection
Space group P3221 P3221 P3221
Cell constants a, b, c (A˚) 118.6, 118.6, 196.2 118.5, 118.5, 195.0 153.0, 153.0, 185.7
Wavelength l (A˚) 1.000 0.890 1.000
Resolution range (A˚)a 30.0–3.0 (3.11–3.00) 20.0–5.5 (5.69–5.50) 40.0–3.4 (3.63–3.40)
Unique reflections 31 375 9737 32751
Completeness (%)a 96.4 (71.6) 100 (99.9) 93.3 (93.6)
Multiplicity 11.3 10.4 4.7
Rsym (%)
a,b 12.4 (39.7) 22.4 (43.4) 16.6 (76.6)
I/s(I)a 21.0 (2.4) 11.3 (3.7) 11.9 (2.1)
Phasing power iso/ano 1.04/0.53
Refinement
Resolution range (A˚) 30.0–3.0 40.0–3.4
Reflections (all) 31 318 32 745
Reflections (test set) 1593 (5.1%) 1622 (5.0)
Rcrys (%) 17.4 19.3
Rfree (%) 23.6 23.8
r.m.s.d.
Bond lengths (A˚) 0.008 0.011
Bond angles (deg) 1.28 1.31
Wilson B-factor (A˚2) 50.9 —
Mean B-factor (A˚2)
Protein 54.6 102.2
Ligand — 113.4
Ramachandran plot (%)
Favoured 97.0 97.0
Allowed 3.0 3.0
Outliers 0 0
a
Values in parentheses refer to the highest resolution shell.
b
Rsym¼ShklSj|Ij,hkl#/IhklS|/ShklSjIj,hkl where /IhklS is the average of the intensity Ij,hkl over j¼ 1,y, N observations of symmetry equivalent
reflections hkl.
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Figure 6.2.1 Crystal structure of human POFUT2 and multiple sequence alignment of ortholog 
sequences. 
 
 
 
 
respectively, and a kcat of 144 per minute. Based on our
structural results, we designed 14 mutations targeting specific
putative functional residues of the enzyme and tested enzy-
matic activity (Figure 3D and E). Out of 14 mutations, 2 did
not yield any soluble protein pointing to a critical function of
these residues in the folding pathway of the protein (D333A
and D265–285). All other mutants expressed and purified
well and equal amounts were used for the activity assay.
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Figure 6.2.2 Structural superposition of human POFUT2 and C. elegans POFUT1.  
 
From the POFUT2 mutants targeting the catalytic mechanism,
E54A and R294A resulted in complete loss of activity while
the D297A and E396A mutants remained active (15 and 8%,
respectively). A change of the highly conserved W92 to
alanine as well as deletion of the entire loop (D90–100)
abolished enzymatic activity. POFUT2 features a unique
loop (265–285) located on the opposite side of the large
cleft (Figure 3D), which protrudes from the C-terminal do-
main and which is attached to the N-terminal domain via a
completely conserved tryptophan residue. We hypothesized
that this residue, W273, is involved in controlling movements
of the N- and C-terminal domain relative to each other during
the catalytic cycle and indeed lost 90% activity when we
mutated W273 to alanine. A series of mutations targeted the
large loop forming one wall of the central cavity (residues
147–152) with the aim of disturbing TSR binding. While the
point mutations reduced the catalytic activity to B10–73%,
removal of the entire loop (D147–152) yielded a completely
inactive enzyme. Alanine mutation of another conserved
residue (W425) located at the entry of the central cavity
and potentially involved in TSR binding also reduced
POFUT2 activity to 38%.
Crystal structure of human POFUT2 in complex with
GDP-fucose
In crystals of native POFUT2, we found the putative GDP-
fucose binding pocket to be partially covered by a loop from
the second molecule present in the a.u. This made it
impossible to obtain a structure of the binary complex by
soaking experiments and despite extensive efforts we did not
obtain crystals in co-crystallization experiments. We only
obtained crystals when we used the catalytically incompetent
POFUT2 E54A mutant that allowed us to solve the structure
of POFUT2 in complex with the sugar donor. Analysis of the
90°
POFUT1: 239–283 POFUT2: 140–156
POFUT2: 293–307
POFUT2: 85–103
POFUT2: 260–287
POFUT1: 66–79
Figure 2 Structural superposition of human POFUT2 and C. elegans POFUT1 in two orientations rotated by 901. POFUT2 (red) and POFUT1
(green) are displayed as cartoon models with transparent surfaces. GDP-fucose bound to POFUT1 is shown as sticks (yellow and atom colours).
Main structural differences are highlighted in close-up images and are labelled.
Figure 1 Crystal structure of human POFUT2 and multiple sequence alignment of orthologue sequences. (A) The human POFUT2 structure is
displayed as cartoon model in two orientations 601 apart. N- and C-terminal domains are in grey and green, respectively, N- and C-termini are
labelled. Disulphides and covalently bound GlcNAc molecules are displayed as sticks in atom colours. (B) Conserved residues from the
multiple POFUT2 sequence alignment (D) are mapped onto the surface of the human POFUT2 structure (100% conservation: red, conserved
motifs I–III among fucosyltransferases: orange). Substrate binding sites are labelled. (C) Mapping of the electrostatic surface potential onto the
surface of the POFUT2 structure (scale: ! 20 to þ 20 kT/e from red to blue). The highly positive surface patch involved in GDP-fucose binding
is boxed, zoomed-in and rotated by 301 in the right image. Computed with the APBS plugin of PyMol (Baker et al, 2001). (D) Multiple sequence
alignment of selected POFUT2 sequences (ClustalW; Larkin et al, 2007). Structural features present in the POFUT2 structure and mutated
residues are indicated.
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Figure 6.2.3 Initial rate of fucosylation of purified wild-type and mutant POFUT2.  
crystal packing revealed the presence of a crystallographic
dimer similarly to the non-crystallographic-symmetry dimer
present in the a.u. of the apo structure but with a reduced
interface enabling access to the GDP-fucose binding site
(Supplementary Figure S3). Clear electron density for GDP-
fucose was present in all four molecules in the a.u. (space
group P3221, 3.4 A˚ resolution) and located at the predicted
position in the narrow cleft leading from the N- and
C-terminal domain interface into the C-terminal domain
(Figure 4A). The guanine purine base is mainly held in
place by stacking interactions with F389 and hydrogen
bonds between the N1 nitrogen and the D371 side chain
while other residues of the pocket additionally contribute
hydrophobic interactions (Figure 4B). The ribose moiety
bulges up from the bottom of the cleft and does not show
any tight interaction with the protein. Instead, the main
affinity for the sugar donor comes from the interaction of
the diphosphate group with the protein. The guanidinium
moiety of R294 forms a salt bridge with the b-phosphate
while the positive dipole located at the N-terminal end of the
last helix (387–400) tightly attaches the diphosphate moiety
to the helix tip where it hydrogen bonds side chain (T388)
and backbone atoms of residues T388 and F389. Strikingly,
the fucose is arranged almost perpendicular to the nucleotide
diphosphate via hydrogen bonds between the O3 hydroxyl
and the P53 carbonyl group and the O2 hydroxyl and the G55
amide nitrogen of the N-terminal domain. This arrangement
presents the activated phosphoester bond at the anomeric
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Figure 3 Initial rate of fucosylation of purified wild-type and mutant POFUT2. (A) Influence of different N-terminal POFUT2 truncations.
(B) Influence of the glycan composition (complex, high mannose, þEndo-H). (C) Presence or absence of varying divalent metal ions (n.d.: not
detected). Columns in (A–C) represent the average of two independent measurements while individual measurements are shown as triangles.
(D) POFUT2 mutations used in the enzymatic in-vitro assay. POFUT2 is shown as a cartoon model with transparent surface in two orientations.
Point mutations (sticks, cyan) and deletions (yellow) are indicated. (E) Relative enzymatic activity of different point and deletion mutations
compared with the wild-type (WT) protein. Experiments were repeated twice and the mean of the two measurements and the individual
measurements are shown. The western blot signal used for quantification of the enzyme input is indicated.
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Figure 6.2.4 GDP-fucose binding in human POFUT2.  
 
carbon to the large open channel where the TSR substrate is
postulated to bind. Both the 1C4 and 4C1 fucose ring con-
formations (C1-O1 bond in equatorial and in axial position,
respectively) have been refined against the low resolution
data (Supplementary Figure S4) and since the 1C4 conforma-
tion resulted in a slightly better fit to the experimental data
we included it in the final model of the complex. The overall
GDP-fucose binding mode in POFUT1 and POFUT2 is similar
but a detailed analysis uncovers important differences which
likely have an impact on the catalytic mechanism (Lira-
Navarrete et al, 2011). In POFUT2, the fucose moiety is
freely accessible from the large central protein cavity where
we expect TSR to bind. This is not the case in POFUT1 where
the additional small helical domain (239–283), that provides
the F261 residue holding the fucose in place, blocks access
together with F199 from the N-terminal domain. In addition,
POFUT1 residue R40 completely covers with its side chain
GDP-fucose from the top thereby limiting access from the
other side. This residue is replaced by G55 in POFUT2 and
GDP-fucose is solvent exposed. In general, GDP-fucose is
much more buried in POFUT1 compared with POFUT2 also
leading to different dihedral angles of the diphosphate group.
Although the sugar donor could only be modelled with
limited accuracy in POFUT2 due to limited resolution, the
binding mode clearly differs in several details.
Structural restraints in TSR for productive fucose
attachment
Our structure of the POFUT2 GDP-fucose complex together
with the structures of fucosylated TSR2-TSR3 of human TSP-1
(Tan et al, 2002) and fucosylated TSR1 of ADAMTS13
(Akiyama et al, 2009) enabled us to build a model of the
full enzyme substrate ternary complex. Superposition of
anomeric fucose carbons in these structures with the
anomeric carbon in the POFUT2 GDP-fucose complex,
followed by manual adjustment, yielded the overall TSR
position. This initial model was used to overlay the TSR4
structure from rat F-spondin (PDB 1VEX) (Pa¨a¨kko¨nen et al,
2006) and energy minimization of the full complex in CNS
(Brunger et al, 1998). We obtained a plausible model of the
ternary complex in which the elongated TSR unit lies in the
deep interdomain cavity of POFUT2 spanning across the
glycosyltransferase (Figure 5A). The TSR module contacts
the highly conserved POFUT2 surface via its flat hydrophobic
side, opposite of the SS-bond pattern and the tryptophan-
arginine stacking (CWR layer), where the B and C strand
show a regular antiparallel b-sheet. In addition, the rippled A
strand contacts the bottom and the side wall of the cleft. The
entire AB loop harbouring the CX2–3(S/T)CX2G motif is in
close contact with POFUT2. Only half of the TSR module was
predicted to interact with POFUT2 whereas the N-terminal
S387
T388
D371
P53
R294
F389
S387
T388
D371
P53
R294
F389
A
B
TSR
binding
Figure 4 GDP-fucose binding in human POFUT2. (A) Structure of the POFUT2 GDP-fucose complex displayed as a cartoon model in grey with
transparent surface. GDP-fucose is shown as sticks in atom colours. (B) Stereo figure of the GDP-fucose (cyan sticks) binding mode in POFUT2
(white sticks). NCS averagedmFo-DFc electron density calculated after molecular replacement and one round of refinement (in absence of GDP-
fucose) is shown as mesh in blue (3s). Hydrogen bonds are displayed as green dotted lines. The orientation is different than in (A) for better
clarity.
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Figure 6.2.5 Model of the POFUT2-GDP-fucose-TSR complex and POFUT2 enzymatic activity 
using mutant TSR as substrate 
part of the A strand and the BC loop including the jar handle
are solvent exposed. Interestingly, we find a second con-
served POFUT2 surface patch located on the 90–100 loop that
could interact with an additional TSR domain (e.g., TSR2–
TSR3 in TSP-1) or with other protein domains on the
C-terminal side of the TSR unit (e.g., EGF repeat in TSP-1
or CA domain in ADAMTS13).
In order to validate our model of TSR binding, we ex-
pressed a series of F-spondin TSR4 mutants in HEK293Tcells,
purified the secreted protein from the medium and analysed
its fucosylation state by mass spectrometry (Figure 5B and C).
Changes to the conserved WXXWXXW motif in the A strand
(in the case of TSR4 of F-spondin L4XXW7XXW10), the key
element of the TSR fold that forms the multi-layered deloca-
lized p-system with the conserved arginine residues from the
B strand (WR of CWR), reduced the efficiency of fucosylation
significantly. Single mutations of W7 and W10 to alanine
produced only 24 and 31% of fucosylated TSR4, double
mutations on both sites further reduced the fucosylation to
14% compared with wild type whereas the L4A mutation did
not have any influence. Next, we introduced mutations in the
AB loop close to the threonine (T*16) that undergoes fuco-
sylation: replacing the valine (V15) next to it with an iso-
leucine or changing the glycine (G20) at the end of the turn to
alanine had only minor effects (86, 75% fucosylation). On the
other hand, when we introduced two additional glycine
residues right before the threonine (GGT*, mimicking the
fucosylation sequon in EGF repeats) to create a larger loop
between the disulphide forming cysteine and the threonine,
fucosylation was completely abolished. The disulphide bond
pattern is a hallmark in the fold of TSR therefore we inves-
tigated how fucosylation is affected by removing SS-bonds.
Mutation of the cysteines forming the SS-bond between the A
and C strand, where we postulated no interaction with
POFUT2, was well tolerated with no reduction in fucosylation
levels (C2,35A). To our surprise, the removal of the second
SS-bond between the A and C strand had no dramatic effect
with 80% fucosylated product (C13,46A). On the other hand,
removal of the SS-bond that connects the AB loop (C17,51A)
with the C-terminal end of the C strand resulted in 55%
reduced fucosylation levels. When we removed both SS-
bonds, which together stabilize the 3D conformation of the
AB loop, we could not detect any fucosylated TSR product.
We superimposed all available structures of TSR modules
(PDB 1LSL, Tan et al, 2002; 1VEX and 1SZL, Pa¨a¨kko¨nen et al,
2006; 3GHM, Akiyama et al, 2009; 2BBX, Tossavainen et al,
2006) at the predicted substrate binding site of POFUT2 and
analysed structural and sequence restraints potentially
involved in substrate recognition. The structural
information was compared with the profile hidden Markov
model (HMM) of the Pfam entry of the thrombospondin type
1 domain (PF00090, http://pfam.sanger.ac.uk; Supplemen-
tary Figure S5) and multiple sequence alignments of all
human TSR type 1 domains present in the Uniprot database
(http://www.uniprot.org) that contain the putative fucosyla-
tion motif (CX2–3(S/T)CX2GG). The sequence data revealed
the enormous sequence diversity besides only a few con-
served residues that seem to be absolutely necessary for the
TSR fold. Taking into account our experimental data about
the contribution of selected TSR structural elements to
POFUT2 fucosylation efficiency, we hypothesized that sub-
strate specificity is not primarily encoded in the protein
sequence but rather in the unusual 3D structure of one half
of the TSR module.
Consequently, we investigated whether a minimal TSR
module containing only seven conserved structural residues
of the TSR hallmark elements (disulphide pattern and side-
chain stacking) would be sufficient as a POFUT2 sugar
acceptor. We designed and expressed a truncated TSR module
based on F-spondin TSR4 consisting of approximately half
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Figure 5 Model of the POFUT2 GDP-fucose TSR complex and POFUT2 enzymatic activity using mutant TSR as substrate. (A) Surface
representation of the POFUT2 GDP-fucose structure with POFUT2 residues coloured as in Figure 1B and GDP-fucose as sticks. TSR4 from rat
F-spondin (PDB 1VEX) is displayed as a cartoon model in cyan. (B) Structure of TSR4 from rat F-spondin. Residues that were mutated for
fucosylation measurements are numbered. (C) Relative fucosylation efficiency of TSR mutants. Wild-type and mutant TSR was expressed and
purified from HEK293T cells and analysed by mass spectrometry for fucosylation efficiency. n.d.: not detected. Experiments were repeated
twice and the mean of two measurements and the individual measurements are displayed.
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the length and tested fucosylation by mass spectrometry. The
first TSR residue of this artificial minimal TSR corresponds to
W10 in the A strand (Figure 5B) and includes the entire AB
loop where the consensus sequence is located. Residues
predicted not to be involved in POFUT2 interaction connect-
ing the B and C strand were deleted and replaced with a short
GSG linker (Figure 6A). This artificial minimal TSR com-
prised only 29 residues compared with 55 for wild-type TSR
and is referred to as mini-TSR in this article.
Wild-type TSR4 and mini-TSR were expressed and isolated
from E. coli and used as acceptor substrates for purified
POFUT2 in a qualitative in-vitro fucosyltransferase assay.
The reaction products were monitored for fucose incorpora-
tion by mass spectrometry. An increase in mass of 146Da
corresponding to the addition of one fucose moiety was
observed for both the wild-type (Figure 6B) and mini-TSR
substrate (Figure 6C). Fucosylation was only observed in
reactions that included POFUT2. Thus, POFUT2 recognizes
and modifies both wild-type and truncated artificial mini-
TSR. We further validated our findings by expressing mini-
TSR with an N-terminal His–FLAG tag in HEK293T cells. The
secreted mini-TSR protein was purified from the culture
medium and analysed by mass spectrometry. We found a
homogenous species of 7004.98Da corresponding to the
tagged mini-TSR with two hexoses and one deoxyhexose
attached (Figure 6D). To further analyse the glycosylation
state of the mini-TSR, secreted and purified protein was
digested with human rhinovirus 3C to remove the tag,
reduced and alkylated, and digested with Lys-C protease
yielding a peptide covering the predicted glycosylation sites.
MS/MS analysis confirmed the sequence (GPWSDCSVTCGK)
and revealed the glycan modifications (Figure 6E). Loss of
one hexose and one hexose-deoxyhexose disaccharide from
the parent ion (m/z 912.36) was observed in the MS spectrum
(m/z 831.33 and 758.30, respectively). In addition, the mass
difference between the b2 and b3 ion corresponded to one
WT-TSR4 TIPCLLSPWSEWSDCSVTCGKGMRTRQRMLKSLAELGDCNEDLEQAEKCMLPECP
Mini-TSR4 --------------------WSDCSVTCGKGMRTR---------------GSG---------------QAEKCMLPECP
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Figure 6 O-fucosylation of mini-TSR. (A) Amino-acid sequences of wild-type TSR4 from rat F-spondin and engineered mini-TSR are compared.
Amino acids that form the three strands are indicated. Wild-type TSR and mini-TSR were expressed and isolated from E. coli. These modules
were used as acceptor substrates in the POFUT2 in-vitro assay and the reaction products analysed by mass spectrometry. Both the wild-type
TSR (B) and mini-TSR (C) show two peaks that differ by 146Da, indicating the presence or absence of one fucose molecule. Wild-type and
mini-TSR are drawn as cartoons with disulphide bonds in yellow and fucose as a red triangle. Mini-TSR is approximately half the size of wild-
type TSR, with a truncated A strand and the deleted BC loop replaced by a three residue linker, GSG. (D) An N-terminal His6–FLAG-3C-tagged
mini-TSR was expressed in mammalian HEK293Tcells, isolated from the medium and analysed by mass spectrometry. The mono-isotopic mass
(7004.98) represents the intact, tagged mini-TSR with two hexoses and one deoxyhexose. (E) Secreted and purified mini-TSR from HEK293T
cell expression was digested with human rhinovirus 3C and Lys-C protease and analysed by mass spectrometry. MS/MS analysis confirmed the
sequence (GPWSDCSVTCGK) and revealed the glycan modifications. Loss of one hexose and one hexose-deoxyhexose disaccharide from the
parent ion (m/z 912.36) was observed in the MS spectrum (m/z 831.33 and 758.30, respectively) and the mass difference between the b2 and
b3 ion corresponded to one hexose molecule attached to the tryptophan. The characteristic ! 120Da fragment (m/z 698.28) represents the
typical signature motif for C-hexosylation.
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hexose molecule attached to the tryptophan and the char-
acteristic ! 120Da fragment (m/z 698.28) revealed the tryp-
tophan hexosylation to be C-linked (Hofsteenge et al, 1994).
In summary, the mass spectrometry analysis demonstrates
that mini-TSR is modified with an O-linked fucose-glucose
disaccharide and a C-linked mannose on the tryptophan
as it is the case for wild-type TSR4 (Hofsteenge et al, 2001).
These experiments confirmed that mini-TSR is a substrate for
POFUT2 both in HEK293T cells and in our in-vitro
fucosyltransferase assay.
Discussion
POFUT2 protein structure and TSR substrate
recognition
Here, we present the crystal structure of human POFUT2 that
together with orthologues forms the GT68 family of inverting
protein O-fucosyltransferases of the GT-B fold (Cantarel et al,
2009). Although many structures of glycosyltransferases are
solved there is only very limited structural information
available for glycosyltransferases that transfer the sugar
moiety to a peptide or protein acceptor. For the three
glycosyltransferase folds (GT-A, B, C) only structures of
GALNT2 and GALNT10 (GT-A), AglB and PglB (GT-C), and
MurG, OGT, and POFUT1 (GT-B) have been solved (Hu et al,
2003; Fritz et al, 2006; Kubota et al, 2006; Maita et al, 2010;
Lazarus et al, 2011; Lira-Navarrete et al, 2011; Lizak et al,
2011). Interestingly, all of these enzymes (except POFUT1)
use flexible solvent exposed protein regions as sugar acceptor
whereas POFUT2 was shown to fucosylate only properly
folded TSR (Luo et al, 2006b). The POFUT2 structure now
gives insight into how substrate recognition, specificity, and
catalysis are achieved with the special requirements of a
properly folded 3D protein sugar acceptor that transiently
forms a protein–protein interface with a glycosyltransferase.
Our data suggest that POFUT2 recognizes key 3D structural
TSR elements formed by the disulphide pattern and side-
chain stacking common to sequence-wise degenerated TSR
modules. A search of the PDB using DALI with coordinates of
a minimal TSR poly-alanine module (regions predicted to
interact with POFUT2) identified only known structures of
TSR domains without discovering this structural motif in any
other protein. Therefore, substrate specificity seems to be
achieved by the structural complementarity of a part of the
TSR fold with the POFUT2 binding site and the wide TSR
sequence diversity does not play a role as long as the critical
TSR fold motif is intact. From our experimental data and the
structural models, we conclude that disrupting the conforma-
tion of the rippled A strand (formed by the WXXWXXW
motif, LXXWXXW in TSR4 from F-spondin) and of the AB
loop (defined by the second and third disulphides) impairs
TSR substrate recognition and fucosylation efficiency
(Figure 5C). Our data of the mini-TSR also show that starting
the A strand directly at the third tryptophan of the
WXXWXXW motif has no negative effect on fucosylation as
the conformation of the shortened A strand is still intact.
Proposed key interactions are located at the entry of the large
TSR binding cavity where conserved POFUT2 residues W152
from the N-terminal domain and W425 from the very
C-terminal part define the most narrow part of the cleft
(B15 A˚) allowing only space for a two stranded b-sheet to
enter the cavity (Figure 7A). C-terminal residues seem to lock
the position of the bound TSR module by interacting with the
backbone bulge formed by the second and third tryptophan
of the LXXWXXW motif of the rippled A strand. Thereby,
C-terminal POFUT2 residues act as a ruler to position the S/T
residue undergoing modification exactly at the right position
for E54-dependent deprotonation and nucleophilic attack at
the anomeric GDP-fucose carbon. This model is supported
by our observation that fucose attachment is reduced by 90
and 61% for the W152A and W425A mutation, respectively
(Figure 3E), and that exchange of the second and third
F-spondin TSR4 tryptophan (responsible for bulge formation)
to alanine results in 75 and 69% reduction of fucosylated
product, respectively (W7, W10 in Figure 5C). The second key
interaction is predicted to take place between the AB loop
(where the consensus motif CX2–3(S/T)CX2G is located) and
the conserved POFUT2 residues Asn51, Pro52, Pro53, Glu54,
Leu58, Asp61, and Glu221 (Figure 7A). These residues,
together with L224 that inserts its side chain exactly where
the C strand starts to crossover the B strand, ensure via TSR
backbone interactions that only the unique 3D motif at the
very tip of the TSR module can undergo fucosylation. This
structural motif is mainly defined by the length and confor-
mation of the AB loop, which is held in place by the two
disulphide bonds and which is encoded in the CX2–3(S/
T)CX2G sequon. Our observation explains experimental
data where insertion of two additional glycines before
the threonine (CX2–3GG(S/T)CX2G, changing the length of
the loop) as well as removing the two SS-bonds, which
together are responsible for pulling the C strand over
the B strand and stabilization of the AB-loop conformation,
completely abolished fucose attachment (Figure 5C).
Rational design of a minimal POFUT2 substrate resulted in
the artificial mini-TSR molecule which we predicted to con-
tain all necessary structural features for folding into the
correct TSR fold needed for productive fucosylation. We
found mini-TSR to be modified with the common glycan
structures known from wild-type TSR, thereby confirming
that it indeed can fold into the correct 3D AB-loop TSR
structure and act as a POFUT2 substrate. This result not
only defines a minimal POFUT2 substrate and validates our
proposed binding mode but also brings new insight into
folding and stability of TSR molecules. It shows that the
correct disulphide bond pattern needed for the proper AB-
loop conformation can be established with a minimal side-
chain stacking unit composed of one tryptophan and one
arginine residue only.
Having realized that POFUT2 substrate recognition is likely
to be driven by the conserved TSR residues responsible for
the unique layered TSR fold, we wondered how the substrate
binding site is able to accept the large charge and size
variation of amino acids on the remaining B40 sequence
positions. Strikingly, we found in our model of the POFUT2
TSR complex that out of the B30 TSR residues building the
upper half of the TSR (predicted to interact with POFUT2) 10
are conserved determining the TSR fold (in the central layer
of stacking residues and SS-bonds) or are part of the con-
sensus motif for fucosylation. Another nine residues are
solvent exposed and likely not involved in POFUT2 interac-
tion. At the 11 remaining TSR positions where wide sequence
diversity is present we find large cavities in POFUT2, ready
to accommodate side chains of different lengths or with
different physicochemical properties (Figure 7B).
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Figure 6.2.7 Structural details of the proposed TSR binding mode in human POFUT2. 
Figure 6.2.8 Proposed enzymatic mechanism for POFUT2-dependent TSR fucosylation.  
 
Our model of TSR–POFUT2 interaction is also compatible
with tryptophan C-mannosylation present on many TSR
(Hofsteenge et al, 2001; Tan et al, 2002) as the CWR layer
with a potentially attached a-mannosyl residue is facing
solvent and would therefore not be involved in POFUT2
interaction. Finally, our structural data also explain why
POFUT2 is specific for TSR modules and why EGF repeats,
the other known protein module to contain O-fucose
modifications, are not accepted as substrate. EGF repeats
simply do not have the critical 3D TSR elements (e.g.,
AB-loop conformation) needed for binding to the POFUT2
active site.
Catalytic mechanism of POFUT2
Structural and biochemical data of wild-type and mutant
POFUT2 allowed us to suggest a catalytic mechanism for
the fucosyltransferase reaction (Figure 8). POFUT2 belongs
to the GT-B family of inverting glycosyltransferases where
the key catalytic residue acts as a general base responsible
for deprotonation of the nucleophile functional group of the
sugar acceptor (Lairson et al, 2008). Only the fully conserved
residues E54 and D297 are in close proximity of the TSR S/T
hydroxyls that undergo fucose attachment. Both residues are
located right at the entry of the GDP-fucose binding site, E54
on a surface exposed loop of the N-terminal domain, and
D297 in a long loop in the C-terminal domain. The E54
carboxylate side chain is closer to the anomeric carbon and
is freely accessible while D297 is located slightly further away
and its side chain is sandwiched between the two
guanidinium groups of R294 and R303 in the native
POFUT2 structure reducing its mobility and, importantly,
lowering its pKa. Complete loss of enzymatic activity for
the E54A POFUT2 mutant (the D297A mutant retained
B16% activity), and the fact that we were able to obtain a
structure of the non-hydrolysed sugar donor complex with
the same catalytically inactive E54A mutant, are strong
arguments for E54 to be the catalytic base of POFUT2.
D297, on the other hand, seems to be needed to correctly
orient the R294 side chain for binding of the GDP-fucose
diphosphate group. Positioning of aspartate, glutamate, or
histidine as the catalytic base on the N-terminal domain
facing the sugar donor binding site (as seen in POFUT2) is
known from other inverting GT-B family members like WaaC
(Grizot et al, 2006), T4 phage glucosyltransferase BGT
(Larivie`re et al, 2003), H. pylori fucosyltransferase a1,3-
FucT (Sun et al, 2007), E. coli MurG (Hu et al, 2003), or
VvGT1 (Offen et al, 2006) of which structures have been
solved and the catalytic base residue has been identified
(Supplementary Figure S6). During E54-dependent deproto-
nation, the TSR S/T nucleophile can attack the anomeric
A B
W425
T423W152
L224
BC A BC A
Figure 7 Structural details of the proposed TSR binding mode in human POFUT2. (A) Surface representation (grey) of POFUT2 with bound
TSR4 (F-spondin) as ribbons (cyan) and the GDP-fucose substrate as sticks. POFUT2 residues predicted to recognize key elements of the TSR
fold are coloured: W152 and W425 (red) scan the width of the substrate; T423 (orange) senses the bulge in the A strand and acts as a ruler;
L224 (pink) scans the crossing over of the C strand; N51, P52, P53, E54, L58, D61, E221 (all in blue) recognize the correct conformation of the
AB loop. Key structural residues of the TSR fold are displayed as sticks in cyan (atom colours). (B) The wide TSR sequence diversity of POFUT2
substrates can be explained by the proposed TSR binding mode. POFUT2 provides large cavities (solid surface, blue) for highly variable TSR
residues (green) thereby tolerating side chains of different size and physicochemical properties at these positions. TSR side chains can also vary
at positions predicted to be solvent exposed (purple) while TSR residues important for the fold and the fucosylation motif are strictly conserved
(orange).
E54
R294
TSR-OH
E54
R294
GDP-fucose
GDP-fucoseTSR
Figure 8 Proposed enzymatic mechanism for POFUT2-dependent
TSR fucosylation. Chemical drawing of the enzymatic reaction. The
carboxylate side chain of E54 deprotonates the TSR S/T hydroxyl
group that attacks as a nucleophile the anomeric carbon of the GDP-
fucose sugar donor. R294 activates the labile bond by forming a salt
bridge with the b-phosphate group. The arrangement of
critical catalytic residues in the model of the ternary POFUT2
GDP-fucose TSR complex is shown. Distances: E54 carboxylate to
TSR-OH 3.1 A˚, TSR-OH to GDP-fucose anomeric carbon 3.3 A˚.
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carbon of the GDP-fucose to form the new glycosidic bond
with inverted configuration followed by release of the two
products. The fucose ring has been modelled in the 1C4
conformation resulting in a better fit to the 3.4 A˚ electron
density if compared with the 4C1 conformation. Interestingly,
the two conformations differ only in the ring flip and anB381
conformational change around the P1-O2P bond. Both ring
conformations would need considerable distortion for in-line
nucleophilic attack geometry seen in other inverting glyco-
syltransferases such as VvGT1 (Offen et al, 2006). Therefore,
the reactive fucose ring conformation will most likely be
established upon binding of the TSR sugar acceptor.
Activation of the labile phosphoester bond of the sugar
donor is mainly achieved by the charged residue R294 that
binds the diphosphate group and by the positive dipoles of
two helices near the diphospho and the pentose moiety.
Mutation of R294 to alanine in the human protein as well
as the corresponding mutation in the C. elegans orthologue
(Canevascini et al, 2006) resulted in complete loss of
enzymatic activity consistent with its role in directly
binding the GDP-fucose diphosphates. A multiple sequence
alignment of different fucosyltransferases reveals that R294 is
also conserved in POFUT1 and FUT8 (Martinez-Duncker
et al, 2003) where mutation of this residue also abolishes
enzymatic activity (Takahashi et al, 2000; Okajima et al,
2005). While the vast majority of inverting GT-B family
glycosyltransferases are metal-ion independent there are
three family members for which metal ions significantly
enhance activity: T4 phage BGT (More´ra et al, 2001),
hamster POFUT1 (Wang and Spellman, 1998), as well as
human POFUT2 which we described here (Figure 3C).
Despite many soaking and co-crystallization trials with
Mn2þ we were not able to localize the cation in anomalous
difference Fourier electron density maps in the POFUT2 apo
structure. In addition, we only obtained crystals of the GDP-
fucose complex when we added EDTA to the crystallization
buffer to remove all remaining metal ions from the protein.
These findings, together with the fact that the enzyme retains
B5% enzymatic activity in the presence of EDTA, point to a
role of metal ions in product release. This is known from
other GT-B fold glycosyltransferases like T4 phage BGTwhere
Mn2þ complexes the pyrophosphate group of the UDP pro-
duct at the place occupied by the sugar moiety in the UDP-Glc
complex structure (More´ra et al, 2001). Similarly, the Mn2þ
binding site has been identified in the crystal structure of a
C. elegans POFUT1 GDP Mn2þ complex where the ion also
binds the pyrophosphate of the GDP product exactly where
the fucose moiety is placed in the GDP-fucose structure.
However, in the latter case the authors do not relate this
finding to the metal-dependent enzymatic activity (Lira-
Navarrete et al, 2011). Other GT-B fold glycosyltransferases
like FUT8 seem to have metal-independent ways of
nucleotide diphosphate release and do not need divalent
cations to reach full activity (Ihara et al, 2006). Kinetic
experiments yielded a kcat of 144 per minute for the
POFUT2 enzyme, a value that is comparable with published
results from other glycosyltransferases (Ihara et al, 2006; Sun
et al, 2007). KM values on the other hand differ with 9.8 mM
for GDP-fucose and 29.5 mM for TSR4. A KM in the low
micromolar range for the sugar donor is common for GT-B fold
glycosyltransferases (Jeanneau et al, 2004; Grizot et al, 2006;
Ihara et al, 2006) while the KM value for TSR4 is rather low.
In summary, POFUT2 seems to utilize a well-established
catalytic mechanism for GT-B fold inverting glycosyltrans-
ferases with E54 acting as general base. This is in contrast to
the suggested mechanism in C. elegans POFUT1 where no
residue acting as catalytic base could be identified and the
reaction after cleavage of the glycosidic bond (facilitated by
R240) proceeds via an oxocarbenium-phosphate ion pair
transition state and subsequent attack of the acceptor OH
group at the anomeric carbon (Lira-Navarrete et al, 2011).
Substrate specificity of protein glycosyltransferases
The mechanism of glycan transfer to a protein or peptide
acceptor has for a long time been poorly understood. It was
largely unknown how short sequence motifs present in
polypeptides of wide sequence diversity can be modified by
a position-specific enzyme. It was only recently that crystal
structures of glycosyltransferases in complex with acceptor
peptides gave insight into substrate specificity and how a few
key elements present in the recognition sequons enable
glycosylation of specific residues. Structures of acceptor
peptide complexes are now available for all glycosyltransfer-
ase families and reveal surprising similarities: GALNT10
(GT-A) (Fritz et al, 2006), OGT (GT-B) (Lazarus et al, 2011),
and PglB (GT-C) (Lizak et al, 2011) all recognize glycosylation
sequons in flexible unstructured protein regions and bind the
substrate peptide mainly via backbone interactions. Many
structured water molecules are present providing an
adaptable protein interface ready to accommodate a wide
range of polypeptides with side chains of different size,
charge, and polarity. Sequon specificity is most clearly
defined in PglB (Asn-X-Ser/Thr) where a WWD protein
motif binds the Ser/Thr residue side chain at the þ 2
position and thereby positions the asparagine correctly for
N-linked glycosylation. A similar mode is used in GALNT2
where the proline at the þ 3 position is specifically bound to
position the Ser/Thr correctly in the active site. For OGT on
the other hand, no O-GlcNAcylation motif has been identified
so far but a preference for residues that form an extended
peptide conformation near the glycosylation site can be
explained by the binding mode of the peptide as seen in the
crystal structures.
Here, we present a completely novel mode of substrate
recognition for protein glycosyltransferases that explains why
the specific fucosylation consensus motif CX2–3(S/T)CX2G
(Hofsteenge et al, 2001) can only be modified in the context
of a properly folded TSR protein domain and how these
structural constraints are not in conflict with the wide
sequence diversity present on fucosylated TSR. POFUT2 has
evolved to specifically recognize unique 3D structural TSR
elements, which are defined by a few strictly conserved
residues and the consensus motif itself. This allows for
wide sequence diversity at all the other TSR positions,
probably reflecting the diverse biological functions of
proteins containing the TSR module.
Materials and methods
A detailed description of expression and purification of wild-type
and mutant POFUT2 and TSR proteins, enzymatic assays and
detection of TSR fucosylation states by mass spectrometry is
given in Supplementary data.
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 Crystallization, data collection and structure determination
POFUT2 crystals were grown at 41C by the vapour diffusion method
in 96-well crystallization plates by mixing 0.1ml of POFUT2 protein
solution (7.5mg/ml) with 0.1ml of crystallization buffer (20mM
Tris–HCl, pH 8.5, 12% PEG 20000). For native data collection,
crystals were soaked in mother liquor containing 25% ethylene
glycol and frozen in liquid nitrogen. For heavy atom derivatization,
crystals were soaked in mother liquor containing 5mM of K2PtCl4
for 6min. Diffraction data were collected at beamlines X06DA and
X10SA at the Swiss Light Source synchrotron in Villigen,
Switzerland. Diffraction images were processed and scaled with
HKL-2000 (Otwinowski et al, 1997). The structure of POFUT2 was
solved by the SIRAS method using two platinum sites per molecule
identified in SHELXD (Sheldrick, 2008). Heavy atom sites were used
for phase calculation and refinement of sites in Sharp (Bricogne
et al, 2003) followed by density modification using Solomon
(Abrahams and Leslie, 1996). Phases from density modification
were then used for automatic model building in PHENIX (Adams
et al, 2010) and in BUCCANEER (Cowtan, 2006) followed by manual
completion of the model using COOT (Emsley et al, 2010).
Structures were refined by the crystallographic simulated
annealing routine followed by individual B-factor refinement in
PHENIX including NCS restraints.
For crystals of the POFUT2 GDP-fucose complex, 13.6mg/ml
of high mannose type E54A POFUT2 was incubated in protein
buffer containing 3.5mM EDTA and 1mM GDP-fucose (Sigma) for
30min on ice before setting up the crystallization experiment.
Crystals were grown at 201C by the vapour diffusion method in
96-well crystallization plates by mixing 0.25ml of protein solution
with 0.25ml of crystallization buffer (20% PEG 3350, 0.2M NaSCN).
Crystals of the complex were cryoprotected and frozen as described
for native crystals. The structure of the POFUT2 GDP-fucose
complex was solved by molecular replacement using PHASER
(McCoy et al, 2007) with the native POFUT2 structure as search
model and subsequent refinement in PHENIX. Clear mFo-DFc
difference electron density for the missing GDP-fucose moieties
was visible in the active sites for all four molecules in the a.u.
The structures of native POFUT2 and of the E54A-POFUT2 GDP-
fucose complex were refined by several rounds of manual
rebuilding in COOT followed by refinement in PHENIX. Of the
four E54A-POFUT2 molecules present in the a.u. only chains A, B,
and C have full occupancy whereas chain D is partially occupied (or
has high mobility). This results in less well-defined 2mFo-DFc
electron density for chain D. All crystal structures were validated
using MolProbity (Chen et al, 2010) and COOT. Structural images for
figures were prepared with PyMOL (http://pymol.sourceforge.net/).
Atomic coordinates and structure factors have been deposited in the
PDB with entry codes 4AP5 (apo) and 4AP6 (GDP-fucose complex).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Supplementary materials and methods 
 
Expression and purification of wild-type human POFUT2 
Full length (lacking the 21 residue long N-terminal signal peptide) human POFUT2 was 
cloned into pSecTagB vector (Invitrogen) with an N-terminal FLAG tag for purification. 
HEK293T cells were cultured as an adherent monolayer in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum (FCS, Sigma) and 2 mM 
glutamine. At 80% confluency, cells were transfected with polyethyleneimine according 
to the manufacturer’s instructions (jetPEI; Polyplus-transfection Inc.). After 48 hours, 
selection of stable lines was started by passaging cells into medium containing 100 !g/ml 
of Zeocin (Invitrogen). Resistant single clones were selected and expanded. The clone 
with highest expression of POFUT2 was selected for large-scale protein expression.  
For a large-scale protein expression, 20 dishes (150 x 15mm, BD Falcon) of confluent 
stable HEK293T cells expressing FLAG-!21-POFUT2 were harvested and split into 200 
dishes with the culture medium containing additional 5 !M of kifunensine (Chang et al, 
2007). After seven days, the conditioned medium was harvested and filtered through a 
0.22 !m filter (Stericup, Millipore). The conditioned medium and anti-FLAG M2 resin 
(Sigma) were mixed in a two liter roller bottle (Greiner Bio-One) overnight at 4ºC. M2 
resin was collected in a 2.5 x 10 cm glass column (Bio-Rad) and washed with 50 ml of 
TBS buffer (20 mM Tris, pH 7.4, 150 mM NaCl), followed by 50 ml of 20 mM Tris-HCl, 
pH 7.4, 1 M NaCl and re-equilibrated in 50 ml of TBS. FLAG-!21-POFUT2 was eluted 
by 100 !g/ml of three times FLAG peptide in 20 mM Tris-HCl, pH 7.4, 300 mM NaCl. 
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To remove N-glycans, 30 kU of Endo Hf (NEB) was added to 1 mg of eluted protein for 3 
hours at 37ºC. The FLAG tag was removed with enterokinase (NEB) at 23ºC for 16 
hours. EndoHf was removed by amylose resin (NEB) according to the manufacturer’s 
instructions, and the flow through was loaded onto a Superdex 200 16/60 column, which 
was equilibrated in 10 mM Tris-HCl, pH 8.8, 300 mM NaCl, 10 mM MgCl2. Fractions 
with POFUT2 were pooled and concentrated by centrifugation using an Amicon Ultra-4 
PL-10 device (Millipore) to 6.5 - 8 mg/ml, aliquoted and stored at -80ºC.  
 
Expression and purification of human E54A POFUT2  
The stable HEK293T cell line expressing E54A-POFUT2 was established as for the wild-
type POFUT2 except that the transfection was performed with Lipofectamine 
(Invitrogen). For large-scale expression, 20 dishes (150 x 15mm, BD Falcon) of confluent 
HEK293T cells expressing His6-FLAG-3C-!36-POFUT2 were harvested and split into 
200 dishes with DMEM supplemented with 10% FCS and 2 mM glutamine. When the 
dishes were confluent, the medium was switched to Pro293a medium (Lonza) 
supplemented with 5 !M kifunensine and 2 mM glutamine. After 96 hours expression 
medium was harvested and filtered (Stericup, Millipore). The medium was incubated 
with Ni-NTA agarose (Qiagen) in a two liter roller bottle (Greiner Bio-One) overnight at 
4ºC. The resin was collected by centrifugation at 100 x g for 5 minutes at 4ºC. After 
washing with three gel volumes of 20 mM Tris-HCl, pH 8.5, 500 mM NaCl, 20 mM 
imidazole, the protein was eluted in the same buffer but containing 500 mM imidazole. 
Eluate was loaded onto a Superdex 200 16/60 column, which was equilibrated in 10 mM 
Tris-HCl pH 8.5, 200 mM NaCl. Fractions with target protein were pooled and buffer 
exchanged into 10 mM Tris-HCl pH 8.5, 50 mM NaCl by gel filtration on a HiPrep 16/10 
desalting column. The sample was further purified by Mono Q 5/50 anion exchange with 
a gradient from 0% buffer B to 50% buffer B in 30 minutes (buffer A: 10 mM Tris-HCl, 
pH 8.5, 50 mM NaCl, Buffer B: 10 mM Tris-HCl, pH 8.5, 1 M NaCl). The protein was 
concentrated to 20 mg/ml using a Amicon Ultra-4 PL-10 device (Millipore) in 20 mM 
Tris pH 8.5, 225 mM NaCl and stored at -80ºC.  
 
Site-directed mutagenesis of POFUT2 
POFUT2 mutants were generated by the QuickChange method (Stratagene). Wild-type 
and mutant POFUT2 were cloned into a pSecTag vector with N-terminal His6-FLAG-3C 
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tag. HEK293T cells were cultured in DMEM supplemented with 10% FCS and 2 mM 
glutamine to 80% confluency before transfection. The cells were transfected by 
Lipofectamine (Invitrogen) using the manufacturer’s protocol. Eight hours after 
transfection, the medium was changed to Pro293a medium (Lonza) supplemented with 5 
!M kifunensine and 2 mM glutamine. Ninety-six hours later, the medium was collected 
and incubated with anti-FLAG M2 resin overnight on roller at 4ºC.  Proteins were eluted 
by 100 !g/ml of three times FLAG peptide in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl. 
POFUT2 mutants were aliquoted and stored at -80ºC before testing the enzymatic activity 
in the in vitro POFUT2 fucosyltransferase assay. 
 
Expression and Purification of TSR4 from F-spondin 
Rat F-spondin TSR4 containing a cleavable N-terminal His-tag was cloned into a 
pOPINF vector (Berrow et al, 2007) and used to transform Rosetta2 expression 
competent E. coli cells. A single colony of E. coli (Rosetta 2) cells was grown overnight 
in 20 ml of GS96 medium containing 1% glucose. The overnight culture was diluted 
1:100 into 0.5 L of auto-induction medium (Studier, 2005) containing 34 !g/ml 
chloramphenicol and 50 !g/ml  carbenicillin. Cells were grown at 37ºC, 225 rpm for 4 
hours, followed by reduction of the temperature to 20ºC for another 20 hours. Cells were 
harvested by centrifugation at 6500 x g for 30 minutes. The cell pellet was resuspended in 
lysis buffer (50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 20 mM imidazole, 0.2% Tween20, 
Complete Protease Inhibitor) and lysed using a high pressure cell disruptor. The lysate 
was cleared by centrifugation and mixed with Ni-NTA agarose (Qiagen). The resin was 
washed with five gel volumes of lysis buffer and the TSR4 was eluted with 50 mM Tris-
HCl, pH 7.5, 500 mM NaCl and 500 mM of imidazole. The eluate was loaded onto a 
Superdex-75 16/60 PG column (GE Healthcare) in 20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl. Fractions containing TSR4 were pooled and buffer exchanged into 20 mM Tris-
HCl, pH 7.5 10 mM NaCl by gel filtration on a HiPrep 26/10 desalting column. TSR4 
was further purified by ion-exchange chromatography on a MonoQ 5/50 column (GE 
Healthcare) and eluted in a linear gradient of 0-500 mM NaCl over 50 minutes. Pure 
TSR4 was aliquoted and stored at -80ºC in 20 mM Tris, pH 7.5, 110 mM NaCl.   
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In vitro LC-MS POFUT2 activity assay 
The reaction mixture for the POFUT2 activity assay contained 20 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 5 mM MnCl2, 10 !M GDP-fucose, 10 !M TSR4 and 1 ng of 
recombinantly expressed pure POFUT2 in a volume of 10 !l. After 10 minutes 
(corresponding to less than 25% substrate consumption) incubation in 0.5 ml protein 
LoBind tubes (Eppendorf) at 37ºC, the reaction was quenched by acidification with 40 !l 
of cold 0.2% trifluoroacetic acid (TFA) and 2% acetonitrile. Fucosylated and non-
fucosylated TSR4 was separated by HPLC using a C18 column with a linear gradient 
from 37% buffer B to 43% buffer B in 15 minutes (buffer A: 2% CH3CN, 0.1% TFA; 
buffer B: 80% CH3CN, 0.1% TFA). The substrate and product of the reaction were 
quantified by integrating the peak area at 280 nm or by ion count from mass spectrometry 
(4000 Q TRAP, Applied Biosystems) in positive ion mode. Both approaches gave the 
same result.  
 
In vitro LC-MS POFUT2 activity assay for kinetics 
Steady-state kinetic parameters of POFUT2 at different concentrations of substrates were 
determined in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM MnCl2 and 2 ng of 
recombinantly expressed POFUT2 in a volume of 10 !l for 20 minutes. The turnover was 
first measured at fixed TSR4 concentrations ranging from 3.3, 10, 20, 40, 80 to 200 !M 
with a stepwise increase of the GDP-fucose concentration from 2.5, 5, 10, 20, 40, 80 to 
160 !M (Fig. S2B). Then, the turnover was determined with fixed concentration of GDP-
fucose at 2.5, 5, 10, 20, 40, 80 and 160 !M with the stepwise increased concentration of 
TSR4 from 3.3, 10, 20, 40, 80, and 200 !M (Fig. S2C). Quantification and analyses of 
the reaction product by mass-spectrometry is described above. Kinetic parameters were 
computed with the GraphPad Prism software by fitting the data to the Michaelis–Menten 
equation. 
 
 
HEK293T cell POFUT2 activity assay using wild-type and mutant TSR4 substrates 
Wild-type and mutant TSR4 of rat F-spondin were cloned into pSecTagB vector 
(Invitrogen) with TEV-myc-His6 at the C-terminus. HEK293-T cells were grown in 
DMEM supplemented with 10% FCS and 2 mM glutamine to 80 % confluence before 
transfection. Cells were transfected with Lipofectamine (Invitrogen) according to the 
manufacturer’s protocol. After 60 hours of expression in Opti-MEM (Invitrogen), the 
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medium was harvested and dialyzed against 20 mM Tri-HCl, pH 8.0, 100 mM NaCl. For 
purification, 200 !l of Co
2+
 TALON resin (Clontech) was incubated with 50 ml of 
medium overnight on a roller at 4ºC. The resin was washed three times with the dialysis 
buffer containing 4 mM imidazole before elution with the same buffer containing 300 
mM imidazole. The eluate was dialyzed against 50 mM ammonium carbonate using a 
Slide-A-Lyzer device (3.5 KDa MWCO). Samples were reduced, carboxymethylated 
(Krieg et al, 1998) and digested with Lys-C or Lys-C/Asp-N (for mutant C(13,46)A and 
C(13,46,17,51)A). The digests were injected onto a Vydac column C18 (1 x 250 mm) for 
high pressure liquid chromatography-mass spectrometry (HPLC-MS) analysis. The 
analysis was performed on an 1100 CapLC system (Agilent Technologies) that was 
connected to a API 300 or a 4000 QTRAP (AB sciex) mass spectrometer. The peptides 
were separated in 0%-70% of buffer B over 120 minutes (buffer A: 2% CH3CN, 0.1% 
TFA; buffer B: 80% CH3CN, 0.1% TFA) and quantification was done by integration of 
peak size in the UV of 280 nm or 214 nm. O-fucosylated peptides were identified and 
confirmed by their mass and neutral losses (Hess et al, 2008; Hofsteenge et al, 2001).   
 
In vitro POFUT2 activity assay using mini-TSR substrate 
The mini-TSR DNA was synthesized by Sigma and cloned into a pOPINJ vector with an 
N-terminal His6-GST-3C tag. After transformation and plating out on LB Agar, a single 
colony of E. coli (BL21 DE3) was picked and inoculated into a 96-well deep-well block 
with 1.5 ml of GS96 medium with 1% glucose, 0.05% glycerol and the culture was 
incubated at 37ºC (225 rpm) overnight. The overnight culture was diluted 1:50 into 2.5 
ml of the same fresh medium in a 24-well deep-well block and incubated at 37ºC with 
shaking at 225 rpm. At OD600 0.6, the culture was cooled to 20ºC before IPTG (0.5 mM) 
induction. Following induction, cells were grown for 20 hours at 225 rpm at 20ºC. Cells 
were harvested by centrifugation and the cell pellet was lysed with 1 mg/ml of lysozyme 
and 3 unit/ml of Benzonase. After centrifugation, the supernatant was incubated with Ni-
NTA agarose and the protein eluted with 50 mM Tris-HCl, pH 7.5, 500 mM NaCl and 
300 mM  imidazole. The eluate was incubated overnight at 4ºC with rhinovirus 3C 
protease for cleavage of the His6-GST tag. The sample was diluted ten times and 
incubated with Ni-NTA agarose and the flow through was collected for the in vitro 
fucosylation assay. 38 !l of wild-type TSR4 and mini-TSR4 from the flow through were 
incubated with 250 !M of GDP-fucose and 5 ng of !36-POFUT2 for 60 minutes at 37ºC. 
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The reaction was quenched by acidification with TFA to a final pH of 2. The mixture was 
analyzed by NanoLC-MS using a Magic C18 HPLC column (75 µm ! 10 cm; Swiss 
BioAnalytics) with a 1200 NanoLC system (Agilent Technologies) connected to a LTQ 
Orbitrap Velos (Thermo Fisher Scientific). The peptides were loaded onto a peptide 
captrap (Michrom BioResources) at a flow rate of 10 µl/min for 5 minutes in 10% A. 
They were eluted at a flow rate of 400 nl/min in 30 min with a linear gradient of 10–80% 
B in A (A: 0.1% formic acid, 0.005% TFA, 2% acetonitrile in H2O; buffer B : 0.1% 
formic acid, 0.005% TFA, 80% acetonitrile in H2O. The MS were acquired in positive 
ion mode with a resolution of 60000 at m/z 400 according to the manufacturer’s 
recommendation. 
 
HEK293T cell POFUT2 activity assay using mini-TSR substrate 
Mini-TSR DNA was cloned into a pSecTag vector with an N-terminal His6-FLAG-3C 
tag. HEK293T cells were transfected as described for E54A-POFUT2. Eight hours after 
transfection, the medium was changed to Pro293a medium (Lonza) supplemented with 2 
mM glutamine. Ninety-six hours after transfection the medium was harvested and 
filtered. Conditioned medium was incubated with Ni-NTA agarose and the mini-TSR 
protein eluted in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 300 mM imidazole. The mass 
of the intact mini-TSR was determined by NanoLC-MS as described above. The mini-
TSR4 peptide (GPWSDCSVTCGK ) for glycan analysis was obtained by proteolytic 
digestion of His6-FLAG-mini-TSR with rhinovirus 3C protease (removal of the N-
terminal tag) and Lys-C protease, followed by reduction/alkylation. The 
GPWSDCSVTCGK peptide was analyzed on the same LC-MS system but using a 
gradient from 0%B-45%B in 30 min. The 2+ ions of this peptide with m/z 912.36 were 
fragmented with HCD using an isolation width of the precursor of m/z 2.0 and 
normalized collision energies of 10%, 15%, 20%, 25% and 30% respectively. All 
fragment spectra containing signals for the peptide were summed up (Fig. 6E). 
 
Influence of glycan composition, metal ions, and N-terminal truncations on 
POFUT2 activity 
Enzymatic activity of different POFUT2 N-glycosylation types was assessed using a 
modified form of the assay developed by Wang and colleagues (Wang et al, 1996). 
Reaction mixtures for assaying enzymatic activity contained 100 mM imidazole, pH 6.8, 
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5 mM MnCl2, protease inhibitor cocktail (Roche), 20 µM TSR4, 20 !M GDP-fucose, 
GDP-[2-
3
H]fucose (300 nCi/!l) and 0.1 ng of different glycoforms of !36-POFUT2 in a 
volume of 25 µl. After incubation for 1h at 37ºC, the reaction was terminated by adding 
200 µl of 0.2% ice-cold trifluoroacetic acid. Radioactive substrate and product were 
separated on a C8 reverse phase Sep-Pak Vac cartridge as described (Kozma et al, 2006). 
Incorporation of [
3
H]fucose into the acceptor substrate was determined by scintillation 
counting.  
For measurements of POFUT2 enzymatic activity in the presence of different metal ions, 
purified "36-POFUT2 with complex type N-glycans was pre-incubated with 2 mM 
EDTA to remove remaining metal ions. The reactions was started by adding GDP-fucose 
to the reaction mixture containing 1 ng POFUT2, 20 !M TSR4, 20 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 2 mM EDTA and 20 mM of either MnCl2, MgCl2, ZnCl2, or CaCl2.  The 
reaction was terminated by adding 37.5 !l of 0.2% trifluoroacetic acid, 2% CH3CN and 
the formation of fucosylated TSR4 was analysed by LC-MS as described above.  
For POFUT2 activity with different N-terminal truncations, "36-POFUT2 or "21-
POFUT2 with complex type N-glycans was incubated with 20 !M TSR4, 20 !M GDP-
fucose, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 5 mM MgCl2.  Reactions were 
terminated by adding 37.5 !l of 0.2% trifluoroacetic acid, 2% CH3CN and the formation 
of fucosylated TSR4 was analysed with LC-MS as described above.  
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Supplementary figure legends 
 
Figure S1 
Comparison of the nearest structural neighbours of human POFUT2. The orientation is 
kept the same for all molecules to facilitate the structural comparison. (A) Human 
POFUT2. (B) C. elegans POFUT1. (C) B. japonicum nodulation fucosyltransferase 
NodZ. (D) E. coli lipopolysaccharide heptosyltransferase WaaC. (E) Human !-1,6-
fucosyltransferase FUT8.  
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Figure S2 
Michaelis-Menten enzyme kinetics for POFUT2-dependent fucosylation of TSR4 from 
rat F-spondin. (A) Chromatogram showing the separation of the fucosylated TSR4 
product from the TSR4 substrate by LC-MS. (B) Formation of fucosylated TSR4 reaction 
product at varying GDP-fucose concentrations and different TSR4 concentrations (3.3-
200 µM). (C) As in (B) but with keeping the GDP-fucose concentration constant (2.5-160 
µM) and varying the TSR4 concentration.  
 
Figure S3 
Superposition of the non-crystallographic-symmetry dimer of the POFUT2 apo structure 
(light green, cartoon model) with a crystallographic dimer of the POFUT2 GDP-fucose 
complex (in cyan with GDP-fucose as sticks in atom colours). Dimers were superimposed 
only on one chain to display the different packing. A rotational and translational shift of 
the symmetry related dimer (~ 10 Å) is clearly visible in the POFUT2 GDP-fucose 
complex. The calculated interface area between symmetry related chains amounts to 1670 
Å2 for the apo structure and is reduced to 1315 Å2 for the POFUT2 GDP-fucose complex 
revealing the opening of the interchain cavity and enabling access to the sugar donor 
binding site. 
 
Figure S4 
Stereo view of the superposition of refined GDP-fucose POFUT2 complex structures 
with GDP-fucose once in the 1C4 (cyan) and once in the 4C1 conformation (gray) as 
sticks in atom colours. A better fit of the fucose moiety to the electron density with a real 
space correlation coefficient of 0.952 (calculated for chain C) was achieved with the 1C4 
conformation versus 0.924 for the 4C1 conformation (Fc versus 2mFo-DFc calculated 
with PHENIX). Selected GDP-fucose binding residues are displayed as fine gray lines in 
atom colours while the E54 side chain from the apo structure is superimposed (sticks in 
gray). 
 
Figure S5 
Profile hidden Markov model (HMM) of the Pfam entry of the thrombospondin type 1 
domain (PF00090, http://pfam.sanger.ac.uk) shown as sequence logo image. Sequence 
stretches present in the mini-TSR are indicated as solid lines. 
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Figure S6 
Cartoon models of GT-B fold inverting glycosyltransferases of known structure where 
the catalytic base (either aspartate, glutamate, or histidine) has been described and its 
position mapped. (A) Human POFUT2. (B) E. coli lipopolysaccharide 
heptosyltransferase WaaC. (C) T4 phage !-glucosyltransferase BGT. (D) H. pylori 
fucosyltransferase "1,3-FucT. (E) E. coli MurG. (F) plant VvGT1. Sugar donors and the 
catalytic base are displayed as sticks in atom colours. In the structure of BGT in complex 
with UDP-glucose the catalytic aspartate (D100) was mutated to alanine. 
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6.3 Tag‐free purification of glycoproteins 
Introduction 
A major obstacle in protein crystallography is the difficulty of expressing and purifying 
proteins of high quality in large quantities. Since glycoproteins usually cannot be 
functionally expressed in bacterial expression systems, cell expression systems 
possessing a glycosylation machinery such as yeast, insect, or mammalian systems 
are usually required. Glycoproteins typically have more than one glycosylation site, 
which can be linked to asparagine, serine, or threonine. The structure of these 
glycans may be protein-specific and/or site-specific, which can also depend on the 
expression organism. For example, the N-glycan structure from HEK293T cells is 
usually a mixture of high-mannose, hybrid, and complex types with multi-antenna N-
glycan and negatively charged sialic acid on the terminus (Chang et al., 2007, 
Chapter 6.1). To improve the diffracting quality of the protein crystal, it is usually 
necessary to simplify the heterogeneity of the N-glycan structure by treating the cell 
with chemicals such as kifunensine, which will interfere with the glycosylation 
pathway or to enzymatically cleave the N-glycans to a single GlcNAc by treatment 
with endoglycosidase H (Chang et al, 2007).  
Purification of recombinant proteins with artificial peptides or protein tags is a 
powerful tool. Purification with artificial tags can usually provide hundred-fold 
increases in purity compared to the crude cell lysate extract. The mild and specific 
elution conditions for affinity purification also make it a practical approach for 
maintaining the activity of the target protein or purifying the protein in complex with 
other components. However, there are some drawbacks in the application of affinity 
tags. For example, the position of the tag may affect the expression level or 
accessibility to the resins. Small-scale test expression with different tags at different 
positions is necessary to select the best construct. Furthermore, the tags usually 
need to be removed to exclude the effect of the tag on the structure or function of the 
target protein. However, proteolytic cleavage of the affinity tag is not always practical 
and can be a time-consuming and laborious process.  
To improve the purification process of glycoproteins, we have developed a method to 
purify these proteins without using artificial peptides or protein tags based on lectin 
affinity chromatography. Lectins are a group of carbohydrate-binding proteins that 
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bind to specific epitopes on carbohydrates. Since the discovery of the first lectin over 
a hundred years ago, many lectins have been identified in bacteria, plants, and 
animals. Lectin column chromatography has been extensively used in the 
fractionation of oligosaccharides, glycopeptides, and glycoproteins (Freeze, 2001; 
Fukuda & Kobata, 1993). In contrast to other purification techniques such as size-
exclusion, ion-exchange, reverse-phase, and normal-phase chromatography, lectin 
affinity chromatography is based on its specificity for carbohydrates; therefore, the 
purification principle is more similar to that of affinity purification of recombinant 
proteins with an artificial tag.  
One of the most well-characterized and widely used lectins is concanavalin A (Con 
A), because it is commercially available and has defined 
specificity. Con A displays high affinity for high-mannose type 
and hybrid-type N-glycans. It recognizes the tri-mannosyl core 
structure on the N-glycan (the boxed structure on the right); 
modification on mannose (Man) with GlcNAc will reduce the 
affinity for Con A, but the affinity will not increase if R is mannose 
(Baenziger & Fiete, 1979). Con A also weakly binds α-
methylmannoside, which is very helpful feature because the 
bound protein can be competitively eluted from Con A by using high concentration of 
α-methylmannoside. Here, we present a purification method for N-glycosylated 
glycoproteins without using an artificial tag. The method has high specificity and high 
binding capacity; >50 mg of pure human POFUT1 was successfully purified by a 
single step of Con A purification.  
Materials and Methods  
Cell culture 
The method for creating a stable HEK293T cell line expressing ∆21-POFUT2 was 
described in Chapter 6.3. The stable line expressing PAD2 (the POFUT2 orthologue 
in C. elegans) was established with the same method. The HEK293T cell line 
expressing ∆23-POFUT1 was kindly provided by Dr. Jeremy Keusch. HEK293T cell 
lines expressing different proteins were all cultured under following conditions. Cells 
were first grown in Dulbeccoʼs modified Eagleʼs medium (DMEM) supplemented with 
10% fetal calf serum (FCS), 2 mM glutamine, penicillin, streptomycin, and Zeozin 
until the cells reached ~90% confluency. The DMEM medium was replaced by 
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Pro293a medium (Lonza) supplemented with 2 mM glutamine and 5 µM kifunensine 
for protein expression. The medium was harvested for purification after 72 h of 
cultivation. 
Reducing volume of conditioned medium by Vivaflow 200 
The Vivaflow 200 (10 kDa, PES, Sartorius) was connected to a peristaltic pump, 
according to manufacturer's instructions. The module was washed first with water 
and then with 400 ml of 20 mM Tris-HCl pH 7.4, 150 mM NaCl, and 1 mM CaCl2. The 
sample was circulated through the system at a flow rate of 250 ml/min. The medium 
(2.5 l) was concentrated to 250 ml in 2 h.    
Western blot 
Proteins were separated on a 4%–12% Bis-Tris gel (NuPAGE, Invitrogen) and 
transferred to a nitrocellulose membrane. The primary antibody was rabbit anti-
human POFUT2 (amino acids 44–58). The secondary antibody was anti-rabbit IgG 
HRP (GE Healthcare). The primary antibody was diluted 1:7500 in 5% low-fat milk 
powder in 20mM Tris-HCl, 150 mM NaCl and 0.05% Tween 20 (TBST), and the 
secondary antibody was diluted 1:10,000 in TBST. The blots were developed using 
the enhanced chemiluminescence detection kit (GE Healthcare). 
Con A affinity chromatography 
A 5-ml HiTrap Con A 4B column (GE Healthcare) was connected to an ÄKTA purifier 
and washed with Buffer A (20 mM Tris-HCl pH 7.4, 300 mM NaCl, 1 mM MnCl2, and 
2 mM CaCl2) before loading the sample. The concentration of CaCl2 and MnCl2 in the 
conditioned medium was adjusted to 2 mM and 1 mM, respectively. The medium was 
loaded and circulated within the column overnight at a flow rate of 1 ml/min. The 
medium was collected the next morning, and the column was washed with Buffer A 
until the A280 was stable. The protein was eluted by the gradient of 0%–50% Buffer 
B (1 M mannosyl pyranose in Buffer A) for 25 min; the flow was paused for 10 min, 
and then, restarted to allow 5 ml to flow. The eluted fractions were analyzed by SDS-
PAGE, and the fractions with target protein were pooled for further processing. 
POFUT2 and PAD2 were purified by the same method, except that a 1-ml Con A 
column was used.      
Endo Hf digestion of POFUT1  
The POFUT1 fraction was buffer exchanged into 50 mM sodium citrate pH 5.5, 300 
mM NaCl, 2 mM CaCl2, and 1 mM MnCl2 by using a HiTrap desalting column (GE 
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Healthcare). The concentration of the protein was adjusted to 0.15 mg/ml. POFUT1 
(1 µg) was digested with 1 U of Endo Hf (New England BioLabs) for 3 h at 37 ºC. The 
digested sample was incubated with Amylose resin. Endo Hf was retained on the 
Amylose resin; the flow through was collected; buffer exchanged into Tris-HCl pH 8.5, 
100 mM NaCl, and 1 mM MnCl2 by using a HiTrap Desalting column; and 
concentrated to 7 mg/mL and 11.45 mg/mL.   
Size‐exclusion chromatography 
Size-exclusion chromatography was used to purify the POFUT2 and PAD2 samples 
after Con A affinity chromatography. Samples were loaded onto a Superdex 200 
16/60 column (GE Healthcare) in 20 mM Tris-HCl pH 7.4, 150 mM NaCl. The 
fractions were checked by SDS-PAGE, and the fractions with target protein were 
pooled, concentrated, and stored.   
Results 
Expression levels in Pro293a 
To purify glycoproteins from conditioned medium of mammalian cells by Con A 
affinity chromatography, the first obstacle is that the serum contains high amounts of 
glycoproteins, which will compete with the recombinant protein for Con A binding and 
contaminate the eluted sample. All our stable HEK293T cell lines were established in 
DMEM medium supplemented with 10% FCS. To avoid the serum in the culture 
medium, we tested POFUT2 expression in Pro293a medium, which is a chemically 
defined, protein-free medium optimized for adherent HEK293 cell lines. We first tried 
to adapt the stable HEK293T cell line to Pro293a medium, but it was impractical 
because of the low growth rate of the cells, which results in low protein yields. Cells 
grown in serum-free medium cannot adhere to the culture dish, which reduces their 
growth rate.  
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Figure 6.3.1 Expression level of POFUT2 in Pro293a medium at different time points 
The expression level of POFUT2 from HEK293T cell in serum-free medium was 
quantified by SDS-PAGE and western blotting. No obvious difference was observed 
between the signals from the medium harvested at different time points, based on 
Coomassie Blue staining, because the major protein in the medium was BSA, which 
also runs at a similar molecular weight on the SDS-PAGE. On the western blot (1°Ab: 
anti-hPOFUT2:44-58), the intensity of the band increased from 24 h to 72 h. The 
expression level of POFUT2, compared to the standard purified POFUT2, was about 
15 mg/l of medium after 72 h of cultivation in Pro293a medium.  
To circumvent the growth-related problem, we cultured the cells in DMEM medium 
supplemented with 10% FCS until the cells reached 90% confluency. The medium 
was then switched to Pro293a medium supplemented with 2 mM glutamine and 5 µM 
kifunensine to produce high-mannose type POFUT2. The conditioned medium was 
harvested at 24 h, 48 h, 72 h, 96 h, and 168 h after exchanging the cells into the 
medium. The same volume of the conditioned medium from each time point was 
analyzed by Coomassie Blue staining and western blotting by using an antibody 
specific to the amino acids 44–58 of human POFUT2 (Fig. 6.3.1). From the results of 
Coomassie Blue staining, no obvious difference in protein expression was observed 
between the different time points. An intense band between 50 kDa and 75 kDa 
could be the residual bovine serum albumin (66 kDa) from the complete medium. 
Although POFUT2 could not be identified by Coomassie Blue staining of the SDS-
PAGE, there was a clear signal on the immunoblot obtained using an antibody 
against the N-terminus of POFUT2 (Fig. 6.3.1). After 24 h in Pro293a medium, a faint 
but clear band was observed. The intensity of the signal increased after 48-h and 72-
h cultivation in the Pro293a medium. We observed a decrease in signal intensity after 
96 h of cultivation. By comparing the signal intensity of 100 ng and 200 ng POFUT2, 
we estimated that the expression level of POFUT2 after 72 h of cultivation in Pro293a 
medium was ~15 mg/l, which is higher than the expression level in the same stable 
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cell line in complete medium (~7 mg/mL). The expression level testing of POFUT2 in 
Pro293a medium suggests that the serum-free and protein-free properties of this 
medium may aid in downstream purification and that it did not compromise protein 
expression levels.  
 
Figure 6.3.2 Reduction of sample volumes by Vivaflow 200 
Western blotting (1°Ab: anti-hPOFUT2:44-58) was used to detect the expression level 
of POFUT2 in Pro293a medium and the concentration efficiency of Vivaflow 200. 
Conditioned medium (1 l) was efficiently concentrated to 50 ml in 30 min without 
significant protein loss.  
The next problem we encountered in the purification of proteins from conditioned 
medium is the large sample volume. A batch of large-scale purification in our 
laboratory contains 4–5 l of conditioned medium. The loading of the medium onto the 
HiTrap Con A column is time-consuming because the maximum flow rate is 4 ml/min. 
Reducing the sample volume during the early steps of purification would increase the 
efficiency of the purification method (i.e., time and sample handling). We tested the 
concentrating efficiency of cross-flow filtration (Vivaflow 200 PES, 10 kDa). 
Conditioned medium (1 l) with POFUT2 after 72 h of cultivation in Pro293a was 
harvested and concentrated by Vivaflow 200. The medium was concentrated to 50 ml 
in 30 min at 4 °C. Importantly, we did not observe POFUT2 in the flow-through 
fraction, and the intensity of the signal in the concentrated fraction was stronger than 
that in the original conditioned medium, as determined on the basis of the data from 
western blotting by using the antibody against the N-terminus of POFUT2 (Fig 6.3.2). 
These data indicate that cross-filtration, as an early purification step, efficiently 
reduced the sample volume without significant sample loss, which can save time and 
effort in downstream purification steps.     
Large‐scale purification of POFUT1 by using the tag‐free purification approach 
Pro293a medium (2.5 l) after 72 h of cultivation was first concentrated 10-fold by 
using Vivaflow 200. A 5-ml Hitrap Con A column was connected to the ÄKTA purifier, 
and the sample was circulated overnight through the Con A column at a flow rate of 
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1.0 ml/min. The unbound fraction was collected in the next morning. After washing 
the column, we first eluted the sample with a linear gradient from 0% B to 50% B 
buffer over 25 min (Fig. 6.3.3A). However, we did not observe a clear elution peak by 
using this gradient, based on the UV A280 signal. It has been reported that some 
proteins bind tightly to the Con A column, and elution of tightly bound proteins can be 
achieved by introducing a short pause during elution (Soper & Aird, 2007). After we 
introduced several pauses during the elution, we observed peaks immediately after 
we restarted the flow. Increasing the concentration of mannosyl-pyranose, as 
recommended by Soper & Aird (2007), did not improve the elution efficiency.  
 
 
Figure 6.3.3 Purification of hPOFUT1 by using the Con A column 
 (A) The Con A column was connected to an ÄKTA purifier, and the elution fractions 
were monitored by reading the A280 (blue). The gradient of buffer B (1 M mannosyl 
pyranose) is shown by the green line, and the fraction number is given on the bottom in 
red. The fraction size was 5 ml. (B) SDS-PAGE analysis of the samples before and 
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after purification on the Con A column. Different fractions eluted from the Con A column 
were loaded into the gel.   
The different column elution fractions from the Con A affinity chromatography column 
were analyzed by SDS-PAGE (Fig 6.3.3B). We observed a weak band at the 
predicted molecular weight for fractions #11 and #12. The intensity of the band 
increased when we introduced pauses in the elution procedure. Although only 0.04% 
of the sample from each fraction was loaded, we still observed a strong band on the 
gel. We also observed a band corresponding to POFUT1 in the flow-through (FT) 
fraction from the Con A column, although the intensity was weaker compared to the 
same band from the conditioned medium. These data suggest that the expression 
level of POFUT1 was high such that loading 2.5 l of conditioned medium saturated 
the column, and some POFUT1 flowed through the Con A column. We pooled 
fractions #11 to #39 and estimated the total amount of protein to be approximately 50 
mg.  
It is known from POFUT2 data that structurally flexible and heterogeneous N-glycans 
on the protein surface can interfere with the crystallization process and decrease the 
diffracting ability of the crystal. Based on the sequence of POFUT1, we know that it 
has two potential N-glycosylation sites: Asn62 and Asn160. Since one of our goals 
was to solve the crystal structure of POFUT1 and compare the catalytic mechanism 
between the two O-fucosyltransferases, we used Endo Hf to remove N-glycans on 
the surface of hPOFUT1.     
 
Figure 6.3.4 Purification of hPOFUT1 with a Con A affinity column 
The purification of high-mannose type POFUT1 can be achieved by single-step Con A 
affinity purification. The N-glycans on POFUT1 can be removed by Endoglycosidase Hf 
treatment.  
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After Endo Hf treatment, we observed a band shift compared to the untreated sample 
by SDS-PAGE (Fig. 6.3.4). However, without N-glycans, POFUT1 tends to precipitate 
at an acidic pH (pH 5.5 for Endo Hf cleavage), which leads to significant sample loss. 
As such, POFUT1 was immediately buffer exchanged into 20 mM Tris-HCl pH 8.5, 
100 mM NaCl, and 1 mM MnCl2, and then concentrated to 7.9 mg/ml. Overall, we 
isolated 15 mg of purified, de-glycosylated POFUT1.      
Purification of POFUT2 by Con A affinity chromatography 
We have shown that tag-free purification of human POFUT1, which has two potential 
N-glycosylation sites, was successful. The N-glycan in medium supplemented with 
kifunensine is high-mannose type, which is a strong ligand for Con A. Different 
glycoproteins may have a different number of N-glycosylation sites; therefore, we 
wished to test whether these proteins could also be purified by the Con A-based 
affinity chromatography method without using an artificial tag.  
Human POFUT2 has three potential N-glycosylation sites, which were shown to be 
fully occupied by electron density map data. Similar to the expression approach for 
human POFUT1, we first cultivated the cells in the DMEM medium supplemented 
with 10% FCS, and the medium was replaced with Pro293a medium supplemented 
with 5 mM kifunensine and 2 mM glutamine when cells reached 90% confluency. The 
medium from twenty 15 cm dishes (~370 ml) was harvested, filtered, and purified 
using a 1-ml HiTrap Con A column. We also used the pause/restart flow approach to 
improve the elution of tightly bound protein from the Con A column. Coomassie Blue 
staining of the elution fractions from the Con A column, (lane 1 in Fig 6.3.5B) showed 
that POFUT2 was contaminated with other proteins, which were removed by size-
exclusion column chromatography (Superdex 200 16/60 column); the chromatogram 
is shown in Figure 6.3.5A. From the signal at A280, we observed two main peaks. The 
first one was eluted around 50 ml, which ran at 200 kDa on the SDS-PAGE gel; 
POFUT2 was eluted in the second peak at ~78 ml from the Superdex 200 column. 
Therefore, compared to the purification procedure of POFUT1, only one additional 
step of size-exclusion chromatography was required to obtain a pure protein. 
Importantly, we could purify a protein that has three N-glycans from medium using an 
artificial tag.        
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Figure 6.3.5 Purification of POFUT2 by Con A affinity chromatography and size-exclusion 
chromatography (SEC) 
POFUT2 was expressed and purified from Pro293a medium in two steps. The elution 
fractions from the Con A column were pooled and purified by SEC. The chromatogram 
from the SEC in (A) and SDS-PAGE analysis of the fractions from the SEC in (B) show 
that POFUT2 can be purified to a single band in two sequential chromatographic steps.    
 Purification of cePOFUT2 (PAD2) by Con A affinity chromatography 
POFUT1 and POFUT2 have two and three N-glycans, respectively, on the protein 
surface. The number of N-glycosylation sites on the protein may affect the binding 
affinity of Con A. Therefore, we investigated the application of this tag-free 
purification approach to purify a protein with only one N-glycosylation site from the 
conditioned medium.        
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Figure 6.3.6 Purification of PAD2 by Con A affinity chromatography and size-exclusion 
chromatography 
PAD2, which only has one N-glycosylation site, was purified sequentially by Con A 
affinity chromatography and size-exclusion chromatography. The chromatogram of 
SEC is displayed in (A), and the samples after Con A purification and SEC were 
analyzed by SDS-PAGE (B).  
We expressed PAD2, which has only one potential N-glycosylation site on Asn205. 
The conditioned medium from the HEK293T stable line expressing PAD2 was 
harvested and circulated in the 1-ml HiTrap Con A column at flow rate of 1 ml/min. 
PAD2 was not eluted from the Con A column with the linear gradient; therefore, it 
was also eluted with the pause/restart approach with 0.5 M mannosyl pyranose. 
Similar to what we observed with POFUT2, PAD2 purified from the Con A affinity 
chromatography column was contaminated with other proteins (lane 2 of Fig. 6.3.6 B). 
An additional step of size-exclusion chromatography successfully removed most of 
the contaminants (Fig. 6.3.5), resulting in a single band in the fractions #20 to #22. 
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These data indicate the binding provided by a single high-mannose type N-glycan is 
sufficient for the tag-free purification of proteins with only one N-glycosylation site by 
Con A affinity chromatography.    
Discussion  
 Production of a large quantity of active, pure protein is crucial to generate high-
quality crystals to elucidate the protein structure by X-ray crystallography; this is 
particularly challenging for proteins modified by N-glycosylation. N-glycosylated 
proteins can usually not be properly expressed in prokaryotic expression systems as 
they lack the glycosylation machinery. N-glycan is generally required for correct 
folding as well as to maintain protein solubility. Glycans on glycoproteins expressed 
in mammalian cells are usually heterogenous. With kifunensine, a compound that 
can inhibit the activity of mannosidase II in the N-glycan processing pathway, the 
high-mannose type N-glycan could still have a different number of mannose groups 
(from Man5–Man9). Although protein expression in mammalian cells has improved in 
the recent years, and the expression levels in an optimized case have reached up to 
1 g/l (Backliwal et al., 2008), production of active glycoproteins for structural studies 
is still a challenging task. In this chapter, we described the production and purification 
of glycoproteins from HEK293T cells with a newly established tag-free purification 
system. The glycoproteins were successfully purified from a serum-free conditioned 
medium by using Con A affinity chromatography without the involvement of an 
artificial tag (illustrated in Fig. 6.3.7). We purified proteins with one, two, or three N-
glycosylation sites; the target proteins were efficiently purified to a single band with a 
single step of Con A affinity chromatography or with an additional step of size-
exclusion chromatography. Although this technique is very promising for the 
purification of glycoproteins, feasible improvements to this purification approach and 
the application of other lectin affinity chromatography methods are discussed below.  
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Figure 6.3.7 Con A purification scheme of human POFUT1  
POFUT1 was purified from the conditioned medium by a single step of Con A affinity 
chromatography. Two N-glycans on the protein can be digested by Endoglycosidase H, 
which leaves a single N-acetylglucosamine on each N-glycosylation site.     
Different cell lines for protein production  
In this work, glycoproteins were produced in adherent HEK293T cells. However, 
culturing of adherent cells can be difficult to scale up. Growing the adherent cells 
involves trypsinization-based harvesting of the cells and reseeding the trypsinized 
cells in new culture dishes, which can become a tedious process when 5 l of cultured 
cells is required (i.e., 250 15 cm culture dishes are required). Moreover, the 
HEK293T cell line has not been adapted to the serum-free system. Cell culture for 
protein expression studies can be divided into two phases. The first phase is 
expansion in the serum-containing medium until the cells grow to 90% confluency. 
The second phase requires switching the medium to serum-free medium for 
production of proteins. A cell line that has the ability to grow in suspension and in 
serum-free medium would be very useful to establish a streamlined workflow.   
Few mammalian cell lines have been engineered to overcome the problems 
associated with large-scale glycoprotein production. HEK.EBNA is a modified HEK 
293 cell line featuring a stable integrated copy of the EBNA-1 gene of the Epstein-
Barr virus. The function of EBNA-1 is to drive episomal replication of the expression 
plasmid carrying the OriP origin of replication derived from the EBV (Van 
Craenenbroeck et al., 2000). A protocol for the adaption of HEK.EBNA cells to grow 
in suspension and in serum-free medium has been described (Meissner et al., 2001). 
The FreeStyle 293 Expression System is a commercial system (Invitrogen) using a 
cell line derived from HEK cells, which is adapted to grow at high density in serum-
free suspension culture. The FreeStyle 293 Expression System also includes specific 
medium and transfection reagents for high transfection efficiency and high protein 
yield. HEK293S is another cell line derived from HEK293 cells. It lacks N-
acetylglucosaminyltransferase I (GnTI) activity, and consequently, the N-glycan 
structure is maintained as the high-mannose type (Reeves et al., 2002). Although no 
study has described their adaptation to serum-free medium, protein production from 
HEK293S cells, which has only Man5 N-glycans, still deems it an attractive cell line 
for producing glycoproteins for structural studies.  
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Saturation of the Con A column can reduce non‐specific binding 
The POFUT1 elution fractions from the Con A affinity column were >95% 
homogeneous (Fig. 6.3.3). On the other hand, the POFUT2 and PAD2 fractions 
eluted from the Con A column were not as pure as POFUT1 (Fig. 6.3.5 & 6.3.6); an 
additional step of gel filtration was necessary to eliminate the contaminants. 
 Like POFUT1, POFUT2 and PAD2 were expressed in the same serum-free medium 
by the same parental cell line. Although the number of N-glycans differs between 
these proteins, which could affect binding to the Con A column, this should not 
contribute to the presence of impurities in the POFUT2 and PAD2 fractions because 
POFUT2 has the highest number of N-glycans. We hypothesize that the impurities 
are because of the amount of target protein loaded onto the Con A column. POFUT1 
is highly expressed, and although a 5-ml Con A column was used (for 2.5 l of 
medium), some residual POFUT1 was still detected in the unbound fraction, 
indicating that we had exceeded the column binding capacity. By comparison, the 
expression of POFUT2 and PAD2 was much lower, and therefore, a 1-ml Con A 
column was used for the purification step (for 400 ml of medium). However, the 
presence of contaminants in the eluted protein fractions suggests the presence of 
unoccupied Con A binding sites on the column, resulting in non-specific binding. 
Indeed, it is known that a 5-ml Con A column can roughly bind 50 mg of POFUT1, 
which is equivalent to 2 mM of N-glycan. Based on this estimation, the same Con A 
column could bind to ~33 mg of POFUT2 (and a 1-ml Con A column could bind ~6.6 
mg of POFUT2). Since the expression level of POFUT2 was ~7 mg/l, we could 
increase the ratio of target protein to Con A to decrease non-specific binding.  
An alternative solution to reduce non-specific binding is to add a Con A ligand to the 
binding buffer. Con A has high affinity for the tri-mannosyl N-glycan core structure, 
but it can also bind to mannosyl pyranose. A low concentration (10 mM) of mannosyl 
pyranose added to the binding buffer may help reduce non-specific binding.   
Purification of glycoproteins from conditioned medium with different lectins  
Many lectins are commercially available in an immobilized form for lectin affinity 
purification (Freeze, 2001). Con A, the lectin used in this chapter, is one of the most 
commonly used lectins because of its availability and stability. Wheat germ agglutinin 
(WGA) is another popular lectin because of its broad specificity. It has high affinity to 
the terminal N-acetylglucosamine, but also binds to terminal sialic acid (NeuAcα2-
3(6)-R) and linear polylactosamine (Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Gal-
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4GlcNAcβ1-R) chains with lower affinity. If the purified protein is not for use in 
structural studies, the protein can be expressed without the supplementation of 
kifunensine, leaving the N-glycans on the protein as a complex with sialic acid and 
polylactosamines, in order to allow purification with WGA.  
Here, we have described an approach for the large-scale expression and purification 
of recombinant glycoproteins without using an artificial protein or peptide tags. The 
inherent N-glycan on the glycoprotein provides a natural tag for purification using the 
Con A lectin. The capacity of the Con A affinity purification is quite high; a single Con 
A column can purify >50 mg of POFUT1 in a single purification step. These features 
make it an attractive technique for glycoprotein purification.       
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7. Summary and Discussion   
In this study, we determined the crystal structure of native POFUT2 and 
enzymatically inactive E54A-POFUT2 in complex with GDP-fucose. We showed that 
POFUT2 belongs to the GT-B superfamily of glycosyltransferases with two 
Rossmann-like domains separated by an inter-domain cleft. GDP-fucose binds to the 
C-terminal domain and we proposed that TSR would bind to POFUT2 in the inter-
domain cleft. Based on the structures and the enzymatic activity assay of wild-type 
and POFUT2 mutants, we proposed a catalytic mechanism of POFUT2. R294 forms 
a salt bridge with the β-phosphate group of GDP-fucose. The carboxylate side chain 
of E54 works as a catalytic base that deprotonates the hydroxyl group on the serine 
or threonine on the TSR, which attacks as nucleophile the anomeric carbon of GDP-
fucose. We also observed that the substrate specificity of POFUT2 for TSR seems to 
be achieved by the structural complementarity of a part of the TSR with the POFUT2 
binding site. The disruption of the unique compact three-strand structure of TSR by 
mutating key residues decreased the fucosylation efficiency. The in vitro and in vivo 
fucosylation of artificial mini-TSR support our model that POFUT2 recognizes 
properly folded TSR through the region around the AB loop.  
Divalent metal ion in GT‐B superfamily 
Unlike glycosyltransferases with the GT-A fold, which have a short DXD motif 
involved in metal binding for catalysis, most of the glycosyltransferases in the GT-B 
superfamily use a metal-ion independent mechanism for catalysis. In the GT-A 
superfamily, the positively charged Mn2+ ion is clearly positioned to neutralize the 
negative charges of the phosphate group of the sugar donor (Ünligil & Rini, 2000). 
However, catalysis of a few glycosyltransferases in the GT-B superfamily is 
stimulated in presence of divalent metal ions. The best characterized 
glycosyltransferase that needs metal ions for full activity is DNA β-
glucosyltransferase (BGT) from T4 phage (Moréra et al, 2001). It has been shown 
that without metal ions in the assay BGT still maintained 10% of activity. The 
presence of metal ions in the activity assay such as Mg2+ and Mn2+ significantly 
increase the activity. Comparing the structures of BGT in complex with GDP-Mn2+ 
and GDP-glucose revealed that the metal ion binds almost the same position as 
glucose in the GDP-glucose complex with the metal ion and the glucose C1 atom 
being only separated by less than 1 Å. In other words, the sugar moiety fills the 
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space occupied by the metal (Larivière et al, 2003). This observation suggested that 
a role of the metal ion in GT-B fold glycosyltransferases is incompatible with 
activating catalysis like in the GT-A superfamily. The authors proposed a secondary 
role in product release after glucose transfer, but the detailed mechanism remains to 
be elucidated.  
Another glycosyltransferase of the GT-B superfamily that needs metal ions for full 
activity is POFUT1. In the activity assay of POFUT1 expressed in CHO cells, it was 
shown that POFUT1 remains active in the presence of EDTA and that divalent metal 
ions such as Mn2+ increase the activity 17-fold (Wang & Spellman, 1998). This 
observation was consistent with the role of metal ions in BGT where metal ions are 
needed for full activity. 
Interestingly, in the recent structures of POFUT1 from C. elegans it was also 
observed that the metal ion occupies the location of the fucose moiety in the GDP-
fucose complex (Lira-Navarrete et al, 2011). The structures of POFUT1 with GDP-
fucose and GDP imposed nicely, which indicated no significant conformational 
change induced by binding of the different ligands (Fig. 7.1). The close-up image of 
the GDP-fucose binding site shows that metal ion cannot co-exist with the fucose 
moiety from GDP-fucose as the ligand binds at the same place.  
 
Figure 7.1 Structure of CePOFUT1 in complex with GDP-Mn2+ and GDP-fucose 
Two POFUT1 structures are imposed and displayed as cartoon models. The structure 
in red is in complex with GDP-fucose (PDB 3ZY6) and structure in green is in complex 
with GDP and Mn2+ (PDB 3ZY2). GDP and GDP-fucose are shown as sticks and Mn2+ 
30º
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is shown as a sphere. The GDP-fucose binding region is highlighted in the close-up 
image.  
The role of the metal ion in the catalytic process of POFUT2 is also unclear. We 
showed that the basic activity of POFUT2 does not require metal ions but that Mg2+ 
or Mn2+ can increase the activity more than 10-fold (Fig. 6.2.3C). The lack of a GDP-
Mn2+ POFUT2 structure makes it difficult to predict if a metal ion would locates in the 
position where fucose binds. Interestingly, crystals of E54A-POFUT2 in complex with 
GDP-fucose were grown in the presence of EDTA. Replacing the EDTA with 5 mM of 
MnCl2 in the crystallization condition did not yield any crystals (unpublished data), 
implying that MnCl2 may also interfere with the binding of GDP-fucose and affect the 
crystal packing. We proposed that the metal ion in POFUT2 plays a similar role as 
the metal ions in BGT and POFUT1 where these ions are not required for sugar 
transfer. Binding of the metal at the binding site of the sugar where it interacts with 
the diphosphate moiety of the hydrolyzed sugar donor may help the release of 
fucosylated product. Further experiments to crystallize POFUT2 with GDP and Mn2+ 
may help to elucidate the binding site of the ion in POFUT2.  
POFUT2 O‐fucosylation on TSRs‐containing proteins  
Most of the TSR does not exist as a single module in the protein; instead several 
TSRs may be linked together and form the multi-TSRs proteins (Fig.5.4.1). Although 
we used a single module TSR4 from rat F-spondin for testing the activity of POFUT2 
and for building our POFUT2-GDP-fucose-TSR4 ternary model (Fig. 6.2.5), we did 
not exclude the possibility that the additional TSR module may affect fucosylation 
efficiency. The structure of TSR23 from TSP-1 was used to replace the TSR4 in the 
model (Fig. 6.1.12), which shows that POFUT2 could interact with two consecutive 
TSRs in the inter-domain cleft. Preliminary results of O-fucosylation of TSR23* show 
that POFUT2 can indeed fucosylate TSR2 on TSR23*, which suggests that the 
second module (TSR3*) would not interfere with the binding of TSR23* to POFUT2 
(Chapter 6.1). Furthermore, the higher fucosylation efficiency of TSR23* compared to 
the single module TSR4 from F-spondin suggests that two consecutive TSR modules 
could act as a better substrate for O-fucosylation than a single TSR module (Chapter 
6.1).  
Interestingly, the recent structure of ADAMTS13-DTC, which contains only a single 
TSR module provides new insight into how POFUT2 recognizes and fucosylates 
TSR-containing proteins (Akiyama et al, 2009). ADATMTS13 is a multi-domain 
protein with a metalloproteinase domain, a disintegrin-like (D) domain, a TSR (T), a 
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cysteine-rich (C) region, a spacer (S), seven TSRs (T2–T8), and two CUB domains. 
The ADAMTS13-DTC encompasses the disintegrin-like (D) domain to the spacer (S), 
and only a single TSR locates between the disintegrin-like domain and the cysteine-
rich domain (Fig. 7.2A). ADAMTS13-DTC was expressed in CHO cells and a 
Glcβ1,3Fuc disaccharide was found on the consensus sequence in the AB loop of 
TSR1 (Akiyama et al, 2009). When we superimposed the TSR1 of ADAMTS13-DTC 
onto the TSR in our model (Figure 6.2.5), we found that entire cysteine-rich region 
and parts of the spacer domain overlap with the N-terminal domain of POFUT2.  
     
(A) Modified from (Akiyama et al, 2009) 
Figure 7.2 The model of ADAMTS13-DTC in complex with POFUT2 
The domain structure of ADAMTS13-DTC was illustrated in (A). Each domain is color-
coded and the color of each domain is consistent with the structure in (B). POFUT2 is 
displayed as grey surface. 
As TSR in the ADAMT13-DTC structure was found to be fucosylated, the POFUT2 in 
CHO cells must have a strategy to accept multidomain proteins as substrate. 
Currently, we hypothesize that POFUT2 binds and fucosylates TSR1 when the 
interdomain arrangement is not yet completed. Binding of POFUT2 to TSR not only 
transfers the fucose to TSR but may also delay the folding of the multidomain protein. 
After the fucose is added to the TSR, POFUT2 is released from ADAMT13 and 
interdomain contacts which the cysteine-rich region can be established.  
In summary, we present the crystal structure of POFUT2 and of the POFUT2-GDP-
fucose complex. We also propose an enzymatic mechanism of fucose transfer to 
TSR. Importantly, we elucidate that the substrate specificity relies on the unique 
three-stranded structure of TSR that precisely presents the fucosylation site to the 
catalytic region in the POFUT2 structure. Future studies of the POFUT2-TSRs 
complex and a comparison of binding affinities between single and two modules will 
uncover the underlying mechanism and function of this unique type of glycosylation.    
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